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Due to their broad-spectrum and bactericidal activity, antimicrobial proteins and 
peptides (AMPPs) are considered as future drug alternatives to combat the escalating 
problem of antimicrobial resistance in medicine. The community of competitive 
culturable and non-culturable bacteria in the rumen present a potential source for the 
discovery of novel bioactive compounds including AMPPs.  
Metagenomic and bioinformatics based techniques were used to prospect two rumen 
bacterial metagenomes for potentially novel antimicrobial genes (proteins) and peptide 
sequences. Novel short antimicrobial peptides (peptides 1-181) and eleven longer 
antimicrobial genes/miniproteins (Gene 6, 17A, 17B palG1 and palG2, H-G1, H-G2, H-
G3, H-G4, H-G5) were identified. Eight of these (peptides 2, 3, 4, 5, 7, 8, 15 and palG1) 
were selected for further analysis. These antimicrobials displayed potent antimicrobial 
activity (minimum inhibitory concentrations ranging from 32 to 64 µg/ml) against both 
Gram positive bacteria strains (including Methicillin sensitive and resistant 
Staphylococcus aureus strains MSSA RN4220 and EMRSA-15, Enterococcus faecalis 
JH2-2 and Listeria monocytogenes NCTC 11994 (serovar 4b)), as well as Gram 
negative bacteria strains (Escherichia coli K12, Salmonella enterica serovar 
Typhimurium SL1344 and Pseudomonas aeruginosa (15692) PAO1 strain H103) in 
Mueller Hinton broth. No haemolytic activity against red blood cells was seen. Data 
obtained indicate that loss of cell viability is due to cytoplasmic leakage and there is 
some evidence of interference with the cell division mechanism.  
The rumen AMPPs identified in this study show great activity against clinically relevant 
human pathogens and to our knowledge are the first rumen AMPs identified using 
metagenomics. Overall, the data support the potential use of AMPs (2, 3, 7), AMPs (2, 
3, 4, 5, 7, 8, 15) and the polypeptide palG1 in the treatment of S. aureus, E. coli and 
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The immediate post-World War 2 generation in developed countries was the first to 
enjoy, from birth, the benefits of a modern health system. These health systems largely 
abolished the pain of many infectious diseases, especially those of childhood, that 
ravaged societies in the past (Bennett 2008). This was made possible by the discovery 
and development of antibiotics in the 20th century, which marked a watershed in the 
treatment of very serious infections, stimulated advances in medical fields and enlarged 
the scope of medical care (Bennett 2008, Raghunath 2008). 
Antibiotics may be natural, semi- or completely synthetic in origin. Although the term 
antibiotic was traditionally used to describe naturally-occurring substances produced by 
microorganisms (which in dilute solutions can selectively inhibit the growth of, or kill 
other microorganisms) and their derivatives, it is now more loosely used to describe 
both natural and synthetic agents (Scholar and Pratt 2000, Cooper et al. 2002). Since 
this discovery, a large number of antimicrobials belonging to different classes have been 
developed. These are distinct in their structural properties, modes of action, and spectra 
of organisms against which they are effective. Indeed, many of these have been 
extremely successful and have brought great benefits to human health (Chopra 2003, 
Projan and Ruzin 2006) 
However, the intensive use and misuse of antibiotics, which was estimated in 2002 to be 
100,000-200,000 tonnes per annum worldwide (Wise 2002, Andersson and Hughes 
2010), has dramatically increased the frequency of antimicrobial resistance among 
human pathogens. This threatens a loss of therapeutic options, and a post-antibiotic era 
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in which present and future medical advances are threatened (Raghunath 2008, 
Andersson and Hughes 2010). 
1.2 Antibiotic resistance 
Antibiotic resistance is one of the greatest challenges for the twenty-first century (Rasko 
and Sperandio 2010). The global rise of antimicrobial resistance in bacteria, combined 
with the decreasing number of innovative antibacterial agents, has led to warnings that 
we may soon lose our ability to treat bacterial infections (WHO 2007). This is because 
the treatment of bacterial infections is increasingly complicated by microorganisms 
which develop resistance to antimicrobial agents (Martinez et al. 2007).  
Antibiotic resistance in bacterial pathogens was identified very soon after the 
introduction of antibiotics into clinical practice as reviewed by (Mazel and Davies 
1999). The prokaryotic cell is versatile and capable of adapting to the introduction of 
antibiotics into the environment. The inherent genetic variation provides a level of 
heterogeneity that ensures survivors in antibiotic charged environments (Raghunath 
2008). A survey of bacterial isolates from the pre-antibiotic years show the presence of 
resistant organisms, although in small numbers (Medeiros 1997). However, in an 
antibiotic charged environment, a selection pressure builds up favouring the resistant 
organisms. This selective pressure which results in a steady rise in Minimum Inhibitory 
Concentrations (MICs) has led to resistance to all major antimicrobial classes (Lowy 
2003, Rice 2006, Raghunath 2008) (see Table 1.1 for a timeline of antimicrobial 
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Antimicrobial resistance is associated with increased patient morbidity and mortality 
rates, and has considerable economic consequences for healthcare systems (French 
2005). For example, mortality rates in infections caused by Methicillin resistant 
Staphylococcus aureus (MRSA) are more than double those caused by Methicillin 
sensitive S. aureus (MSSA) (Whitby et al. 2001, Livermore 2003). Although there are 
still gaps in our knowledge, the overall significance of the problem of antibiotic 
resistance has subsequently led to an increased understanding of the contributing 
variables and molecular mechanisms underlying the development and spread of 
antimicrobial resistance, as evidenced by the large volume of literature on resistance.  
There is therefore urgent need for the next generation of newer, safer and effective 
antibiotics and therapeutic treatment strategies, if we are to avoid a ‘post-antibiotic’ era 
and the negative societal and medical consequences of multidrug resistant bacterial 
infections (Alanis 2005). 
1.3 Important pathogenic bacteria and current antibiotic treatment 
strategies 
Over the past decade, there has been renewed public concern over infectious disease as 
a major public health threat. Human population growth over the years and an 
increasingly globalized microbial world has resulted in the emergence of infectious 
diseases (McMichael 2004). The spectrum of human pathogens and the infectious 
diseases they cause is continuously changing through evolution and changes in the way 
human populations interact with their environment and each other (Waldvogel 2004, 
van Doorn 2014). We are now faced with a growing population of pan-resistant bacteria 
that threaten to move us into a “postantibiotic era”. Some of the more problematic drug-
resistant pathogens encountered today include methicillin-resistant Staphylococcus 
aureus (MRSA), vancomycin-resistant Enterococci (VRE) and Streptococcus 
pneumoniae, among the Gram-positive bacteria and multidrug-resistant Acinetobacter 
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baumannii, Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa 
among the Gram-negative bacteria (Fish 2002, Lister et al. 2009). For the purpose of 
this thesis, MRSA, E. coli and Enterococcus faecalis are discussed below. 
1.3.1 Staphylococcus aureus 
S. aureus is a bacterium commonly found on the skin and in the nose of healthy people, 
its major habitats being the nasal membrane and the skin of warm-blooded animals 
(Whitt and Saylers 2002). S. aureus is a facultatively anaerobic, non-motile, Gram-
positive coccus, around 0.6 µm in size, which appears as grape-like clusters when 
viewed through a microscope. It produces large, round, golden yellow colonies, often 
with haemolysis when grown on blood agar plates (Ryan and Ray 2004). S. aureus is 
catalase positive, that is, it is able to produce the enzyme catalase and convert hydrogen 
peroxide to water and oxygen. This makes the catalase test a very useful method to 
distinguish staphylococci from enterococci and streptococci. It is also primarily 
coagulase positive (i.e. produces an enzyme that causes clot formation (Ryan and Ray 
2004). 
S. aureus is recognised as the most frequently isolated nosocomial pathogen (Kuroda et 
al. 2001, Otto 2008). It can bring about complicated infections and serious hospital-
acquired infections in all tissue types and organ systems due to its ability to produce an 
extensive array of cell surface proteins and secrete an abundance of extracellular 
enzymes like coagulase, protein A and toxins such as exfoliate toxins, superantigens, 
alpha, beta and delta toxins as well as toxic shock toxin (Projan and Norvick 1997, Lee 
and Bohach 2004), which promote disease by destroying constituents of host tissue, 
assisting dissemination of bacteria and counteracting host defence components 
(Ardvidson 2006, Lee and Lee. 2006)  (Figure 1.1).  
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Figure 1.1 Structure of S. aureus and summary of its surface virulence factors. 
Panel A shows the surface and secreted proteins. The synthesis of many of these proteins is 
dependent on the growth phase, and is controlled by regulatory genes such as agr. Panels B 
and C show cross sections of the cell envelope. Many of the surface proteins have a 
structural organization similar to that of clumping factor, including repeated segments of 
amino acids (Panel C). TSST-1 denotes toxic shock syndrome toxin 1. Source: (Lowy 
1998). 
 
S. aureus readily acquires resistance against all classes of antibiotics by one of two 
distinct mechanisms: mutation of an existing bacterial gene or horizontal transfer of a 
resistance gene from another bacterium (Grundmann et al. 2006). Staphylococcal 
resistance to penicillin is mediated by penicillinase production (a form of β-lactamase); 
an enzyme which breaks down the β-lactam ring of the penicillin molecule (Lowy 2003, 
Kernodle 2006). Resistance problems encountered with the use of penicillin prompted 
the search for improved penicillin antibiotics (Bush 2003b). New β-lactams such as 
methicillin, oxacillin and flucloxacillin which were able to withstand penicillinase 
mediated hydrolysis and had anti-staphylococcal activity were derived from 
modification of the basic penicillin molecule (Greenwood 2003, Bush 2003a).  
7 
 
Methicillin-resistant S. aureus (MRSA) was identified in 1961, the same year 
Methicillin was introduced into clinical practice for the treatment of β-lactamase 
producing strains of staphylococci (Chopra 2003, Lowy 2003), which has spread 
rapidly to become recognized as a major threat to public health all over the world 
(Lindsay and Holden 2004). About 89 to 95% of S. aureus isolates have been found to 
be Methicillin resistant (Ippolito et al. 2010). This makes Methicillin-resistant 
Staphylococcus aureus (MRSA) the most commonly identified antibiotic-resistant 
pathogen in many parts of the world (Berger-Bachi and Rohrer 2002, Ug and Ceylan 
2003, Grundmann et al. 2006). Methicillin resistance results from the expression of an 
additional penicillin binding protein (PBP), (PBP2') (through the acquisition of the 
mecA gene), which has a low affinity for β-lactams and is able to take over catalysis of 
essential transpeptidation reactions from the native PBPs inactivated by methicillin to 
maintain peptidoglycan cross-linkage (Chopra 2003). This renders the bacterial cell not 
only resistant to methicillin, but to most β-lactams (Hiramatsu et al. 1997, Davies et al. 
2007, Stapleton et al. 2007)- see Figure 1.2 below for an illustration of the action of β-




Figure 1.2 Action of beta-lactam antibiotics: the beta-lactam (purple double cubes) is 
a structural analogue of D-alanyl-D-alanine residues. It inactivates S. aureus PBPs (in 
red), but cannot bind to PBP2' (in green; MRSA-specific PBP) with high affinity. 
Therefore, MRSA can continue peptidoglycan synthesis in the presence of beta-lactams 
whereas methicillin-susceptible S. aureus cannot. Source: (Hiramatsu 2001). 
 
 
As a result of the emergence of MRSA, glycopeptides (e.g. vancomycin and 
teicoplanin) naturally-occurring antibiotics with activity against many species of Gram-
positive bacteria were introduced (Fraimow and Courvalin 2006). Vancomycin binds to 
the important substrates for the cell wall-synthesizing machinery,
 
i.e., the D-alanyl-D-
alanine residue (DDR) of the lipid II precursor, and thereby inhibits utilisation of the 
substrate by glycosyltransferases
 
(cell wall synthesizing enzymes) to produce the 
nascent peptidoglycan
 
chain (Hiramatsu 2001). Again, clinical isolates of Vancomycin 
Intermediate S. aureus (VISA) and Vancomycin-Resistant S. aureus (VRSA) MRSA 
have been reported (Hiramatsu et al. 1997, Chang et al. 2003, Menichetti 2005). VRSA 
resistance is mediated by the acquisition of the VanA gene which originates from 
enterococci (Lowy 2003, Weigel et al. 2003). In the presence of the vanA gene in 
transposon Tn1546, enterococci
 
can replace the DDR of peptidoglycan with D-Ala-D-
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Lac (an alternative peptidoglycan to which vancomycin will not bind) to prevent
 
their 
cell wall components from being bound to vancomycin (Cetinkaya et al. 2000, Tenover 
2006) (see Figure 1.3 below). 
 
 
Figure 1.3 Action of vancomycin.  
The antibiotic binds to D-alanyl- D-alanine residues of the murein monomer. The murein 
monomer bound by vancomycin does not serve as a substrate for glycosyltransferases. 
Source: (Hiramatsu, 2001). 
 
 
The use of antistaphylococcal β-lactam antibiotics is still widely accepted as the 
standard of care to treat methicillin sensitive S. aureus (MSSA) whenever possible 
(Chang et al. 2003, Khatib et al. 2006, Kim et al. 2008, Schweizer et al. 2011). 
However, Vancomycin and daptomycin (a lipopeptide) are the only FDA-approved 
agents for the treatment of MRSA bacteremia in the United States and Teicoplanin is a 
potential alternative to Vancomycin (Holland et al. 2014). Today, several antibiotics are 
employed in the treatment of staphylococcal infections and combination therapy is often 
favoured over monotherapy. Therefore, high quality trials comparing treatment 
strategies, antibiotics and treatment durations are still needed to better inform the 
management of this common, serious infection and there is still an urgent need to search 
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for new novel anti-staphylococcal therapies. Teixobactin, a new antibiotic discovered 
more recently in uncultured bacteria, (Ling et al. 2015) is favoured as the next agent 
with potential for treatment of MRSA infections, pending FDA approval. 
1.3.2 Escherichia coli 
E. coli is a Gram-negative, non-sporulating, facultatively anaerobic rod, which either 
uses peritrichous flagella for mobility or is non-motile. They are about 2 µm long and 
0.5 µm in diameter and grow in warm moist environments at 37°C (Hartl and 
Dykhuizen 1984). E. coli can be identified with a variety of biochemical reactions, the 
most useful being the indole test for the differentiation of E. coli from other members of 
the Enterobacteriaceae (Xia 2010). It can be recovered easily from clinical stool 
specimens on general or selective media (most often MacConkey or eosin methylene-
blue agar) at 37°C under aerobic conditions (Balows 1991). 
E. coli is a facultative anaerobe of the normal intestinal flora of humans and other 
mammals (Nataro and Kaper 1998, Kaper et al. 2004). E. coli has also been widely 
exploited as a cloning host in recombinant DNA technology. It is however more than 
just a laboratory model or harmless commensal. The organism typically colonizes the 
infant gastrointestinal tract within hours of life (Drasar and Hill 1974, Berg 1996) and 
remains harmlessly confined to the intestinal lumen. However, even “nonpathogenic” 
strains of E. coli can become versatile and deadly pathogens causing different infections 
in an immunosuppressed host or where the normal gastrointestinal barriers are breached 
(Nataro and Kaper 1998, Kaper et al. 2004, Croxen and Finlay 2010). The most 
common E. coli infections are diarrhoeal/enteric disease, meningitis/sepsis and urinary 
tract infection. It is also one of the leading causative agents of foodborne infections 
worldwide. Like most mucosal pathogens, E. coli infection follows colonization of a 
mucosal site, evasion of host defenses, multiplication, and host damage (Nataro and 
Kaper 1998).  
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E. coli implicated in human diseases are broadly classified into two major categories: 
the diarrhoeagenic E. coli and the extraintestinal pathogenic E. coli (Russo and Johnson 
2000). Among the intestinal diarrhoeagenic E. coli pathogens, there are currently six 
well studied categories including Enteropathogenic E. coli (EPEC), Enterohaemorrhagic 
E. coli (EHEC)/Shiga toxin-producing E. coli (STEC), Enterotoxigenic E. coli (ETEC), 
Enteroaggregative E. coli (EAEC), Enteroinvasive E. coli (EIEC) and Diffusely 
adherent E. coli (DAEC) (Nataro and Kaper 1998). Extraintestinal pathogenic E. coli 
(ExPEC) includes two major pathotypes: uropathogenic E. coli (UPEC) and neonatal 
meningitis E. coli (NMEC) which colonize a variety of anatomical locations and cause 
various infections outside the gastrointestinal tract, among which urinary tract infections 
are the most common (Russo and Johnson 2000, Karch et al. 2005) (Figures 1.4 and 1.5 
below illustrate the pathogenic schema of diarrhoeagenic and extraintestinal pathogenic 






Figure 1.4 Pathogenic schema of diarrhoeagenic E. coli. Source: (Kaper et al. 2004). 
AAF, aggregative adherence fimbriae; BFP, bundle-forming pilus; CFA, colonization factor 
antigen; DAF, decay-accelerating factor; EAST1, enteroaggregative E. coli ST1; LT, heat-





Figure 1.5 Pathogenic schema of extraintestinal E. coli. Source: (Croxen and Finlay 
2010). a Uropathogenic E. coli (UPEC) attaches to the uroepithelium through type 1 pili, 
which bind the receptors uroplakin Ia and IIIa; this binding stimulates unknown signalling 
pathways (indicated by the question mark) that mediate invasion and apoptosis. Binding of 
type 1 pili to α3β1 integrins also mediates internalization of the bacteria into superficial 
facet cells to form intracellular bacterial communities (IBCs) or pods. Sublytic 
concentrations of the pore-forming haemolysin A (HlyA) toxin can inhibit the activation of 
Akt proteins and leads to host cell apoptosis and exfoliation. Exfoliation of the 
uroepithelium exposes the underlying transition cells for further UPEC invasion, and the 
bacteria can reside in these cells as quiescent intracellular reservoirs (QIRs) that may be 
involved in recurrent infections. b Neonatal meningitis E. coli (NMEC) is protected from 
the host immune response by its K1 capsule and outer-membrane protein A (OmpA). 
Invasion into macrophages may provide a replicative niche for high bacteraemia, allowing 
the generation of sufficient bacteria to cross the blood–brain barrier (BBB) into the central 
nervous system. Attachment of NMEC is mediated by type 1 pili binding to CD48 and 
OmpA binding to ECGP96. Invasion involves cytotoxic necrotizing factor 1 (CNF1) 
binding to 67 kDa laminin receptor (67LR; also known as RPSA, as well as type1 pili and 






E. coli strains cause diverse intestinal and extraintestinal diseases by means of virulence 
factors that affect a wide range of cellular processes. These virulence factors are 
normally encoded on genetic elements that can be exchanged between different strains 
or could be mobile elements which later become fixed into the genome. The versatility 
of the E. coli genome is conferred mainly by two genetic configurations: virulence-
related conserved plasmid families and chromosomal pathogenicity islands, each 
encoding multiple virulence factors (Wood et al. 1986, Nataro et al. 1987, Hales et al. 
1992). Although plasmids and pathogenicity islands carry clusters of virulence traits, 
individual traits may be transposon encoded e.g. heat-stable enterotoxin (ST) or phage 
encoded like Shiga toxin (So and McCarthy 1980, O’brien et al. 1992). There are also 
hundreds of serotypes of E. coli which are classified on the bases of various surface 
antigens referred to as Somatic (O), Capsular (K), Flagellar (H) and Fimbrial (F) 
(Edwards and Ewing 1972, Small and Falkow 1986, Lior 1994) (Table 1.2). 
E. coli diarrhoea infections caused by various diarrhoeagenic E. coli normally do not 
normally require antibiotic treatment (Xia 2010). Potentially fatal infections such as 
infant meningitis and severe infections are generally treated with antibiotics. Commonly 
prescribed antibiotics include fluoroquinolones and cephalosporins and nitrofurantoin 
(Fadda et al. 2005). Although antibiotics have been very useful in treating E. coli 
infections in the past, the increase in antibiotic resistance in E. coli make treatment of E. 






Table 1.2 Virulence factors in E. coli infection pathotypes. (Adapted from (Nataro and Kaper 1998, Clarke et al. 2003, Johnson and Russo 
2005, Clermont et al. 2007, Wiles et al. 2008, Johnson and Nolan 2009, Abraham 2011, Santos et al. 2013)). 
Pathotype Associated H 
antigens 
Virulence genes Serotypes Plasmids 
ETEC H9, H27, H11, 
NM, H42, NM, 
H7, H11, H12, 
H7, H28, H10, 
H20,NM 
 
Sta, Stb, Eastl, F4 (K88) F18, F41 
(in neonatal diarrhoea) including F5 
(K99), F6 (987P)  (in post-weaning 
diarrhoea) 
O6, O8, O9, O11, 
O15, O20, O25, 
O27, O45, O64, 
O78, O101, O128, 
O138,O141, O147, 
O148, O149, 
O157, O157, O173 
FIB, FIIA, I1, FIC 
ExPEC H7 (generally less 
defined) 
Fimh, papG I to III, flu, focG, sfaS, 
afa/draBC, hlyA, cnfl, fyuA, iutA, 
iroN, kpsMT II, kpsMT III, kpsMT 
K1, kpsMT, traT K5, iss, irp2, (in 




FIB, FIIA, I1, FIC,Y B/O 
EPEC H34, NM, H2, H12, 
NM, H6, NM, H21, 
H27, NM, H6, NM, 
H2, H12, H6 
 
BfpA to L, bfpU, bfpP, bfpT, bftV, 
bfpW, escC, D, F, J, N, escR to V, 
sepQ, sepZ, Eae, tir, espA, B, D, F, 
G, map, ler, cesD, T, F. 





com9 (pIP71A), IncA/C (pSN254), IncB/O (pTP113), IncD, IncFIA 
(Plasmid F), IncFIB (pO157), IncFIC (Plasmid F), IncFIIA (pR100), 
IncFIV (pSU316), IncFV (pED208), IncFVI (pSU212), IncFVII 
(pSU221). IncHI1 (pR27), IncHI2 (pR478), IncHI3 (Mip233), 
IncHII (pHH1508a), IncI1 (pR64), IncI2 (R721), IncJ (ICE R391), 
IncK (pR387), IncL/M (pCTX-M3), IncN (R46), IncP-α (RP4), 
IncP-β (pB4), IncP-γ (pQKH54), IncP-δ (pEST4011), IncP6 (IncG) 
(Rms149), IncP7 (pCAR1), IncP9 (pWWO), IncQ1 (RSF1010), 
IncQ2 (pTC-F14), IncR (pK245), IncT (pRts1), IncU (pFBAOT6), 
IncV, IncW (pR7K), IncX1 (pOLA52), IncX2 (pR6K), IncY (P1) 
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Antibiotics which were once effective in the treatment of E. coli infections including 
fluoroquinolones (e.g. ciprofloxacin- widely used oral antibacterial drug in the 
community) and cephalosporins (widely used for intravenous treatment of severe 
infections in hospitals) have become increasingly less effective (Besser et al. 1999). 
Multidrug resistance (MDR) to three or more drugs including streptomycin, 
cephalothin, tetracycline, ampicillin and trimethoprim has been reported (Taye et al. 
2013, Ansari et al. 2015). AmpC-mediated β-lactam resistance in E. coli is an emerging 
problem (Odeh et al. 2002, Philippon et al. 2002, Wong-Beringer et al. 2002). High 
level AmpC production is typically associated with in vitro resistance to all β-lactam 
antibiotics except for carbapenems and cefepime. In addition, treatment failures with 
broad-spectrum cephalosporins have been documented (Odeh et al. 2002, Wong-
Beringer et al. 2002). According to the World Health Organisation (WHO) 
Antimicrobial Resistance Global Report on Surveillance 2014, resistance in E. coli to 
fluoroquinolones, broad-spectrum penicillins (e.g. ampicillin or amoxicillin) and third-
generation cephalosporins is widespread (WHO. 2014). Resistance to third-generation 
cephalosporins is mainly conferred by extended spectrum beta-lactamases (ESBLs) 
which destroy many beta-lactam antibacterial drugs. Carbapenems usually remain the 
only available treatment option for severe infections, as E. coli strains that have ESBLs 
are generally also resistant to several other antibacterial drugs. Moreover, carbapenem 
resistance in E. coli, mediated by metallo-betalactamases, which confer resistance to 
virtually all available beta-lactam antibacterial drugs, is a recently emerging medical 
threat (Menashe et al. 2001, Rawat and Nair 2010, Picozzi et al. 2013). Considering the 
limited therapeutic options for infections caused by some E. coli strains (Russo and 
Johnson 2006), research on developing effective vaccines and identifying risk factors in 
E. coli infections with an aim to prevent infections are ongoing. 
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1.3.5 Enterococcus faecalis 
Enterococcus faecalis is a non-motile, Gram-positive, facultatively anaerobic lactic acid 
bacterium of about 0.6-2.0 µm in size, that appear singly, in pairs and in short chains 
under the microscope (Leavis et al. 2006, Ch. Schroder et al. 2015). It tolerates a wide 
variety of growth conditions, including temperatures of 10°C to 45°C, hypotonic, 
hypertonic, acidic, or alkaline environments. Sodium azide and concentrated bile salts, 
which inhibit or kill most microorganisms, are tolerated by enterococci and used as 
selective agents in agar-based media (Huycke et al. 1998). Although all enterococci are 
usually considered strict fermenters because they lack a Kreb’s cycle and respiratory 
chain (Willett 1992), Ent. faecalis is an exception since, exogenous hemin can be used 
to produce cytochromes which provide a growth advantage to Ent. faecalis during 
aerobic growth (Pritchard and Wimpenny 1978, Brugna et al. 2010). Enterococci are 
usually catalase negative but some strains occasionally produce pseudocatalase.  
Ent. faecalis is normally a gut commensal and is found in many animals (from 
cockroaches to humans) and in the environment (Huycke et al. 1998). It is also a 
frequent cause of many serious human infections, including urinary tract infections, 
endocarditis, bacteremia, and wound infections alongside Ent. faecium (Rice et al. 1995, 
Huycke et al. 1998, Kau et al. 2005). Ent. faecalis causes a variety of healthcare 
associated infections (HCAIs) of which urinary tract infections are the most common, 
responsible for approximately 110,000 cases yearly (Huycke et al. 1998, Kau et al. 
2005). Enterococci are the second most common organisms recovered from catheter-
associated infections of the bloodstream and urinary tract, and from skin and soft-tissue 
infections in hospitals in the United States (Arias and Murray 2008, Hidron et al. 2008). 
Infections with Ent. faecalis can be especially troublesome to treat because of their 
frequent resistance to multiple antibiotics, including vancomycin, a drug of last resort 
for many Gram positive infections (Huycke et al. 1998). Enterococci are also relatively 
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impermeable to aminoglycosides, and the serum concentrations of aminoglycosides 
required for bactericidal activity are much higher than can be achieved safely in 
humans. However, the simultaneous use of a cell wall-active agent raises the 
permeability of the cell so that an intracellular bactericidal aminoglycoside 
concentration can be achieved without excessive toxicity (Baddour et al. 2005). 
Linezolid inhibits the growth of Ent. faecalis but quinupristin-dalfopristin (Synercid) 
does not because Ent. faecalis are intrinsically resistant to quinupristin-dalfopristin. Ent. 
faecalis are also often resistant to kanamycin and amikacin although many isolates still 
exhibit some susceptibility to ampicillin and penicillin. Surgery and cardiac valve 
replacement may be the only chance of cure in some patients with endocarditis resulting 
from enterococci for which there is no synergistic bactericidal combination (Baddour et 
al. 2005). 
Enterococci are intrinsically resistant to many antibiotics (Dunny et al. 1995, Huycke et 
al. 1998). Unlike acquired resistance and virulence traits, which are usually transposon 
or plasmid encoded, intrinsic resistance is based in chromosomal genes, which typically 
are nontransferrable. The first reports of strains resistant to penicillin began to appear in 
the 1980s (Bush et al. 1989, Sapico et al. 1989). Enterococci often acquire antibiotic 
resistance through exchange of resistance-encoding genes carried on conjugative 
transposons (Chavers et al. 2003). Detailed reviews on enterococcal resistance 
mechanisms are ample in literature (Arias and Murray 2012, Hollenbeck and Rice 2012, 
Kristich et al. 2014 ) (Figure 1.6). Vancomycin-resistant enterococci, VRE (Uttley et al. 
1989), in particular Ent. faecium, are often multidrug-resistant, however, vancomycin-
resistant Ent. faecalis are usually penicillin susceptible. Susceptibililty, intermediate 
level resistance and complete resistance to vancomycin are considered as MICs ≤ 4 
µg/ml, 8-16 µg/ml and >16 µg/ml respectively. Five phenotypes of vancomycin 
resistance VanA B, C, D and E in enterococci have been described (Chavers et al. 
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2003). VanA and VanB phenotypes are more clinically important and result from the 
acquisition of new genetic determinants of resistance carried on transposon Tn 1546 
(Cetinkaya et al. 2000). The genes encoding VanA and VanB are found primarily in 
Ent. faecium and some strains of Ent. faecalis. Infective Endocarditis (IE) cases are 
often caused by the VanA, B, or C phenotypes (Cetinkaya et al. 2000, Chavers et al. 
2003). The VanA phenotypes display a high-level of vancomycin resistance (MIC >64 
µg/ml) and teicoplanin resistance. The VanB phenotypes have intermediate to high-
level vancomycin resistance (MIC 4 to 1024 µg/ml) and susceptibility to teicoplanin, 
while and VanC phenotypes possess low to intermediate level Vancomycin resistance 
(MIC 2 to 32 µg/ml) (Chavers et al. 2003).  
 
 
Figure 1.6 Mechanisms of enterococcal antibiotic resistance. Source: (Arias and 
Murray 2012). Resistance of Ent. faecalis to the lipopetide daptomycin has been shown to 
involve altered interactions with the cell membrane and requires the membrane protein LiaF 
and enzymes involved in phospholipid metabolism, such as a member of the 




VRE are significant multidrug-resistant opportunistic pathogens in the hospital 
environment and the potential spread of enterococcal vancomycin resistance 
determinants to other species remains a concern (Chang et al. 2003). Wiser use of 
antimicrobial drugs, possibly guided by novel techniques for rapid microbiological 
diagnosis, and the nascent trend toward the development of narrower-spectrum 
antimicrobials may diminish some of the selective pressures favouring VRE. Continued 
development of new drugs by the pharmaceutical industry, aided by genomics, high-
throughput screening, rational drug design, and novel therapies offer the best prospect 
of effective bactericidal monotherapy for enterococci and long-term solutions to the 
problem of VRE (Eliopoulos and Gold 2001). 
1.4 Discovery of novel antimicrobials 
Antibiotic resistant strains of pathogens, often with multiple antibiotic resistance 
continue to emerge (House of Lords Select Committee for Science and Technology 
(HLSCST) 1998) and there is decreased discovery of novel antibiotics (Mollering 
1995). This means that the rate of loss of efficacy of old antibiotics is outstripping their 
replacement with new ones for many species of pathogenic bacteria (Hancock 2007). 
The traditional answer to the problem of antimicrobial resistance has been to introduce 
new antimicrobial agents and alternative treatments that kill the resistant mutants. 
Unfortunately, after more than 50 years of success, the pharmaceutical industry is now 
producing too few antibiotics, particularly against Gram-negative organisms to replace 
antibiotics that are no longer effective for many types of infections.  
Although analogues of existing antibiotic families kill resistant bacteria and prolong the 
life of each family for decades, this well of discovery will eventually dry out (Coates 
and Hu 2007). Therefore, the discovery of novel families of antimicrobials at regular 
intervals is important if modern medicine is to continue in its present form. This is 
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because growth on media has been an essential step to the development of antibiotics 
and to date, antibiotics such as streptomycin have been derived from bacteria that grow 
on artificial solid or liquid media. However, as most species of bacteria will not grow on 
artificial media (Diaz-Torres et al. 2006), antimicrobials are yet to be isolated from non-
culturable bacteria. Nevertheless, it is now possible to clone large fragments of non-
culturable bacterial genomes and to express them using recombinant DNA technology 
(Garcia Martin et al. 2006, Jones and Marchesi 2007, Lee et al. 2007) (Figure 1.7 below 
shows one method by which this can be achieved). Since the screening of whole 
bacteria against novel, natural and chemical compound libraries may produce new 
antibiotics, non-culturable bacteria such as those from the rumen may be an alternative 
source for novel compounds (Coates and Hu 2007). 
 
 
Figure 1.7 A method for screening non-culturable bacteria for novel compounds. 
The unfilled circle on the left of the diagram depicts the non-culturable bacterium. Within 
the circle is the smaller ring, which shows the bacterial genome with the thick black 
segment representing the coding region for synthesis of a novel antibiotic. The DNA of the 
coding region is extracted, inserted into a vector and this is transfected into a culturable 
bacterium or other host that expresses the antibiotic. Antibiotic biosynthesis often involves 
multiple pathways that are found on relatively large genomic segments of DNA, and 





1.5 Introduction to ruminants 
Herbivores play a central role in the survival and well-being of mankind. In addition to 
food, herbivorous animals are sources of clothing and motive power for transport and 
other activities of humans (Hobson and Stewart 1997, Russell and Rychlik 2001). The 
group of herbivores mostly used by humans are the ruminants (Russell and Rychlik 
2001). Ruminants of agricultural importance are mainly cattle, sheep, deer and goats, 
and of these, the most attention has been paid to the first two species. While humans 
and other animals have digestive systems with enzymes which digest animal and plant 
protein and lipids, plant sugars and some polysaccharides such as starches, they have 
poor mechanisms for digesting the much more abundant structural polysaccharides of 
plants: cellulose, hemicelluloses and pectins, all of which can be digested by ruminants 
(Balch 1959, Hungate 1966). Ruminant species occupy an important niche in 
agriculture because of their unique ability to digest roughages (plant cellulose, 
hemicellulose and pectins) (Bowen 2006, Brulc et al. 2009). The ruminant has three 
compartments in its digestive tract before the true gastric stomach (abomasum). These 





Figure 1.8 The digestive tract of a healthy adult ruminant showing the various 
compartments (reticulum, rumen, omasum, abomasum, small intestine, cecum, 
colon, and rectum). Source: (Russell 2000). 
 
1.5.1 The reticulum 
The reticulum is a flask-shaped compartment with a “honeycomb” appearance (Bowen 
2003, Visser 2005) (Figure 1.9). It sits underneath and towards the front of the rumen 
lying against the diaphragm. Ingesta flow freely between the reticulum and rumen, as 
they are only separated by a small muscular fold of tissue and are sometimes considered 
as one organ, referred to as the reticulorumen (Parish 2011). The main function of the 
reticulum is to collect smaller digesta particles and move them into the omasum while 
the larger particles remain in the rumen for further digestion (Parish 2011). The 
reticulum also causes the regurgitation of ingesta during rumination and acts as a 




Figure 1.9 Inside structures of the ruminant stomach. Showing (A), papillae lining 
of the rumen (B), honeycomb appearance of the reticulum (C), many folds- ‘manypiles’ 
of the omasum and (D), the abomasum (Source: (Correa 2007). 
 
1.5.2 The rumen 
The rumen resembles a large fermentation vat of 100 or more litres in volume in adult 
cattle and 10 litres in sheep (Hobson and Stewart 1997, Visser 2005, Bowen 2009). It 
hosts a large population of microorganisms, especially bacteria, ciliated protozoa and 
anaerobic fungi, which digest cellulose from plant cells (Hobson and Stewart 1997, 
Kamra 2005). The rumen environment is anaerobic and it is lined with papillae for 
nutrient absorption (Figure 1.9). The tissue of the rumen and the omasum absorb 
volatile fatty acids (VFAs), which are the by-products of microbial fermentation. Gases 
such as carbon dioxide, methane and hydrogen sulphide are also produced in the rumen. 
For optimum ruminal fermentation and fiber digestion, ruminal pH should lie between 
6.0 and 6.4, although, even in healthy cows, ruminal pH will fluctuate below this level 
for short periods during the day (Mutsvangwa and Wright 2012). The environment in 
the reticulorumen is however, weakly acidic and is populated by microbes that are 
adapted to a pH roughly between 5.5 and 6.5 (Dijkstra et al. 2005, Mutsvangwa and 
Wright 2012). Also, in normal conditions, the ruminal milieu is anaerobic (as any 
ingested oxygen is quickly scavenged) with a markedly negative redox potential, 
reflecting the absence of oxygen and a strong reducing power (Marden et al. 2005). 
1.5.3 The omasum 
The Omasum or “manyplies”, so called because it contains numerous tissue leaves 
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(laminae) that help grind digesta (Parish 2011) (Figure 1.9), is spherical in shape and is 
situated to the right side of the abdomen (Balch 1959, Nickel et al. 1987). Water and 
short-chain fatty acids absorption occurs in the omasum and the folds assist in the 
removal of fluid from the digesta on their way to the abomasum (Dirksen 1990). The 
omasum also serves to filter large particles which return to the rumen for further 
digestion (Hungate 1988). 
1.5.4 The abomasum 
The abomasum is the “true stomach” of a ruminant and corresponds to the gastric 
stomach of non-ruminants (Figure 1.9). It secretes hydrochloric acid and other digestive 
enzymes, which aid in digestion. The low pH in the abomasum (ranges from 2.0 to 4.0) 
facilitates initial protein breakdown and kills the microorganisms, which have spilled 
over from the rumen (Visser 2005, Parish 2011). 
1.6 The rumen microbial ecosystem 
In young ruminants, small pieces of vegetation together with some milk enter the 
developing rumen through contact from the mother and surroundings and become 
substrates for microbes (Hobson and Stewart 1997). The rumen is subject to continuous 
inoculation with microorganisms of many different kinds, from many sources (Hungate 
1966). The rumen inoculum can be provided by airborne transfer from nearby adult 
animals or implements and clothing of farm workers moving between areas of young 
and old stock, from saliva and faeces of mother and other animals in the group, and 
contaminated vegetation (Hungate 1988). It is possible to isolate many species of 
microorganism from the rumen. However, many of these will be in very low numbers 
and merely passing through the rumen and dying off, as they may not be adapted for life 
in the rumen. On the other hand, others will be ‘true’ rumen organisms and will replace 
dying components of the rumen flora and contribute to the ‘dynamic steady state’ of the 
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rumen population (Stewart et al. 1992, Odenyo et al. 1994, Hobson and Stewart 1997, 
Kamra 2005). 
The efficiency of ruminants to utilize such a wide variety of feeds is due to the highly 

















) (Hespell et al. 
1987, Klieve and Bauchop 1988, Hobson and Stewart 1997, Sylvester et al. 2004, 
Wright and Klieve 2011). Nonetheless, this is not a true representation of the number of 
rumen microbes as many of them are non-culturable. In one study (Edwards et al. 
2004), only 11% of the bacterial diversity was represented by cultured isolates, and of 
the 11%, not all of the representative cultured isolates were of ruminal origin. Microbial 
population numbers and composition are affected by a number of factors of which diet 
is probably the most important. Smaller numbers of facultative anaerobic bacteria, 
flagellate protozoa and mycoplasmas are also believed to be present but their 
contribution to the overall fermentation is considered minimal (Dehority and Orpin 
1997). 
The net result of the reactions carried out by the complex microbiome of the rumen is 
the bioconversion of feed into such form as is utilizable by the animal as a source of 
energy e.g. microbial protein, short chain volatile fatty acids including acetic, propionic 
and butyric acids and gases such as methane and carbon dioxide (Kamra 2005, Brulc et 
al. 2009).  
1.6.1 Rumen bacteria 
Based on standard physiological characteristics, the microbial ecosystem of the rumen 
typically harbours representatives of several divergent taxonomic groupings of bacteria, 
which are active in the degradation of feed components (Stewart et al. 1992, Krause and 
Russell 1996, Kamra 2005). Strictly anaerobic techniques and habitat simulating media 
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have been used to isolate a variety of bacteria from the rumen (Hungate 1944, Hungate 
1950, Hungate 1969, Dehority et al. 1989). More recently, ruminal bacteria have been 
re-evaluated with newer more objective methods of classification (Krause and Russell 
1996, Deng et al. 2008). It is not yet possible to clearly answer the question of how 
many rumen bacterial species there are (Krause and Russell 1996), however, knowledge 
of evolutionary conservation of 16S/18S ribosomal RNA (rRNA) and their encoding 
genes (rDNA) (Pace et al. 1986, Wheelis et al. 1992, Raskin et al. 1997) has facilitated 
the use of modern molecular techniques to enumerate microbes. Molecular 
characterisation and classification scheme, which predict natural evolutionary 
relationships without cultivating the organisms is now possible (Mackie et al. 2000). 
The wide range of aerobic, facultative and anaerobic organisms found especially in 
young ruminants have been reviewed (Bryant et al. 1958, Hungate 1966, Jayne-
Williams 1979, Stewart et al. 1988). Anaerobic species found in relatively large 
numbers include Bifidobacterium sp. (Scardovi 1981), Peptostreptococcus sp. (Bryant 
et al. 1958, Jayne-Williams 1979), Propionibacterium acnes (Gutierrez 1953) and many 
clostridia and Bacteriodes. Alysiella filiformis is a strict aerobe found on rumen 
epithelia of young lambs (Mueller et al. 1984). It is more commonly found in the buccal 
cavity, but can occasionally establish on the rumen epithelium as a transient colonizer 
(Mueller et al. 1984, Mueller et al. 1984). Other aerobic organisms isolated from the 
rumen are P. aeruginosa, Micrococcus varians, Alkaligenes faecalis, Flavobacterium 
spp. and several spore-forming Bacillus species. Staphylococci and streptococci are the 
genera of facultative anaerobes most frequently found in the rumen. Others include Ent. 
faecium. Coliforms are also present in low numbers. 
Rumen bacteria vary greatly in their substrate specificity. Some, such as, Ruminobacter 
amylophilus and Fibrobacter succinogenes are specialists, which utilize mainly starch 
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or its degradation products, and cellulose or its breakdown products respectively 
(Russell et al. 2009, Wanapat and Cherdthong 2009). Others like strains of Butyrivibrio 
fibrisolvens are generalists, which hydrolyse a range of substrates including starch, 
cellulose, xylan and pectin. Others like Selenomonas ruminantium can only utilize 
hydrolysis products, being unable to hydrolyse many polymers. Oxalobacter formigenes 
obtains energy from the reduction of oxalate. Tables 1.3 to 1.5 show the main 
characteristics of predominant rumen bacteria. 
However, the functionality of most rumen bacteria is not known because most of them 
cannot be grown in the laboratory. It is estimated that only about 15- 20% of rumen 
microbes have been identified and characterised to date using conventional culturing 
and microscopy (Sirohi et al. 2012), and although large numbers of bacterial operation 
taxonomic units (OTUs) have been identified by ribosomal RNA gene (rrn) sequences, 
more species-level OTUs remain to be identified (Kim et al. 2011). It has also been 
shown that the diversity of estimates for all bacterial groups in the rumen are much 
greater than previously suggested (Edwards et al. 2004, Yu et al. 2006, Kim et al. 2011). 
Moreover, in another study (Kim et al. 2011), it was concluded that to achieve 99.9% 
coverage at species level, at least 78218 bacterial sequences would be needed in 
















Table 1.3 Bacterial diversity of the rumen microbial ecosystem of domestic and 
wild animals (Adapted from (Kamra 2005)). 
Substrate Bacteria 





F. succinogenes, Ruminococcus flavefaciens, R. albus, 
Clostridium cellobioparum, C. longisporum, C. lochheadii, 
Eubacterium cellulosolvens  
 




Streptococcus bovis, Rum. Amylophilus, Prev. ruminicola  
Sugars/dextrins 
 
Succinivibrio dextrinosolvens  Succ. amylolytica  
Sele. ruminantium , Lactobacillus acidophilus, L. casei,  
L. fermentum,, L. plantarum, L. brevis,, L. helveticus 
Bifidobacterium globosum, B. longum,, B. thermophilum 
B. ruminale,  B. ruminantium  
 
Pectin Treponema saccharophilum, Lachnospira multiparus  
 





Prev. ruminicola, Rum. amylophilus, C. bifermentans 







M. elsdenii, Wollinella succinogenes, Veillonella gazogenes, 
Oxal. formigenes, Desulphovibrio desulphuricans, 
Desulphatomaculum ruminis, Succiniclasticum ruminis 
 
Lipolytic bacteria Anaerovibrio lipolytica  
 
Acetogenic bacteria  
 
Eub. limosum,  Acetitomaculum ruminis 
 
Tannin degraders  
 

















Table 1.4. Fermentation characteristics of some rumen cocci. Source: (Hobson and Stewart 1997). Abbreviations: A, acetate; B, n-
butyrate; F, formate; iB, isobutyrate; iV, isolvalerate; L, lactate; P, propionate; S, succinate; V, n-valerate +, positive reaction; -, negative reaction; d, reaction 













1.6.2 Rumen protozoa 
Rumen protozoa represent a substantial part of the rumen microbial population, 
contributing up to 50% of the total microbial biomass (Williams and Coleman 1992). 
Rumen protozoa were detected in domestic ruminants (Gruby and Delafond 1843) in 
the early nineteenth century. However, due to highly specific growth requirements and 
their complex morphology, our understanding of the role of protozoa in rumen 
fermentation is still limited. Ciliate protozoa in the rumen are classified on the basis of 
the micro- and macronucleus, the presence and morphology of exterior spines, lobes or 
internal skeletal plates and the shape and size of cells (Dogiel 1927, Ogimoto and Imai 
1981, Williams and Coleman 1992). Based on such morphological characteristics a 
large number of genera and species have been described, but it is not clear to what 
extent these represent true species (Regensbogenova et al. 2004, Regensbogenova et al. 
2004) and the validity of these observations has been questioned, because many of the 
‘species’ described exhibit a substantial morphological plasticity (Dehority 1994).  
The most prevalent protozoa of the rumen are the ciliated protozoa (Williams and 
Coleman 1997). Although flagellates like Trichomonas spp., Monoceromonas sp. and 
Chilomastix sp., have been reported, their status as “true” rumen residents is disputed 
because almost nothing is known of their metabolism (Jensen and Hammond 1964). The 
ciliate protozoa of the rumen have been classified into two groups, i.e. holotrich and 
entodiniomorphid protozoa (depending on their morphological characteristics), both of 
which belong to the subclass Trichostomatia (Hungate 1966). Ruminal holotrichs are 
represented by 15 different genera of ciliate protozoa that are classified within two 
separate taxonomic orders (Isotrichidae and Buetschliidae) (Williams and Coleman 




Figure 1.10 Phylogenic tree summarizing the major groups of rumen ciliate 
protozoa.  
The enzymatic profile of holotrich protozoa indicates that they have amylase, invertase, 
pectin, esterase and polygalacturonase in sufficiently large quantities. These degrade 
pectin, which is an insoluble carbohydrate to enable utilisation of starch and soluble 
sugars as energy sources (Mould and Thomas 1958, Abou Akkada and Howard 1961, 
Bailey and Howard 1963, Williams 1979). Hemi-cellulases and cellulases have also 
been reported but in considerably lower levels compared to those present in 
entodiniomorphid protozoa (Mould and Thomas 1958, Abou Akkada and Howard 1961, 
Bailey and Howard 1963, Williams 1979, Williams and Coleman 1985). 
Entodiniomorphid protozoa also contain proteolytic enzymes and amino acid degraders 
(Abou Akkada and Howard 1961, Williams and Coleman 1992). A tryptophanase has 
























1.6.3 Rumen anaerobic fungi 
Yeasts and anaerobic fungi have long been recognized as typical inhabitants of the 
rumen. Flagellated anaerobic fungal zoospores were observed as early as 1910, but were 
mistakenly thought to be flagellate protozoa. These ‘flagellates’ were identified as fungi 
for the first time by (Orpin 1975) following new culture methods (Jensen and Hammond 
1964), and were named as Neocallimastix frontalis. N. frontalis zoospores grew into 
mycelia which turned into a reproductive stage of rhizoids bearing zoosporangium. N. 
frontalis was confirmed to be a true fungus by the presence of chitin in its cell wall 
(Orpin 1977), and was the first strictly anaerobic fungus to ever be described. Several 
strains of anaerobic fungi have been reported in the rumen of different ruminants 
(Kamra 2005, Liggenstoffer et al. 2010). However, only six genera and 20 species of 
anaerobic fungi have been described, mainly on the basis of their morphological 
characteristics: Anaeromyces, Caecomyces, Cyllamyces, Neocallimastix, Orpinomyces 
and Piromyces (Griffith et al. 2009, Kittelmann et al. 2012). Two new genera 
Oontomyces and Buwchfawromyces have been identified in more recent studies 
(Callaghan et al. 2015, Dagar et al. 2015). 
The anaerobic fungi found in the rumen play an active role in fiber degradation as 
evidenced by the presence of different fiber degrading enzymes including glycoside 
hydrolases, cellulases, xylanases, and esterases (Williams and Orpin 1987, Teunissen 
and Op den Camp 1993, Wubah et al. 1993, Paul et al. 2003). Fungi have also been 
shown to attach to the most lignified tissue of plant feed material (Akin and Rigsby 
1987). 
1.6.4 Rumen archaea 
Rumen archaea are strictly anaerobic methanogens which make up between 0.3 and 
3.3% of the rumen microbiome. The methanogens in the rumen are found free in the 
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rumen fluid, attached to particulate material, rumen epithelia and rumen protozoa 
(Janssen and Kirs 2008). There is also evidence that methanogens attach to anaerobic 
fungi (Jin et al. 2011). Methanogens that have been cultured from the rumen are 
assigned to seven species, i.e. Methanobacterium formicicum, Me. bryantii, 
Methanobrevibacter ruminantium, Met. millerae, Met. olleyae, Methanomicrobium 
mobile, Methanoculleus olentangyi (Paynter and Hungate 1968, Jarvis et al. 2000, Rea 
et al. 2007), although Methanosarcina spp. and Met. smithii have also been reported 
(Joblin et al. 1990, Joblin 2005). 
The mixed microbial community ferments a large part of the incoming feed to volatile 
fatty acids (VFAs), NH4
+
, CO2, and H2. Some of these end products are metabolized by 
the methanogens, most notably CO2, and H2 (Janssen and Kirs 2008). Efficient H2 
removal leads to an increased rate of fermentation by eliminating the inhibitory effect of 
H2 on the microbial fermentation (Hungate 1967, Wolin 1979, McAllister and Newbold 
2008). Therefore, although methanogenic archaea make up only a small part of the 
rumen microbes, they play an important role in rumen function and nutrition (Kamra 
2005, Janssen and Kirs 2008). 
1.7 Rumen Microbial Interactions 
A number of studies have been conducted on the interrelationships between rumen 
fungi, bacteria and protozoa (Dehority and Tirabasso 2000), and regardless of the 
complicated interrelationships between them, bacteria are believed to play a major role 
because of their numerical predominance and metabolic diversity (Windham and Akin 
1984, Akin and Benner 1988, Cheng 1999). The role and importance of anaerobic fungi 
in the overall rumen fermentation remains a major question to be answered in spite of 
their unique ability to degrade the more resistant plant cell wall (Orpin 1994, Orpin 
1997). A more recent analysis of muskoxen rumen metatranscriptome resulted in a 
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much higher percentage of cellulase enzyme discovery and an 8.7x higher rate of total 
carbohydrate active enzyme discovery per gigabase of sequence than previous rumen 
metagenomes (Qi et al. 2011). This study provided a snapshot of eukaryotic gene 
expression in the muskoxen rumen, and identified a number of candidate genes coding 
for potentially valuable lignocellulolytic enzymes (Qi et al. 2011). 
The synergism and antagonism among the different groups of microbes that make up 
the cellulolytic biofilms in the rumen is so diverse and complicated that it is difficult to 
quantify the role played by particular groups, however, the net result of these reactions 
is the fermentation of cellulose and other plant material in the rumen (Stewart 1999, Lee 
et al. 2000, Kamra 2005). A consequence of this high level of diversity and population 
density of rumen microbes is increased opportunity for interaction between cells and 
presumably, intense competition between many organisms with similar phenotypes but 
different genotypes (Teather 1999). The fact that the rumen is a contained environment, 
with significant levels of mixing, means that there is opportunity for both direct and 
indirect interactions between all parts of the microbial population, and according to 
(Wolin et al. 1997), these metabolic interactions are essential for sustaining the 
microbial community and its collective activities. In general, interactions can be either 
positive or negative within and between microbial types. These associations have been 
described in three terms: mutualism, commensalism and parasitism (Prins 1975). Some 
of the interactions that have been observed in the rumen are discussed below.  
1.7.1 Protozoal interactions 
1.7.1.1 Protozoa-bacteria interactions 
The most obvious interaction between the ruminal ciliate and bacteria is a predator- 
prey relationship, although symbioses and parasitism have been exemplified (Williams 
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et al. 1993, Williams and Lloyd 1993). Gutierrez and workers first recognized predation 
of rumen bacteria by rumen ciliate protozoa (Gutierrez 1955, Gutierrez and Hungate 
1957, Gutierrez 1959). Predation does not appear to be species-specific and is more a 
function of bacterial concentration. Bacteria attached to fiber, i.e. cellulolytic and 
hemicellulolytic species are an exception as they may be less likely ingested by 
protozoa (Prins 1991). Bacteria constitute the main source of nitrogenous compounds 
for protozoal growth. The proportions of bacterial species present and the overall size of 
the bacterial population can be 50-90% lower in faunated animals than in ciliate free 
animals (Williams and Coleman 1997). Defaunation improves the efficiency of net 
microbial synthesis in the rumen and increases the flow of microbial protein to the small 
intestines (Jouany 1989). Axenic bacterial-free cultures of rumen protozoa have not 
been established and so the protozoa must be considered as parasitic. The bacteria can 
function in the absence of protozoa, but the converse does not appear to be true 
(Dehority 1998). 
1.7.1.2 Protozoa-protozoa interactions 
The best-known interaction between rumen protozoa is predation of one ciliate species 
by another (Eadie 1962, Eadie 1967). Predation by species of Diplodinium, 
Elytroplastron, Enoploplastron, Entodinium, Metadinium, Ostracodinium, and 
Polyplastron on other rumen ciliates and cannibalistic predation by P. multivesiculatum 
have been reported (Williams and Coleman 1992). Polyplastron requires the presence of 
Epidinium for growth in vitro, as it appears to be a food source (Coleman 1972, 
Coleman and J. 1978). They are engulfed and can be replaced by species of 
Diplodiniinae but not Entodinia. Entodinium bursa also has an obligate requirement for 
the spineless form of Entodinium caudatum. The engulfed protozoa are digested and are 
an important source of protein (Williams and Coleman 1992).     
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1.7.1.3 Protozoa-fungi interactions 
The evidence for predation of fungi by protozoa in co-cultures is variable. Defaunation 
either led to increase (Orpin 1977, Soetanto et al. 1985, Romulo et al. 1986) or no 
significant effect on fungal densities (Jouany 1989, Williams and Withers 1991, 
Williams and Withers 1993). Ruminal ciliates reduced N. patriciarum 
carboxymethylcelluase activity, while the cellulolytic activity per unit biomass of 
Piromyces sp. increased in the presence of ruminal ciliates (Morgavi et al. 1994, 
Widyastuti et al. 1995). In another study, combined cell-free lysates of N. frontalis and 
individual ciliates exhibited enhanced hemicellulolytic activity, whereas the activities of 
some cellulolytic enzymes were reduced in the presence of Entodinium spp. (Williams 
et al. 1993). However, studies in vitro have confirmed protozoal predation of fungal 
rhizoids (Joblin 1990). Scanning electron microscopy also clearly showed that 
Polyplastron multivesiculatum, Eudiplodinium maggii and Entodinium spp. are able to 
ingest fungal rhizoids and sporangia (Williams and Coleman 1992, Williams et al. 1993, 
Williams and Lloyd 1993, Williams et al. 1994). 
1.7 2 Bacterial interactions 
1.7.2.1 Bacteria-fungi interactions 
Anaerobic fungi, through their penetration and degradation of plant tissue and their 
production of hydrogen (H2), may actively shape the remainder of the microbial 
community, such as bacteria, archaea, and ciliate protozoa. Methanogens in turn use the 
H2 produced by fungi, and stable co-cultures of fungi and methanogens have been 
successfully established in vitro (Bauchop and Mountfort 1981, Mountfort et al. 1982, 
Fonty et al. 1988). Fungi are also involved in cross feeding by releasing sugars and 
other metabolites, which serve as energy sources for bacterial species. They may also 
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depend on bacteria to supply their nutritional requirements of B vitamins and amino 
acids (Williams et al. 1994, Theodorou et al. 1996).   
In addition, although anaerobic fungi are very actively cellulolytic when grown in pure 
culture, they have been shown to be less active in mixed cultures with cellulolytic 
bacteria. Some cellulolytic bacteria including strains of R. flavefaciens and R. albus 
have been shown to produce soluble proteins that inhibit cellulolysis by growing fungi 
(Stewart et al. 1992, Bernalier et al. 1993). A chitinolytic bacterium similar to C. 
tertium has also been reported to inhibit cellulolysis in several types of anaerobic fungi 
by expressing chitinases (Kopecny et al. 1996). 
1.7.2.2 Bacteria-Bacteria interactions 
Interactions between bacterial species can be positive i.e. synergism and cross-feeding 
or negative, i.e. production of compounds inhibitory to other bacterial species (Dehority 
1998). Positive interactions, which have been observed, include the marked synergism 
in digestion of structural carbohydrates (Dehority and Scott 1967). Studies on the major 
cellulolytic species, F. succinogenes, R. albus and R. flavefaciens show that they 
effectively digest cellulose alone with no increases observed when any two were 
combined in the same fermentation. However, when the non-cellulolytic organism Prev. 
ruminicola was combined with any of the cellulolytic species, digestion was increased 
(Dehority and Scott 1967). Synergism between F. succinogenes and Prev. ruminicola 
enhanced activity against purified pectin (38% increase), whereas, neither of these 
organisms have previously shown much activity against pectin (Osborne and Dehority 
1989). Combining a hemicellulose degrading but non-utilizing cellulolytic species with 
a non-degrading but utilizing hemicellulolytic species results in extensive hemicellulose 
digestion from intact forage (Coen and Dehority 1970, Morris and Vangylswyk 1980, 
Osborne and Dehority 1989, Dehority 1993). On the other hand, it has also been 
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observed that some co-culture combinations reduced the extent of digestion. Decreases 
in forage degradation have been observed between F. succinogenes and R. flavefaciens 
(Saluzzi et al. 1993) when simultaneously present in a fermentation medium and 
between R. albus and R. flavefaciens (Odenyo et al. 1994). 
Other positive interactions include cross feeding of hydrolysis products, utilization of 
end products and essential nutrients. For example, non-cellulolytic bacteria can utilize 
cello- dextrins produced by cellulolytic species (Russell 1985). Increase in xylan 
utilization has been observed when R. flavefaciens was co-cultured with Met. smithii 
(Williams et al. 1994). Production of nutrients by one species, which is essential for the 
growth of another species also occurs in the rumen (Wolin et al. 1997). 
1.8 Introduction to antimicrobial peptides 
Antimicrobial peptides (AMPs) are an integral part of the innate host defence system of 
many organisms including vertebrates, invertebrates, plants and bacteria (Wiesner and 
Vilcinskas 2010), with broad spectrum activity against several groups of organisms 
including bacteria, fungi, viruses and parasites (Jenssen et al. 2006). Due to this, AMPs 
represent one of the most promising new sources of antibiotics and future strategies for 
defeating the threat of antimicrobial resistance in bacterial infections (Hancock 1997). 
Bacteriocins (briefly discussed in section 1.9) were among the first antimicrobial 
peptides to be isolated and characterized (Gratia 1925). This was followed by the 
discovery of gramicidins and polymyxins (including Polymyxin B and Colistin) in 1939 
and 1960 respectively (Dubos 1939, Dubos 1939, Wright and Welch 1960). These early 
antimicrobial peptides tended to be cytotoxic and the availability of alternative agents 
against pneumococci infections limited their usage as injectables (Hancock 1997). 
AMPs have also been referred to as anionic antimicrobial proteins/peptides, cationic 
host defence peptides, cationic amphipathic peptides, α-helical antimicrobial peptides 
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and cationic AMPs (Groenink et al. 1999, Bradshaw 2003, Brown and Hancock 2006, 
Harris et al. 2009, Huang et al. 2010, Riedl et al. 2011). Many AMPs have been 
discovered or synthesized to date. There are 2544 (250 bacteriocins from bacteria, 2 
from archaea, 7 from protists, 13 from fungi, 317 from plants, and 1915 from animals) 
and 5547 AMPs (3904 natural and 1643 synthetic) in the antimicrobial peptide database 
(APD2) and LAMP- a database linking antimicrobial peptides (Wang et al. 2009, Zhao 
et al. 2013). The biophysical and structural characteristics of AMPs play an important 
role in their activity against pathogenic bacteria. These include secondary structure, 
charge, amphipathicity and hydrophobicity. The individual importance of these 
parameters are difficult to determine as they all influence each other, however, some 
general trends have emerged from studies with model peptides (Zhao 2003, Cirac 
2011). Antibacterial peptides are the most studied AMPs to date and most of them are 
cationic AMPs (Bahar and Ren 2013).  
Cationic AMPs are generally defined as peptides of up to 50 and less than 100 amino 
acids in residues with a net positive charge of +2 to +9 at neutral pH owing to the 
presence of multiple basic amino acids, lysine (K) and arginine (R) (and of modified 
amino acid residues for the bacterially produced lantibiotics and polymyxins) over 
acidic residues and a substantial portion (≥30% or more) of hydrophilic amino acid 
residues (Hancock 1997, Hancock and Chapple 1999, Powers and Hancock 2003, 
Giuliani et al. 2007). Another common trait shared by cationic peptides is their ability to 
fold into either amphipathic or amphiphilic conformations (have both a hydrophobic 
face comprising non-polar amino acid side chains and a hydrophilic face of polar and 
positively charged residues), induced by interaction with bacterial membranes or 
membrane mimics (Powers and Hancock 2003). Cationic peptides not only have 
antimicrobial activities against Gram positive and Gram negative bacteria but have also 
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been shown to have activity against fungi, protozoa, viruses, and have anticancer and 
immunomodulatory properties (Baker et al. 1993, Aley et al. 1994, Mohammad et al. 
1995, Scott et al. 1999, Johnstone et al. 2000, Wong et al. 2013).  
Cationic peptides rarely have the exceptionally high in vitro antimicrobial activities 
demonstrated with some conventional antibiotics against selected bacteria (Piers et al. 
1994, Gough et al. 1996). Some AMPs do however, have minimum inhibitory 
concentrations (MIC) in the range 1-8 µg/mL that are competitive with those found for 
even the most potent antibiotics against resistant organisms (such as P. aeruginosa, A. 
baumanii, Stenotrophomonas maltophilia, methicillin resistant S. aureus, vancomycin-
resistant enterococci, extended spectrum 6-lactamase-producing E. coli, and multiple-
antibiotic-resistant Gram negative bacteria (Hancock 1997). These peptides, at 
concentrations around the MIC, kill bacteria much more quickly than conventional 
antibiotics do, an observation that has been ascribed to their mode of action. Some 
naturally resistant bacteria e.g. Burkholderia cepacia and Serratia marcescens exist by 
virtue of a non-interactive outer membrane and production of specific proteases, 
respectively (Hancock 1997). However, AMP MICs against clinically antibiotic 
resistant and clinically susceptible strains of a given species do not vary greatly and 
most cationic peptides do not induce resistant mutants even after as many as 20 
passages on an antibiotic concentration close to the MIC (Hancock 1997). 
1.8.1 Mode of action of cationic AMPs 
Due to the renewed interest in AMPs as therapeutic alternatives, the mode of action of 
AMPs is extensively being studied. These studies have indicated that all antimicrobial 
peptides interact with membranes and tend to divide peptides into two mechanistic 
classes: membrane disruptive and non-membrane disruptive (Hwang and Vogel 1998, 
Oren and Shai 1998, Epand and Vogel 1999, Hancock and Chapple 1999, Shai 1999, 
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Hancock and Rozek 2002, Zasloff 2002, Huang 2006). However, there is evidence that 
AMPs can act in alternative ways by inhibiting several cellular processes such as cell 
wall synthesis, enzymatic activity, macromolecular synthesis (nucleic acid and protein 
synthesis) and that the action responsible for killing bacteria at the minimal effective 
concentration varies from peptide to peptide and from bacterium to bacterium (Lehrer et 
al. 1989, Yonezawa et al. 1992, Kragol et al. 2001, Patrzykat et al. 2002, Yeaman and 
Yount 2003, Brogden 2005, Hancock and Sahl 2006, Jenssen et al. 2006, Nicolas 2009). 
In order to explain the mechanism of action of AMPs against bacteria, the morphology 
of the bacterial cell must be taken into account. The rigid structure of the bacterial cell 
wall provides strength and shape and protects the cell from changes in its environment. 
The differences in the composition of bacterial cell wall also determines mode of action 
of AMPs (Figure 1.11 illustrates the molecular basis of cell selectivity in different cell 
types). Whereas, Gram positive bacteria cell wall is composed of a peptidoglycan layer 
and a single cytoplasmic bilayer, the Gram negative cell wall is composed of two 
bilayers, an outer negatively charged lipopolysaccharide (LPS) -phospholipid molecule 




 and an inner single 
cytoplasmic membrane. One of the most interesting properties of AMPs is their cell 
selectivity for prokaryotic over mammalian membranes. Lower affinity of AMPs can be 
explained by the zwitterionic (neutral) phospholipids which make up outer membranes 
of mammalian cells (Matsuzaki 2009, Melo et al. 2009). The strong presence of 
membrane stabilizing sterols also protects mammalian cells and makes them less 




Figure 1.11 Molecular basis of cell selectivity of AMPs. AMPs form amphipathic 
structures with a positively charged face (blue) and a hydrophobic face (brown). 
Electrostatic interaction between the positive charges of AMPs and negatively charged 
components (red) at the mammalian cell surface (left) and bacterial surface (right) is the 
major driving force for cellular association. Source: (Matsuzaki 2009). 
 
The mechanism of action against Gram
 
negatives is better studied. The initial 
association of peptides with the bacterial membranes occurs through electrostatic 
interactions between the cationic peptide and the anionic LPS in the outer membrane of 
Gram
 
negative bacteria and wall-associated teichoic acids in Gram
 
positive bacteria 
leading to perturbation of the membrane. Since cationic peptides have higher affinity for 
the LPS than divalent cations (Hancock and Chapple 1999), cationic peptides displace 
these divalent cations and cause a local disturbance in the outer membrane, which 
facilitates the formation of destabilized areas through which the peptide translocates the 
outer membrane in a process termed self-promoted uptake (Hancock 1997, Hancock 
2001) (Figure 1.12). The peptides then associate with the outer monolayer of the 
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cytoplasmic membrane. It is at this point that membrane disruptive and non-membrane 
disruptive mechanisms diverge, depending on whether this reorientation leads to 
perturbation of the integrity of the cytoplasmic membrane or peptide translocation into 
the cytoplasm (Powers and Hancock 2003). Membrane disruptive peptides are generally 
reported to be of the α-helical structural class although, not all α-helical peptides are 
membrane disruptive (Park et al. 1998, Friedrich et al. 2001, Patrzykat et al. 2002). 
 
 
Figure 1.12 Self-promoted uptake of cationic peptides across the outer membrane.  
Unfolded cationic peptides are proposed to associate with the negatively charged (mainly due to 
the presence of highly anionic lipopolysaccharide [LPS]) surface of the outer membrane. They 
then either neutralise the charge over a patch of outer membrane, creating cracks through which 
the peptide can cross the outer membrane (a) or actually bind to the divalent cation binding sites 
on lipopolysaccharide, and disrupt the membrane (b). Once the peptide has crossed the outer 
membrane, it will interact with the negatively charged surface of the cytoplasmic membrane. 
Source: (Hancock 2001). 
  
Several AMP membrane interaction and disruption models have been developed to 
explain membrane disruption. The most prominent mechanistic models include the 





Figure 1.13 Mechanisms of AMP-mediated membrane disruption (a) barel-stave 
model, (b) carpet model (c) micellar aggregate (toroidal pore) model. Source: (Melo et al. 
2009). 
 
1.8.1.1 Barrel-stave model 
In the barrel-stave model, the amphipathic peptides reorient perpendicular to the 
membrane and align (like the staves in a barrel) in a manner in which the hydrophobic 
sidechains face outwards into the lipid environment while the polar sidechains align 
inward to form transmembrane pores. Progressive recruitment of additional peptide 
monomers leads to a steadily increasing pore size proposed to allow leakage of 
cytoplasmic components and also disrupt the membrane potential (Ehrenstein and Lecar 




hydrophobic core of the membrane without inserting the polar groups of the lipid. 
Pardaxin, alamethicin and Gramicidin S have been shown to kill bacteria using this 
model (Rapaport and Shai 1991, Sansom 1993, Yang et al. 2001, Zhang et al. 2001). 
The major argument against this model is the lack of preferred stoichiometries for the 
“pores” as demonstrated by the wide variability in conductance increases induced by 
peptides in model membranes (Wu et al. 1999). 
1.8.1.2 Carpet model 
In the alternative carpet model (Pouny et al. 1992), the peptides do not insert into the 
membrane but align parallel to the bilayer through a relatively diffuse manner (‘carpet-
like’ cluster of peptides), remaining in contact with the lipid head groups and effectively 
coating the surrounding area. This orientation leads to a local disturbance in membrane 
stability, causing the formation of large cracks, leakage of cytoplasmic components, 
disruption of the membrane potential and, ultimately, disintegration of the membrane 
(breakage into pieces and lysis of the microbial cell when a threshold concentration of 
peptide is reached) (Oren and Shai 1998). This model has been used to describe the 
mode of action of antimicrobial peptides, such as dermaseptin and its natural analogues, 
cecropins, and the human antimicrobial peptide LL-37 (Pouny et al. 1992, Gazit et al. 
1995, Ghosh et al. 1997, Oren et al. 1999). 
1.8.1.3 Micellar aggregate model 
The alternative micellar aggregate model (Matsuzaki et al. 1997, Hancock and Chapple 
1999) suggests that the peptides reorient and associate in an informal membrane-
spanning micellar or aggregate-like arrangement and further indicates that collapse of 
these micellar aggregates can explain translocation into the cytoplasm. After binding to 
the phospholipid head groups, the peptides insert into the membrane and then cluster 
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into unstructured aggregates that span the membrane. These aggregates are proposed to 
have water molecules associated with them providing channels for leakage of ions and 
possibly larger molecules through the membrane. This model essentially differs from 
the other two, in that, only short-lived transmembrane clusters of an undefined nature 
are formed (informal channels with a variety of sizes), which allow the peptides to cross 
the membrane without causing significant membrane depolarization, and once inside the 
cell, the peptides exert their killing activities on intracellular targets. AMPs melittin, 
magainin and LL-37 have been proposed to exert this mechanism (Brogden 2005, 
Jenssen et al. 2006, Leontiadou et al. 2006, Sengupta et al. 2008). 
Regardless of which model is correct, the net result of membrane disruption would be 
the rapid depolarization of the bacterial cell leading to rapid cell death, with total killing 
occurring within 5 minutes for the most active peptides (Friedrich et al. 1999). 
Membrane depolarization however, is not a lethal event per se, and in the absence of 
evidence of a catastrophic collapse of cytoplasmic membrane integrity, the specific way 
in which membrane disruption results in cell death is yet to be determined (Powers and 
Hancock 2003). Any of the above models might be correct depending on the peptide 
examined, such that certain peptides may function through a barrel-stave mechanism, 
while others may function through a micellar aggregate or carpet mechanism.  
1.8.2 Classification of cationic AMPs 
The vast diversity of these AMPs which arise from their antimicrobial function and the 
different pathogenic microbe challenges they face in each host organism (Hancock and 
Sahl 2006) makes it difficult to classify them. They can be classified according to their 
biosynthesis pathway (as non-ribosomally synthesised (Mootz and Marahiel 1997, Konz 
and Marahiel 1999) and ribosomally synthesised peptides (Nissen-Meyer and Nes 
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1997)). They can also be classified according to their secondary structures, source, type 
of and predominant amino acid residues (as defensins, histatins, cathelicidins 
lantibiotics, and peptaibols (Klaenhammer 1993, Franklin et al. 1994, Van Den Hooven 
et al. 1996, Hwang and Vogel 1998, Ganz 2003, Zanetti 2004)). For ease, they are 
broadly classified into four major groups: α-helical, β-sheet, loop and extended peptides 
based on their secondary structures (Koradi et al. 1996, Hancock and Lehrer 1998) 
(Figure 1.14). Several synthetic variant peptides which fall into these structural classes 
have also been produced.  
 
Figure 1.14 Structural classes of antimicrobial peptides: (A) β-sheet, (B) α-helical, 





1.8.3 Structure function relationships of AMPs  
Peptides undergo significant conformation changes upon binding to the target cell. The 
importance of these secondary structures (conformations) in the activity of AMPs has 
been extensively studied in order to extract a structure-function relationship. 
1.8.3.1 α-helical peptides 
Linear AMPs with an α-helical structure (Fig 1.14 B) are one of the larger and better 
studied classes of AMPs. These AMPs tend to be disordered and are highly flexible in 
aqueous solution. They are characterized by their α-helical conformation upon 
interaction with membranes and membrane-mimicking environments (Powers and 
Hancock 2003). They are often found to be amphipathic and can either absorb onto 
membrane surfaces or insert into the membrane as a cluster of helical bundles. They 
may also contain a bend in the centre of the molecule which may be critical for 
selectivity by suppressing haemolytic activity (Zhang et al. 1999).  
Magainins (1 and 2) are one of the most studied AMPs of the α-helical class. The 23 
amino acid peptides were first isolated from the African clawed frog Xenopus laevis, 
and possess modest antimicrobial activities (50 µg/ml) against E. coli (Zasloff 1987). 
The structure of magainin 2 was determined by Proton Nuclear Magnetic Resonance 
(
1
H NMR) Spectroscopy in the presence of dodecylphosphocholine (DPC), and sodium 
dodecylsulfate (SDS) micelles and was shown to adopt an amphipathic α-helical 
conformation with a slight bend centred at residues 12 and 13 (Gesell et al. 1997). Its 
antimicrobial mechanism has been proposed to involve selective bacterial membrane 
permeabilization leading to disruption of membrane potential (Matsuzaki 1998). This 
mechanism is supported by the observation that no difference exists between D- and L 
enatiometric peptides, ruling out the involvement of a chiral receptor or an enzyme as a 
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target (Bessalle et al. 1990, Wade et al. 1990). The mechanism of action has been 
shown to follow the micellar-aggregate model of antimicrobial activity where magainins 
interact with negatively charged phospholipids and spontaneously form transient, 
membrane spanning pores, which, upon collapse, permit peptide translocation to the 
inner leaflet (Matsuzaki et al. 1995, Matsuzaki et al. 1997). Membrane disruption 
(Matsuzaki et al. 1989, Matsuzaki et al. 1991, Matsuzaki et al. 1995) and magainin 
induced depolarization has also been demonstrated in model in E. coli  as well as in and 
model systems (Juretic et al. 1989, Juretic et al. 1994). N-Terminal truncation of α-
helical magainin 2 indicates that truncation of the peptide to fewer than 20 residues (i.e. 
deletion of residue 4 and above) results in a compound that is unable to span the lipid 
bilayer and thus, from a mechanistic perspective, explains the corresponding loss of 
antimicrobial activity (Zasloff et al. 1988). However, α-helical peptides with as few as 
13 residues can possess antimicrobial activity so an ability to span a lipid bilayer is not 
an obligate requirement for activity of α-helical peptides (Zhang et al. 2001). 
In both the membrane-disruptive and non-membrane-disruptive mechanisms of peptide 
antimicrobial activity, the initial step is the interaction of the cationic peptide with the 
negatively charged cell surface. Therefore, to determine the forces leading to favourable 
association and ascertain if this step is simply driven by electrostatic attraction, the 
contribution of charge toward the activity of magainin 2 was investigated using 
analogues with varying cationic charges (Dathe et al. 2001). It was observed that charge 
increase to +5 is accompanied by a corresponding increase in antimicrobial activity, 
while further increase of charge to +7 did not alter the maximal activity observed at +5, 
but increased, haemolytic activity. Interestingly, experiments using model membranes 
composed of the anionic lipid phosphatidylglycerol found that an increase in charge 
actually led to a decrease in membrane permeabilizing ability. This is likely a result of 
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the corresponding decrease in hydrophobicity that accompanies an increase in charge 
(Dathe et al. 2001). 
1.8.3.2 β-sheet peptides 
In contrast to linear α-helical peptides, β-sheet peptides (Figure 1.14 A) have a more 
restrained conformation due to their cyclic structure formed either by disulfide bonds as 
in the case of human β-defensins tachyplesins, lactoferricin and protegrins (Nakamura 
et al. 1988, Jones et al. 1994, Harwig et al. 1995, Matsuzaki 1999, Hancock 2001) or by 
cyclization of the peptide backbone as in the case of gramicidin S, polymyxin B and 
tyrocidines (Prenner et al. 1999, Zaltash et al. 2000, Bu et al. 2002). They are largely 
characterized by the presence of an antiparallel β-sheet in aqueous solution that may be 
further stabilized upon interactions with lipid surfaces. Larger peptides within this 
peptide class may also contain small helical segments (Powers and Hancock 2003). 
Tachyplesins are the best characterized β-sheet peptides. Originally isolated from the 
haemocytes of the Japanese horseshoe crab, Tachypleus tridentatus, and with only 17–
18 residues (Nakamura et al. 1988), they represent a convenient scaffold for structure–
activity studies due to their small size and availability of a high-resolution  NMR 
structure. Tachyplesin I is an antiparallel β-sheet (residues 3–8 and 11–16) connected by 
a type I β-turn (residues 8–11), stabilized by two disulfide bonds (residues 3 and 16 and 
residues 7 and 12) with an amidated C-terminus (Kawano et al. 1990). It has moderate 
antimicrobial activity (<12.5 μg/ml MIC) against E. coli K12 (Nakamura et al. 1988) 
and a high affinity for lipopolysaccharides (Hirakura et al. 2002). 
Although the structure and in vitro activity of this group of peptides especially 
tachyplesins are well characterized, the exact mechanism of antimicrobial activity 
remains poorly understood. Whereas tachyplesins have a high affinity for LPS, they 
also have intracellular targets and have been shown to bind DNA (Yonezawa et al. 
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1992) and are effective at inducing lipid flip-flop and undergoing membrane 
translocation but do not cause substantial calcein release from model membrane systems 
(Zhang et al. 2001). This suggests these peptides disrupt lipid organization leading to 
the translocation of peptide molecules across the bilayer but do not form long-lived 
pores or channels (transient pore formation) (Matsuzaki et al. 1997). Thus, these 
peptides may function through a micellar-aggregate or related model of translocation as 
seen in the α-helical magainin. 
Several structure activity relationships (SAR), to understand the importance of disulfide 
bonds in the antimicrobial activity of this group of peptides, have been carried out. 
Generally, linearization and replacement of cysteine residues with certain amino acids 
like Alanine (A), Aspartic acid (D) and Leucine (L), lead to reduced antimicrobial 
activity or inactivation of the peptides as well as reduced calcein release from model 
membranes (Matsuzaki et al. 1993, Tamamura et al. 1993, Matsuzaki et al. 1997, Rao 
1999) while analogues with aromatic and hydrophobic residues retained broad spectrum 
activity (Tamamura et al. 1998). These studies suggest that the cyclic structure is 
essential for antimicrobial activity while it may not be crucial for membrane 
permeabilization (Matsuzaki et al. 1997, Tamamura et al. 1998, Rao 1999). Moreover, 
major differences in solution and micelle-bound structures of tachyplesin and a linear 
analogue analysed by  NMR highlight the need for high-resolution peptide 
structures, rather than simple conformational analyses by circular dichroism, to provide 
detailed structure–activity information (Laederach et al. 2002). 
1.8.3.3 Extended peptides  
Linear peptides with an extended structure (Figure 1.14 C) lack classical secondary 
structures (generally due to their high proline (P) or glycine (G) contents) and are 
characterized by overrepresentation of specific amino acids. For example, Histatin 
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produced in saliva is highly rich in histidine (H) residues (Tsai and Bobek 1998) and 
indolicidin isolated from the cytoplasmic granules of bovine neutrophils is highly rich 
in tryptophan (W) residues (Selsted et al. 1992). These extended peptides form their 
final structures by hydrogen bond and Van der Waals interactions with membranes 
instead of through interresidue hydrogen bonds (Powers and Hancock 2003).  
Indolicidin, a 13-residue, C-terminal amidated peptide is the best characterized 
representative of this group of peptides. It has the highest known proportion of 
tryptophans (5 out of 13 residues) in a peptide and its conformation is dependent on its 
environment (Selsted et al. 1992). It possesses reasonable antimicrobial activity (MIC of 
10 μg/ml) against E. coli but a lower affinity for LPS compared to other peptides such 
as the β-hairpin tachyplesins (Falla et al. 1996, Hirakura et al. 2002). The structure of 
indolicidin has been determined by  NMR in both anionic SDS and zwitterionic 
dodecylphosphocholine (DPC) micelles and it exists in an extended conformation in 
both lipid environments, but takes a more bent conformation due to two half-turns about 
residues 5 and 8 in neutral DPC micelles (Rozek et al. 2000).  
It has been hypothesized that indolicidin acts by disrupting the cytoplasmic membrane 
of E. coli by voltage-induced channel formation driven by membrane potential (Falla et 
al. 1996, Subbalakshmi and Sitaram 1998, Wu et al. 1999) as its size (25×32 Å) makes 
it possible to span biological membranes (Selsted et al. 1992). In other studies however, 
indolicidin was unable to completely depolarize the cytoplasmic membrane of E. 
coli and S. aureus (Wu et al. 1999, Friedrich et al. 2000) arguing against membrane 
disruption as a mechanism. The peptide has also been shown to induce filamentation 
of E. coli, which is thought to be a result of DNA synthesis inhibition (Subbalakshmi 
and Sitaram 1998). In order for this mechanism to be effective, membrane translocation 
must obviously occur. Therefore, in accordance with the micellar-aggregate model of 
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antimicrobial activity, both hypotheses combine to explain the actions of indolicidin; 
the formation of informal aggregate channels that, upon collapse, lead to translocation 
of the peptide into the cytoplasm (Powers and Hancock 2003). 
Several indolicidin analogues (including CP-11 and CP10A) have been synthesized to 
understand the importance of tryptophan and proline residues and the charge 
requirements for antimicrobial activity (Falla et al. 1996, Subbalakshmi et al. 1996, 
Zhang et al. 2001). It appears to be conformational changes rather than changes in 
charge or hydrophobicity that account for differences in activity in the case of the 
indolicidin family of peptides. For example, change in conformation from extended to 
helical in the analogue CP10A, led to increased membrane insertion and improved 
membrane translocation, allowing better access to the cytoplasm and cytoplasmic target 
(Friedrich et al. 2001). 
1.8.3.4 Loop peptides  
The last class of cationic peptides to be outlined in this thesis are the loop peptides (Fig 
1.14 D). They are made up of lantibiotics e.g. nisin and mersacidin, and peptides with 
loop structures imparted by the presence of a single bond (disulfide, amide or 
isopeptide), e.g. thanatin, lactoferricin B and bactenecin-1. Thanatin, a 21-residue, loop 
peptide isolated from the spined soldier bug, Podisus maculiventris (Fehlbaum et al. 
1996) is the only member of this group with an available high-resolution solution 
structure determined by  NMR. It is an anti-parallel β-sheet, formed by residues 8–
21, stabilized by the single disulfide bond between residues 11 and 18 (Mandard et al. 
1998). The peptide has reasonable antimicrobial activity against Gram-negative and 
Gram positive bacteria as well as fungi (Fehlbaum et al. 1996) and is comparable in 
activity to members of the β-sheet family of peptides. 
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Although, the exact antimicrobial mechanism of thanatin remains unknown, it is 
thought to act on targets other than the membranes, as treatment with peptide does not 
induce changes in permeability and mechanism of killing is believed to be dependent on 
the organism (Fehlbaum et al. 1996). Both D- and L-enantiomers are equally active 
against Gram-positive and fungal species but only L-thanatin is active against Gram-
negative bacteria, thus suggesting that a stereospecific target such as a receptor may be 
involved in Gram-negative bacteria while non-specific interactions dominate in both 
fungi and Gram-positive bacteria (Fehlbaum et al. 1996). Truncation of the C-terminus 
or beyond the third N-terminal residue has also been shown to greatly reduce activity as 
the loop region alone is completely inactive (Fehlbaum et al. 1996).   
1.8.4 Therapeutic potential of AMPs 
The considerations that will determine any clinical use of cationic peptides include 
toxicity, stability, immunogenicity, route of application, and formulation (Hancock 
1997). Cationic peptides have several assets that make them excellent prospects as 
novel antimicrobial agents. In addition to their microbicidal activity, they also possess 
other biological activities and have potential applications as signalling molecules, 
immune modulators, antitumor agents, drug delivery vehicles and plant transgenesis 
mediators (Zhang and Falla 2010, Pushpanathan et al. 2013, Otvos and Ostorhazi 2015, 
Wang et al. 2015). There is also potential for AMP use as topical therapy and wound 
healing (Otvos and Ostorhazi 2015). Such treatments are likely to be effective and safe 
because the more toxic cationic peptides and lipopeptides, including gramicidin S and 
polymyxin B, are already in skin creams. Unlike most antibiotics, at least some cationic 
peptides neutralise LPS and prevent endotoxemia during cell killing and/or lysis (Gough 
et al. 1996). This ability to prevent endotoxinaemia, which not all cationic peptides 
possess, is a great advantage for these peptides over other antibacterial agents. AMPs 
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have also been shown to possess “enhancer” activity (ie, synergy with classical 
antibiotics) (Corrigan and Bell 1971, Hancock et al. 1995). The more resistant an isolate 
is to a given antibiotic, the more profound is the enhancement of activity by an 
appropriate cationic peptide. Thus cationic peptides have the ability to serve as 
antiresistance compounds. Cationic peptides with excellent activity against a broad 
range of bacteria would be especially indicated where there is a risk from seriously 
resistant pathogens or where current treatments are ineffective. 
Intense research efforts over the years to overcome the hurdle of AMP use, have led to 
significant advances including optimizing peptide activity and stability under 
physiological conditions, lowering toxicity, deciphering the role of AMPs in modulating 
the immune system and how this can be exploited for therapeutic benefit. Therefore, 
despite some initial draw backs, (high cost of production, unwanted side effects, 
insufficient stability and activity under physiological conditions and upcoming adaptive 
bacterial resistance), which hindered cationic AMP use as therapeutics, more cationic 
peptides now seem to enter clinical trials (Table 1.6 below), indicating some success in 
developing peptides into therapeutics (Fox 2013, Ashby et al. 2014, Strempel et al. 
2015). Nonetheless, a knowledge gap still exists and continuous efforts into peptide-
based drug design is encouraged if these bottlenecks are to be completely overcome. 
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Table 1.6 Antimicrobial peptides in clinical development. (Adapted from (Gordon et al. 2005, Fjell et al. 2012, Fox 2013, Ashby et al. 
2014)). 




22-amino-acid linear antimicrobial 
peptide, isolated from the skin of the 
African clawed frog (Xenopus laevis) Diabetic foot ulcers III (complete) 
Dipexium Pharma (White Plains, New 
York)/MacroChem/Genaera) (formerly 
Magainin Pharmaceutical Inc.) 
Omiganan 
Synthetic cationic peptide derived 





Synthetic cationic peptide derived 
from bovine indolicidin 
catheter-related bloodstream 
infections III (being repeated) Microbiologix Biotech Vancouver, BC 
Omiganan 
(CLS001) 
Synthetic cationic peptide derived 
from bovine indolicidin 
Severe acne and rosacea; anti-
inflamotory II/III Cutanea Life Sciences/Migenix 
MBI 594AN Indolicidin (Bovine) topical Rx for acne IIB 
Microbiologix Biotech Vancouver, BC, 
Canada 
Iseganan (IB-367) 
synthetic 17-mer peptide from pih 
protegrin 1 
oral mucositis in patients 
undergoing radiation therapy III Ardea Biosciences 
OP-145 
Synthetic 24-mer peptide derived 
from LL-37 for binding to 
lipopolysaccharides or lipoteichoic 
acid 
Chronic bacterial middle-ear 
infection II (complete) OctoPlus (Leiden, The Netherlands) 




peptide Nasally colonized MRSA I/IIA Lytix Biopharma (Oslo) 
NVB302 Class B lantibiotic C. difficile I Novacta (Welwyn Garden City, UK) 
MU1140 Lantibiotic 
Gram-positive bacteria 
(MRSA, C. difficile) Preclinical Oragenics (Tampa, Florida) 
hlF1-11 
Cationic peptide fragment  
comprising amino-terminal  
amino acids 1–11 of  
human lactoferricin 
Bacteraemia and fungal  
infections in immuno-
compromised 
haematopoetic stem cell  





21 amino acids; rich in arginine and 
hydrophobic amino acids 
Multiresistant Gram-positive 
bacteria Preclinical Adenium Biotech Copenhagen 
Avidocin and 
purocin 
Modified R-type bacteriocins from P. 
aeruginosa 
Narrow spectrum antibiotic for 
human health and food safety Preclinical AvidBiotics (S. San Francisco, California) 
IMX924 
Synthetic 5-amino-acid peptide 
innate defense regulator 
Gram-negative and Gram-positive 
bacteria (improves survival and 
reduces tissue damage) Preclinical 
Iminex (Coquitlam, British Columbia, 
Canada) 
IMX-942 
Synthetic 5-amino-acid peptide 
derived from  innate defense 
regulator IDR1 and bactenecin 
Nosocomial infection, febrile 
neutropenia and  
Immunomodulation during 
mucositis II 
Iminex (Coquitlam, British Columbia, 
Canada) 
PAC-113 
Synthetic 12-mer peptide derived 
from Histatins 3 and 5 (Human) 
Mouth rinse for oral candidiasis in 
HIV patients II (complete) 
Pacgene Biopharmaceuticals (life science) 
Vancouver Canada 
Xoma-629 
derivative of Human Bactericidal 
Permeability-increasing protein (BPI) Impetigo II Xoma (US) Berkeley, CA 
Neuprex (rBPI21) BPI (Human) 
To reduce inflammatory 
complications in pediatric open 
heart-surgery patients. I/II Xoma (US) Berkeley, CA 
PMX-30063 
Arylamide oligomer mimetic of a 
defensin 
Acute bacterial skin infections 
caused byStaphylococcus spp. II PolyMedix 
Delmitide 
(RDP58 
Semisynthetic D-amino acid 
decapeptide derived from HLA class 
I B2702 Inflammatory bowel disease II (complete) Genzyme 
Ghrelin Endogenous host-defense peptide 
Airway inflamation, chronic 
respiratory infection and cystic 
fibrosis II 
University of Miyazaki, japan; Papworth 
Hospital Cambridge 
Plectasin 
Fungal defensin; candidate in 
development 
is an amino-acid substitiution variant Bacterial diseases Preclinical Novozymes 




Bacteriocins were among the first antimicrobial peptides to be isolated and 
characterized. Strains of Escherichia coli were observed to inhibit one another (Gratia 
1925). A few years later, lactococci were reported to produce antibacterial substances 
(Rogers 1928). These compounds were initially called antibiotics. The term 
‘bacteriocin’ was however introduced in the 1950s to differentiate these ribosomally 
synthesized peptides (Whitehead 1933) from classical antibiotics (Jacob et al. 1953). 
Bacteriocins have been defined as antibacterial proteins produced by some bacterial 
strains, which are bactericidal to other, often closely related bacterial strains, with 
different inhibitory mechanisms (Hoover and Steenson 1993).  
Bacteriocins have been grouped into different classes. Class I bacteriocins are described 
as small membrane peptides with unusual amino acids (with sulfur containing ring, i.e. 
lanthionine rings). Class II bacteriocins are also small (20-60 amino acids), heat-stable, 
positively charged peptides but do not contain lanthionine amino acids. They are further 
divided into subclasses IIa, IIb, IIc, IId and IIe. Class III bacteriocins are large heat-
labile proteins. Class III is divided into subclasses IIIa and IIIb. Class IV bacteriocins 
are complex bacteriocins containing lipid or carbohydrate moieties and class IV is a 
newly established group as they have not been adequately characterized at the 
biochemical level (Nes and Holo 2000, Sablon et al. 2000, Sonomoto and Zendo 2011). 
Nisin is the most studied and best understood bacteriocin (Jack et al. 1995). The term 
nisin was coined to describe the N inhibitory substance of L. lactis (Mattick and Hirsch 
1947). It is a Class I lantibiotic containing 34 amino acids with 5 unusual lanthionine 
rings and some dehydrated residues (Liu and Hansen 1990, Breukink et al. 1998). Nisin 
molecules facilitate the loss of intracellular solutes by assembling in the cell membrane 
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to form a barrel-like structure (Moll et al. 1999). Although many bacteriocins can only 
inhibit closely related strains of species, nisin is active against a variety of Gram-
positive bacteria. However, nisin producing lactococci are resistant to its activity. This 
resistance is conferred by immunity proteins (Nis I, F, E and G) (Dodd et al. 1996, Saris 
et al. 1996).    
1.10 Antimicrobial production in rumen bacteria 
The first evidence of bacteriocin production among rumen isolates was found in Strep. 
bovis (Iverson and Millis 1976). More recently, a bacteriocin was purified from a 
bacterium originally thought to be Strep. bovis but is rather from an isolate closely 
related to Strep. gallolyticus LRC0255 (Whitford et al. 2001). The bacteriocin of 
LRC0255 (bovicin 255) is a positively charged molecule, which inhibits nisin-sensitive 
but not nisin-resistant Strep. bovis cells (Mantovani et al. 2001). Another bacteriocin, 
bovicin HC5, isolated from a strain closely related to Strep. bovis produced a 
bacteriocin-like substance that could inhibit both nisin-sensitive and nisin-resistant 
Strep. bovis strain JB1 (Mantovani et al. 2001, Mantovani et al. 2010). Bacteriocin 
production has also been reported in Strep. bovis isolates from Australian ruminants 
(Joachimsthal et al. 2010).Bovicin HC5 has also been shown to have activity against 
Sal. Typhimurium (Prudêncio et al. 2015). 
Many strains of Buty. fibrisolvens have also been reported to produce bacteriocins that 
could inhibit other Butyrivibrios (Kalmokoff et al. 1996). Two Butyrivibriocins purified 
from Buty. fibrisolvens OR79 (a lantibiotic) and Buty. fibrisolvens AR10 (homologous to 
acidocin, a Class IIc bacteriocin produced by L. acidophilus respectively) have a wide 
spectra of activity and were able to inhibit a wide variety of Gram-positive ruminal 
bacteria (Kalmokoff et al. 1997, Kalmokoff and Teather 1997, Kalmokoff et al. 1999). 
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In another study, Buty. fibrisolvens strain Jl5 produced a bacteriocin that inhibited Buty. 
fibrisolvens AR10 and also catalyzed potassium efflux and a decrease in ATP and 
electrical cell membrane potential in Buty. fibrisolvens 49 (Rychlik and Russell 2002). 
In other studies, a strain of R. albus, which produced a soluble, heat stable 
proteinaceous substance that inhibits the growth of R. flavefaciens, was discovered 
(Odenyo et al. 1994, Odenyo et al. 1994). R. albus strains have also been shown to have 
inhibitory effects against Buty. fibrisolvens (Chan and Dehority 1999). Bacteriocin 
producing Ent. faecium strains CCM4231 and BC25 have also been isolated from the 
rumen although Ent. faecium is not a dominant ruminal bacterium (Laukova and 
Czikkova 1998, Morovsky et al. 1998). These strains both inhibited Strep. bovis 
although the latter strain appeared to be bacteriostatic rather than bactericidal (Laukova 
and Czikkova 1998). Many lactobacilli, especially L. fermentum have been shown to 
inhibit the growth of Strep. bovis (de Klerk and Smit 1967, Wells et al. 1997).   
It has been speculated that bacteriocins produced by ruminal bacteria may provide 
effective alternatives to antibiotics as feed supplements in ruminants (Teather and 
Forster 1998, Pieterse and Todorov 2010). In order for ruminal bacteriocins to be 
effective, they must be relatively stable, have a broad spectrum, and remain active (not 
subject to resistance) (Russell and Mantovani 2002). In this era of antimicrobial 
resistance and decreased drug discovery, one may also speculate that bacteriocin 
produced by rumen bacteria may provide alternatives to exploring novelty in drug 
discovery for human use. 
1.11 Metagenomics for biotechnology 
Several ruminal bacteriocins have been found to date, but only from bacteria that have 
been cultivated. In order to increase their discovery rate, and that of other novel 
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antimicrobials, culture independent methods can be used to assess the rumen 
microbiota. It is possible to access and explore the total genetic information of this 
unexplored, uncultured microbiota (i.e. the microbial community DNA), the so-called 
‘Metagenome’ (Handelsman et al. 1998, Ekkers et al. 2012) through direct isolation and 
cloning of all micro-organisms living in a defined habitat without any need to isolate 
and cultivate any cells (Handelsman et al. 1998, Biddle et al. 2008).  
Metagenomics, a term first used by Handelsman and colleagues (Handelsman et al. 
1998), is a methodology that applies genome sequencing or assays of functional 
properties to culture-independent analysis of complex and diverse (‘meta’) populations 
of microbes (Wooley and Ye 2009). Metagenomic research bypasses the need for 
isolation and cultivation of microorganisms (Simon and Daniel 2011) and attempts to 
directly determine the whole collection of genes within an environmental sample 
(Wooley and Ye 2009). By enabling an analysis of many as yet unculturable and often 
unknown microbes, metagenomics is revolutionizing the field of microbiology 
(Handelsman 2004, Cowan et al. 2005, Wooley and Ye 2009, Suenaga 2012). It 
promises to provide new and diverse enzymes and biocatalysts as well as bioactive 
molecules and has the potential to make industrial biotechnology an economic, 
sustainable success (Li and Qin 2005, Lorenz and Eck 2005, Langer et al. 2006, Ferrer 
et al. 2009, Chistoserdova 2010, Singh 2010). 
Metagenomic analyses are usually initiated by the isolation and purification of DNA 
from the environment (Streit and Schmitz 2004). The genetic material is then 
transferred into surrogate organisms to generate a metagenome clone library. The 
classical approach includes the construction of small insert libraries <10kb in a standard 
sequencing vector and in E. coli as a host strain (Henne et al. 1999, Handelsman 2004, 
Cowan et al. 2005, Daniel 2005, Hugenholtz and Tyson 2008). Additional hosts 
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including Streptomyces lividans, P. putida and Thermus thermphilus, amongst others 
have also been employed (Wang et al. 2000, Martinez et al. 2004, Albers et al. 2006, 
Angelov et al. 2009, Craig et al. 2010). Large insert libraries have been generated using 
cosmids (Entcheva et al. 2001, Courtois et al. 2003), fosmids (Quaiser et al. 2002, 
Quaiser et al. 2003, Treusch et al. 2004) (both up to 40kb) and bacterial artificial 
chromosomes (>40kb) (Rondon et al. 2000). 
Screens of metagenomic libraries in search for biological products have been performed 
using two different approaches, i.e. using (i) sequence-based screening (mining of the 
genetic information by sequencing and PCR) and (ii) functional screening of clones 
(function-based screening) (Schloss and Handelsman 2003, Streit and Schmitz 2004, 
Daniel 2005, Schmeisser et al. 2007, Ferrer et al. 2009, Kakirde et al. 2010, Singh 2010, 
Suenaga 2012) (Figures 1.15 and 1.16). Significant progress has been made using both 
sequence- and function-based approaches, allowing the isolation of high quality DNA 




Figure 1.15 Metagenomic library construction and subsequent screening 
procedures. Source: (Singh 2010). 
1.11.1 Sequence-based screening 
In this approach, the search for a particular function or protein is performed by mining 
the metagenomic sequence data. Once putative homologues are found, the exact 
sequence information can be obtained by PCR amplification and expression in surrogate 
organisms (Singh 2010). This approach has been successfully used in the discovery of 
several enzymes, including chitinases, hydrogenases, lipases and carboxypeptidases 
(Lefevre et al. 2007, Ferrer et al. 2009, Maroti et al. 2009, Schmidt et al. 2010, Prive et 
al. 2015). However, its major drawback is that it depends on the availability of 
homologous sequence data. Therefore, it would fail to identify novel enzymes that have 
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the same function, but a different structure than known enzymes (Schmeisser et al. 
2007, Singh 2010).    
1.11.2 Function-based approach 
Here, a function-based assay in which surrogate organisms are tested for a particular 
activity, such as reactions catalyzed by particular enzymes, or properties attributed to 
particular metabolites like antibiotics and anti-tumor agents is used (Singh 2010). The 
major problem of this approach is the logistics and facilities required to screen millions 
of clones for desired functions (Singh 2010). More so, function-based metagenomic 
studies often fall short of yielding products with sufficient novelty for biotechnological 
processes (Beloqui et al. 2008, Hill and Fenical 2010, Singh and Macdonald 2010). This 
is probably due to low level of gene expression in the library host (van Elsas et al. 2008) 
as genes may not be translated properly, particularly if they are not bacterial in origin or 
because the sensitivity of the screening methods used is too low for detecting gene 
expression (Gabor et al. 2004). However, as sequence information is not required, this 
approach alone bears the potential to identify entirely novel classes of genes encoding 
known or novel functions (Handelsman 2004, Riesenfeld et al. 2004, Daniel 2005, 
Ferrer et al. 2009, Gloux et al. 2011). Three different function-driven approaches 
(Simon and Daniel 2009), which have been used to recover novel biomolecules, include 
phenotypical detection of desired activity (mostly using chemical dyes) (Beloqui et al. 
2010, Liaw et al. 2010, Gloux et al. 2011), heterologous complementation of host 
strains or mutants (Riesenfeld et al. 2004, Wang et al. 2006, Simon et al. 2009, Chen et 




Figure 1.16 Schematic overview of the major function-based metagenomic 




1.12 Metagenomics- exploring the rumen bacteria: a potential source 
for novel antimicrobials 
Direct genomic or metagenomic cloning also offers the opportunity to capture genes 
encoding the synthesis of novel antimicrobials (Schloss and Handelsman 2003), 
whether from species with already known antimicrobial properties (bacteriocin 
production), or from completely new species. Indeed turbomycin (Gillespie et al. 2002), 
long-chain N-acetylated amines (Newman and Cragg 2007), isonitrile functionalized 
antibiotics (Hugenholtz et al. 1998), and the pigments violacein and indigo (Rappe and 
Giovannoni 2003) were originally isolated from soil-based metagenomic libraries. The 
rumen is a rich microbiota of culturable and non-culturable bacteria, which behave 
cooperatively and competitively and so presents a potentially rich source of novel 
products, particularly antimicrobials. However, little has been done to prospect the 
rumen bacteria for novel antimicrobials and this project aims to address these areas in 
depth. 
1.13 Aims of study 
Due to the fact that bacterial resistance to antimicrobials poses an important threat to 
human health, there is a need to urgently develop tools with which we can develop 
novel antimicrobials and predict the potential for the evolution of resistance to novel 
drugs and treatment schemes (Levy and Marshall 2004, Martinez et al. 2007). We now 
have knowledge of the diverse ruminal microbial species, the interactions between them 
and their potential as possible sources of antimicrobial compounds. Modern methods 
(i.e. genomic approaches) therefore, can be used to explore novelty in the rumen, reduce 
the likelihood of resistance developing by choosing antibiotic targets for which the 
resistance mechanism confers a high fitness cost and for which the rate and extent of 
compensation is low (Andersson and Hughes 2010).    
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The aim of this thesis therefore, was to prospect rumen bacteria for novel 
antimicrobials, firstly from a fosmid-based rumen bacterial metagenomic library 
previously created in the Institute of Biological, Environmental and Rural Sciences 
(IBERS), and secondly from an already existing 268GB rumen metagenomic sequence 
dataset (Hess et al. 2011) using both functional and sequence based metagenomics and 
advanced bioinformatic mining tools respectively. The work also sought to characterize 
the antimicrobial activities and mode of action of the antimicrobial proteins identified. 
The information generated may provide novel antimicrobial compounds and will be 
relevant to the treatment of multidrug resistant bacterial infections; potentially 
















General materials and methods 
2.1 Bacterial strains 
Bacterial strains used for antimicrobial activity testing in this project were all gifts from 
Bath University. They include Methicillin sensitive Staphylococcus aureus (MSSA) 
RN4220, Escherichia coli K12, Salmonella enterica serovar Typhimurium SL1344, 
Enterococcus faecalis JH2-2 and Listeria monocytogenes NCTC 11994 (serovar 4b). E. 
coli TOP10 (Invitrogen, Carlsbad CA, USA) was used for cloning (to host expression 
vectors for protein expression). Other bacterial strains used include Epidemic 
Methicillin resistant Staphylococcus aureus EMRSA-15 and Pseudomonas aeruginosa 
(15692) PAO1 strain H103. For the screening assays, a mini-Tn5-lux mutant in P. 
aeruginosa PAO1 strain H103 (P. aeruginosa PAO1 strain H1001) was used because of 
its high luminescent property (St. George’s University, London, UK). 
2.2 Antimicrobial agents and chemicals 
Ampicillin, Chloramphenicol, Ciprofloxacin, Vancomycin, Polymyxin B and 
Tobramycin were purchased from Sigma-Aldrich (Poole, Dorset, United Kingdom). 
Bactenecin Bac2A was purchased from Eurogentec Ltd Southampton UK). All stock 
solutions were dissolved in the appropriate solvent prior to dilution in sterile distilled 







Table 2.1 Antimicrobial agents used in this study 
Antimicrobial agent Solvent 
Vancomycin H2O 
Tobramycin H2O 
Polymyxin B H2O 
Ampicillin H2O 
Chloramphenicol H2O 
Bactenecin Bac2A H2O 
Ciprocloxacin H2O 
 
2.3 Bacteriological media and culture conditions 
Mueller Hinton (MH) (Sigma-Aldrich UK) and Luria Bertani (LB) broth and agar 
(Fisher Scientific Leicestershire, UK) were routinely used for all bacterial cultures. 
When leakage assays were performed under buffered conditions, 5mM HEPES (pH 7.2) 
supplemented with 5mM glucose was used (Wu and Hancock 1999). Media were 
prepared and sterilized according to the manufacturers’ instructions. 
Bacterial strains were grown using standard conditions unless otherwise specified. 
Broth cultures were incubated at 37
o
C for 18-20 hours with aeration and cultures on 
solid media were incubated at 37
o
C for 18-24 hours, except for List. monocytogenes 
which was incubated at 30
o
C.  
2.4 Rumen metagenomic library construction 
The fosmid metagenomic library used in this study has been previously constructed at 
the Institute of Biological Environmental and Rural Science (IBERS) at Aberystwyth 
University (Privé 2012, Privé et al. 2015). Metagenomic libraries were constructed from 
DNA extracted from bovine rumen content fractionated into strained rumen fluid (SRF), 
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solid-attached bacteria (SAB) and liquid associated bacteria (LAB), ligated into a 
fosmid vector and subsequently transformed into an E. coli host (Prive et al. 2015). 
Briefly, rumen contents were collected from four rumen-fistulated, non-lactating 
Holstein cows (average weight of 731 kg) housed at Trawscoed experimental farm 
(Aberystwyth, Ceredigion, Wales). The animals were fed a diet composed of a mixture 
of grass silage and straw (75:25) ad libitum and ~1 kg of sugar beet nuts was fed at 
0700 h daily with constant access to fresh water. Sampling was completed 2 h after 
concentrate feeding. SRF, SAB and LAB were harvested as described by (Huws et al. 
2010). 
Metagenomic DNA was extracted from 200 µl of SRF, SAB and LAB using the 
BIO101 FastDNA
®
 Spin Kit for Soil (Qbiogene, Cambridge, UK) following the 
supplier’s protocol, except that after the first step, the samples were shaken three times 
for 30s, in a FastPrep bead beater (Qbiogene, Cambridge, UK) at 6 m/s with cooling on 
ice for 30s between each shake. The libraries were constructed using the CopyControlTM 
pCC1FOSTM vector and the reagents supplied in the CopyControlTM Fosmid Library 
Production Kit (Epicentre, Cambio Ltd., Cambridge, UK), following the supplier’s 
recommendations. All clones were picked using a colony picker Genetix QPix2 XT 
(Genetix Ltd., New Milton, England), and subcultured for 20 h in 384-well plates 
(Genetix Ltd., New Milton, England) containing LB broth with 12.5 µg/ml 
chloramphenicol and 20% glycerol. They were then stored at -80°C. 
Fosmid libraries consisted of 7,744, 8,448 and 7,680 clones with an average insert size 
of 30 to 35 kbp for SRF, SAB and LAB respectively (Prive 2011). Only the solid 
attached bacteria (SAB) fosmid library with 8,448 clones was used in this study. 
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2.5 Bacteriological techniques 
2.5.1 Determination of susceptibilities to antimicrobial agents 
Minimal inhibitory concentrations (MICs) were determined using two-fold serial 
dilutions of antimicrobial agents in LB broth as described by the National Committee of 
Clinical Laboratory Standards (NCCLS) (NCCLS, 1997). MICs for antimicrobial 
peptides and comparator antimicrobials were measured using a modified broth 
microdilution method in LB broth. Briefly, the peptides were dissolved and stored in 
sterile microcentrifuge tubes. The assay was performed in sterile U bottom 
polypropylene 96 well microplates with lids (Greiner Bio One Ltd, Stonehouse, UK). 
Serial dilutions of antimicrobials were performed in sterile distilled water at 10-fold the 
desired final concentrations. Ten microlitres of this 10 fold dilutions were added to each 
well of the 96 well microplate containing 90 µl of LB broth per well. Bacteria from 
overnight culture (adjusted to 1 × 10
8
 CFU/ml) were added to the plate at a final 
inoculum concentration of 5 × 10
5
 CFU/ml (Cherkasov et al. 2008, Wiegand et al. 
2008). The MIC was defined as the lowest concentration of drug that inhibited visible 
growth of the organism after an 18-24 hour incubation at appropriate temperature.  
2.6 Molecular biology materials and methods 
2.6.1 Vectors 
The pTrcHis TOPO® vector (Invitrogen, Carlsbad, CA, USA) was used to clone PCR 
products for protein expression as described in section 4.2.2.1. 
2.6.2 DNA and plasmid DNA extraction  
DNA was extracted using a QIAprep® Spin Miniprep kit (Qiagen, Crawley, UK). 
Bacterial overnight cultures were pelleted by centrifugation at 4,000 x g for 10 minutes. 
The supernatant was discarded; pelleted cells were resuspended in 250 µl of Buffer P1 
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and transferred to a sterile 1.5ml microcentrifuge tube. Buffer P2 (250 µl) was then 
added and thoroughly mixed by inverting the tube and allowed to stand for 5 minutes. 
This was followed by the addition of 350 µl Buffer N3 to the tube and mixed 
thoroughly to neutralize the lysis reaction. The tube was then centrifuged in a bench-top 
microcentrifuge (Heraeus Biofuge Fresco microlitre centrifuge, Thermo Scientific UK) 
at 13,000 x g for 10 minutes. The supernatant from the previous step was applied to a 
QIAprep column and centrifuged at 13,000 x g for 1 minute to bind the plasmid DNA to 
the column. Buffer PB (500µl) was added to the column and centrifuged at 13,000 x g 
for 1 minute. The flow-through was discarded and 750 µl of buffer PE was added to the 
column and centrifuged at 13,000 x g for 1 minute to wash the bound DNA. 
Centrifugation step was repeated after discarding flow through to remove residual wash 
buffer. The QIAprep column was placed in a sterile 1.5ml microcentrifuge tube and 50 
µl of elution buffer EB was added to the centre of the column to elute the plasmid DNA. 
This was allowed to stand for 1 minute at room temperature and then centrifuged at 
13,000 x g for 1 minute. The flow through (extracted DNA) was stored at -20°C for 
further analysis. As advised by the supplier, the elution Buffer EB was pre-warmed at 
70°C before use for longer plasmid DNA (up to 30-35 kb) extraction. 
2.6.2.1 DNA Extraction from milled rumen samples 
When DNA was to be extracted from milled rumen samples, the FastDNA® SPIN Kit 
for Soil (MP Biomedicals) was used to extract DNA as described by the manufacturer. 
Briefly, up to 100 mg of rumen sample was added to a Lysing Matrix E tube. Sodium 
Phosphate Buffer (978 µl) and MT Buffer (122 µl) were then added to the tube and 
homogenized in a FastPrep® Instrument for 40 seconds at a speed setting of 6.0. The 
tube was then centrifuged at 14,000 x g for 5-10 minutes to pellet debris. The 
supernatant was transferred to a clean 2.0 ml microcentrifuge tube, to which 250 µl 
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Protein Precipitation Solution (PPS) was added and mixed by inverting the tube by hand 
10 times. This was followed by centrifugation at 14,000 x g for 5 minutes to pellet 
precipitate. The supernatant was then transferred to a clean 15 ml tube for better mixing 
and DNA binding. Resuspended Binding Matrix suspension (1.0 ml) was then added to 
the supernatant in the 15 ml tube and inverted by hand for 2 minutes to allow binding of 
DNA after which it was allowed to stand in a rack for 3 minutes to allow settling of 
silica matrix. Some of the supernatant (500 µl) was then removed to waste before re-
suspending Binding Matrix in the remaining amount of supernatant. The mixture was 
subsequently transferred (600 µl at a time) to a SPIN™ Filter and centrifuged at 14,000 
x g for 1 minute. After centrifugation, the catch tube was emptied, and the pellet was 
carefully resuspended in 500 µl prepared SEWS-M (ethanol added) using the force of 
the liquid from the pipette tip and centrifuged again at 14,000 x g for 1 minute. The 
residual wash solution on the matrix was ‘dried’ by centrifugation at 14,000 x g for 2 
minutes. The catch tube was then discarded and replaced with a new, clean catch tube 
and the SPIN™ Filter was air dried for 5 minutes at room temperature. Finally, 50 µl of 
DNase/ Pyrogen-Free Water (DES) was added to the SPIN filter and incubated for 5 
minutes at 55˚C in a heat block or water bath (to increase DNA yield). This was 
followed by centrifugation at 14,000 x g for 1 minute to bring eluted DNA into the 
clean catch tube. Eluted DNA was stored at -20°C for extended periods or 4°C until use. 
2.6.3 DNA quantification 
DNA quantification after extractions and polymerase chain reaction (PCR) 
amplifications were carried out using BioTek’s Epoch™ Multi-Volume 
Spectrophotometer System run by Gen5™ 2.0 Microplate Data Analysis software 
(BioTek Instruments, Inc. Vermont, USA). DNA samples (2 µl) were placed on the 
Take3™ Multi-Volume Plate and absorbance recorded at 260 280 and 320 nm. The 
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ratio 260/280 nm (to evaluate purity), absorbance values, and concentrations of samples 
were calculated by the Gen5™ software. 
2.6.4 Agarose gel electrophoresis 
The size and integrity of extracted DNA and PCR products were visualised and assessed 
by agarose gel electrophoresis using a 1.5% (w/v) agarose in TAE buffer (40 mM Tris, 
pH 8.0, 20 mM acetic acid, 1 mM EDTA, BioRad Ltd., Hemel Hempstead, UK). The 
agarose solution was dissolved in a microwave on high heat until clear (~ 3 minutes) 
and cooled to approximately 50°C, after which GelRed
TM
 Nucleic Acid Gel Stain 
10,000X in water (Biotium Inc. USA) was added and mixed thoroughly to a final 
concentration of 1X GelRed
TM
 (1:10000 dilution). The appropriate sized comb was then 
placed into a casting tray containing the agarose solution and allowed to polymerise at 
room temperature for ~ 30 minutes depending on gel size. When solidified, the combs 
were removed and the gel was transferred to an electrophoresis tank (Horizontal 
Electrophoresis Unit, Sigma-Aldrich) which contained 1X TAE above the level of the 
gel.  
Samples for agarose gel electrophoresis were prepared by mixing a 4:1 ratio (v/v) with 
blue/orange 6X loading dye (Promega UK Ltd., Southampton, UK), containing 0.4% 
orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10 
mM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0). This step was not required for PCR 
products prepared using pre-stained Taq polymerase or PCR Mastermix (e.g. MyTaq™ 
Red Mix). The reference ladder (1kb ladders, Promega UK Ltd., Southampton, UK) was 
mixed in a 4:1 ratio (v/v) with the same loading dye. A total of 5 μl of samples and 
ladder were loaded into individual wells of the agarose gel. 
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Ladder and samples were loaded on the gel, and electrophoresis was performed at a 
constant voltage (100V) until the dye front was near the end of the gel. Gel image was 




 system (BIO-RAD Hertfordshire, 
UK) and analysed by Quantity One 1-D Analysis Software (BioRad Ltd., Hemel 
Hempstead, UK). 
2.6.5 DNA gel extraction and purification 
DNA Gel Extraction and purification was carried out using the QIAquick Gel 
Extraction Kit (Qiagen). DNA fragments were excised from the agarose gel with a clean 
sterile, sharp scalpel. The gel slice was weighed and placed in a colourless 
microcentrifuge tube. Three volumes of Buffer QG was added to 1 volume of gel (100 
mg ~ 100 µl). For example, add 300 µl of Buffer QG to each 100 mg of gel (the 
maximum amount of gel slice per QIAquick column being 400 mg). The gel slice was 
then incubated at 50°C for 10 minutes or until it was completely dissolved (by vortexing 
the tube every 2–3 minutes during the incubation). Attention was paid to the yellow 
coloration of the mixture which indicates that Buffer QG is at pH ≤7.5 the pH at which 
adsorption of DNA to the QIAquick membrane is most efficient. Isopropanol (1 gel 
volume) was added to and mixed with gel sample. For example, if the agarose gel slice 
is 100 mg, add 100 µl isopropanol. The sample was then applied to a QIAquick spin 
column in a 2ml collection tube and centrifuged at 13000 rpm for 1 minute. The flow-
through was discarded and 0.5 ml of Buffer QG was again added to QIAquick column 
and centrifuged for 1 minute to remove all traces of agarose. The sample was washed by 
adding 0.75 ml of Buffer PE to the column and centrifuged for 1 minute after a 5 minute 
incubation time. The flow-through was once again discarded and the column 
centrifuged for an additional 1 minute at ≥10,000 x g (~ 13,000 rpm). Finally to elute 
the DNA, the QIAquick column was transferred into a clean 1.5 ml microcentrifuge 
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tube, and 30µl of Buffer EB (10 mM Tris·Cl, pH 8.5) was added to the centre of the 
QIAquick membrane, allowed to stand for 1 minute at room temperature and 
centrifuged for 1 minute at maximum speed and store at -20°C until required. 
2.7 Synthesis of antimicrobial peptides/peptide library 
In order to support the development of a class of drugs such as antimicrobial peptides, 
which can be used to discover new lead drug structures against multiresistant bacteria, a 
fast, easy and inexpensive method to synthesize peptides such as Spot-synthesis 
technology (Frank 1992, Kramer and Schneider-Mergener 1998) is necessary. The 
SPOT method follows standard fluorenyl-methoxy-carbonyl (Fmoc) chemistry on 
conventional cellulose sheets, allows the parallel synthesis of large numbers of 
addressable peptides in small amounts, can utilize more than 600 different building 
blocks and the cost per peptide is less than 1% of peptides synthesized conventionally 
on resin (Hilpert et al. 2007). Synthesis of unpurified peptides in the peptide library was 
completed at St. Georges University of London in collaboration with Dr Kai Hilpert’s 
group and is described below. Synthesis of purified peptides on resin was done at >95% 
purity by GenScript USA Inc (Piscataway, New Jersey, USA).   
2.7.1 Spot cellulose membrane activation 
Using the spot synthesis technique allows several hundred peptides to be constructed 
onto cellulose membranes. However, to improve yields of peptides, the membranes first 
need to undergo a functionalization step in which an ester bond is formed between the 
hydroxyl groups found on cellulose membranes and the carboxyl group of the amino 
acid glycine.  
Briefly, four, 10 cm by 15 cm membranes were cut from Whatman 50 ash-free paper 
and placed in a chemical resistant box.  2 x 2.97 g Fmoc-glycine was weighed into 2 x 
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50 ml Falcon tubes, into each of these a solution containing 45ml amine free 
dimethlyformamide (DMF), 1870 µl diisoproplycabomide (DIC) and 1586 µl N-
methylimidiazole (NMI) was added, this solution was then topped up with enough DMF 
to achieve a total volume of 50 ml per Falcon. Twenty-five millilitres of the solution 
was added to each of the chemical resistant boxes containing the membranes, care was 
taken to remove any air bubbles that formed beneath the membrane. The boxes were 
placed on a platform rocker and left to gently rock overnight at room temperature. 
The next day the solution was discarded from the boxes and membranes were washed 
three times with 20 ml DMF per box per wash. Next, 20 ml of 20% piperidine in DMF 
was added to each box and left to react for 20 minutes whilst undergoing gentle rocking 
at room temperature. After 20 minutes the solution was discarded and the membranes 
were subjected to five DMF washes and five ethanol washes (20ml per box per wash), 
all washes were performed on a rocking platform. Finally 20 ml 0.1% bromophenol 
blue in ethanol was added to each box. A blue staining of the membrane occurs in the 
presence of free amine groups of the glycine. Each membrane was then washed three 
times with 20 ml ethanol and left in the chemical resistant box to dry overnight in the 
fume hood. 
2.7.2 Synthesis of peptides 
Peptides were synthesised using solid phase Fmoc peptide chemistry using Intavis 
multipep RSi automated peptide synthesiser. All amino acids used were L-amino acids 
with acid labile side group protection and a base labile Fmoc amine protection. Peptides 
were synthesised either onto cellulose or resin supports according to the protocol stated 
in the “multipep RSi Manual” supplied by Intavis Bioanalytical instruments. The 
protocol for spot synthesis uses 0.5 M amino acid in N-methyl-2-pyrrolidone (NMP) 
which is activated by the robot using 1.1 M hydroxybenzotriazole (HOBt) in NMP and 
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1.1 M diisopropylcarbomide (DIC) in NMP. Deprotection of the amino Fmoc group 
happens prior to coupling and is carried out using 20% Piperidine in DMF. To improve 
peptide yields each amino acid coupling is carried out in duplicate. Uncoupled amino 
acids were acetylated at the end of each dual coupling cycle with 5% acetic anhydride in 
DMF. This process takes place in a cyclic manner until the peptide synthesis is 
complete, a schematic representation can be seen in Figure 2.1. 
 
 
Figure 2.1 A schematic representation of the repeated cycle implemented in spot 
peptide synthesis. 
 
During the first cycle, after Fmoc deprotection with piperidine and the completion of 





















detect free amino groups. These free amino groups indicate the position of the peptide 
spots and therefore were marked with a pencil so each peptide spot could be visualised 
and later punched out from the membrane. 
The process of peptide synthesised on resin follows a similar protocol to the one 
described above, however, the chemicals used in the activation of the amino acids were 
O-(1H-Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HBTU) and N-methylmorpholine (NMM), no acetylation step was involved and all 
peptides were synthesised on 2-Cl-(Trt)-Cl resin using a 5 µM synthesis scale. 
2.7.3 Side chain deprotection of cellulose bound peptides 
Amino acids used during the peptide synthesis contain acid labile side chain protection 
moieties that prevent unwanted cross reactions and these were removed following the 
completion of the synthesis as follows: Under a fume hood cleavage solution A  (5 ml 
Dichloromethane (DCM), 2 ml H2O, 3 ml Triisopropyl silane (TIPS), 90 ml 
Trifluoroacetic acid (TFA)) was added to chemical resistant boxes containing the 
membranes (25 ml per box). The reaction was left for 30 minutes at room temperature 
and then the solution was removed. Cleavage solution B (45 ml DCM, 2 ml H2O, 3 ml 
TIPS, 50 ml TFA) was then added to the boxes (25 ml per box). TFA is a highly 
corrosive acid and therefore special safety measures were employed during its use. 
After 2 hours, the solution was discarded and the membranes were washed three times 
in 20 ml DCM, followed by three washes in 20 ml DMF, then three washes in 20 ml 
ethanol and three washes in 20ml 10 mM Tris buffer (pH 7.5). The membranes were 
then left in sterile demineralised water overnight and air dried the following day. 
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2.7.4 Peptide cleavage from the membrane  
The dried membranes were placed in a glass desiccator and a vacuum was created. 
Under a fume hood ammonia gas was gradually entered into a chemical resistant 
balloon using a regulator attached to the ammonia canister, then from the balloon the 
ammonia was transferred into the desiccator. This process was repeated until the 
pressure in the balloon and the desiccator reached equilibrium, i.e. the balloon did not 
fully deflate when attached to the desiccator, this indicates that the desiccator was 
saturated with ammonia.  The membranes were left in the desiccator overnight and the 
next morning the desiccator was gradually opened over a period of 1 hour and then the 
membranes removed. 
The individual spots (marked in pencil during the synthesis) were then punched out of 
the membrane using a single spot hole puncher, each spot was then individually 
transferred to a well of a polypropylene 96 well plate where it was solubilised in 200 µl 
sterile water. The final yield of peptide was determined by Thermo Scientific Nanodrop 
spectrophotometer according to the manufacturers protocol (ThermoFisher Scientific 
2010). The yields for each peptide were approximately 300 µg/ml per spot, which 
equated to around 60 µg of crude (un-purified) peptide per spot. 
2.7.5 Side chain deprotection and precipitation of peptides produced on 
resin  
The deprotection and precipitation of peptides synthesised on resin was carried out 
according to the 24 column resin protocol from (Biosciences 2001). Briefly, the 
resin/peptide in columns were washed several times with tert-Butyl Methyl ether in the 
peptide synthesiser to remove all traces of DMF, the column module was then removed 
and dried overnight in a desiccator.  The next day resin/peptides from each column were 
removed and placed into 15 ml falcon tubes. Afterwards, 12 ml of cleavage solution C 
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(11.1 ml TFA, 600 µl TIPS, 300 µl water) was prepared in a glass test tube, and into 
each Falcon tube containing peptide and resin 500 µl of cleavage solution C was added 
and left for 5 hours. After 5 hours had elapsed, the solution contained within the Falcon 
tubes was diluted with ice cold tert-Butyl Methyl ether to precipitate the peptide. The 
Falcon tubes containing the solution were then centrifuged for 5 minutes at 4000 rpm to 
form a peptide and resin pellet that was washed several times with ether. The peptide-
resin pellet was then dried in a vacuum desiccator overnight and dissolved in H2O the 
following day (at which point the resin could be removed by filtration). The peptides in 
solution were frozen in a -80⁰C freezer and lyophilised in an Edwards Freeze Dryer 
Modulo the following day. The peptide powders were then ready to be weighed and 
solubilised in sterile demineralised H2O at a stock concentration of 2 mg/ml. The 
peptide solutions were then stored in a -20⁰C freezer until required. All work was 
carried out under a fume hood. 
To determine the purity of the sample reverse phase analytical High performance liquid 
chromatography (HPLC) was carried out on the peptides. This was done using a C18 
column (25 cm x 4.6 mm x 5 µm) with a 1 ml/minute flow rate and a 30 minute run (0 
minute 0.1% TFA, 0 – 20 minutes 0.1% TFA – 80% acetonitrile, 20 – 22 minutes 80 – 
100 % acetonitrile , 22 – 30 minutes 100 % - 0% acetonitrile). 
2.8 Software used  
BioEdit: BioEdit (version 7.0.5.3) is a sequence alignment editor for sequence analysis and 
editing, available at [http://www.mbio.ncsu.edu/bioedit/bioedit.html] (November 2010) 
(Hall, 1999). 
BLAST: The Basic Local Alignment Tool Search (BLAST) finds regions of local 
similarity between sequences. The program compares nucleotide or protein sequences to 
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sequence databases and calculates the statistical significance of matches (Altschul et al., 
1997). It is available at [http://blast.ncbi.nlm.nih.gov/Blast.cgi].  
CLUSTALW: The ClustalW2 program was used for multiple sequence alignments of DNA 
and protein sequences. It is available at [http://www.ebi.ac.uk/Tools/msa/clustalw2/].  
RAST/MG-RAST: The Rapid Annotation using Subsystem Technology (RAST) is an 
automated service for annotating bacterial and archaeal genomes (Aziz et al., 2008). The 
software identifies protein-encoding, rRNA and tRNA genes, assigns functions to the genes, 
predicts which subsystems are represented in the genome and uses this information to 
reconstruct the metabolic network of the organism. The service is available at 
[http://rast.nmpdr.org/] (November 2010). 
SignalP 4.1 Server: predicts the presence of signal peptide cleavage sites in amino acid 
sequences from different organisms available at http://www.cbs.dtu.dk/services/SignalP/ 
(Petersen et al. 2011).  
VecScreen: is a system for quickly identifying segments of a nucleic acid sequence that 
may be of vector origin. It is available at 
http://www.ncbi.nlm.nih.gov/VecScreen/VecScreen. html. 
MATLAB toolbox Gait-CAD (Mikut et al. 2008): including the Peptides Extension 
Package (Mikut 2010) were used for most of the computational analysis. Gait-CAD is 
free software and can be downloaded from http://sourceforge.net/projects/gait-cad/ but 
requires the commercial MATLAB software to work. 
PHYRE2 and PEP-FOLD: were used for protein 3D structure prediction (Kelley and 
Sternberg 2009, Maupetit et al. 2009, Thevenet et al. 2012, Kelley et al. 2015) 
PyMoL: was used for viewing protein structures (Schrödinger 2010). 
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2.9 Filtering steps followed in the identification of putative novel 
antimicrobials  
Many methods and filtering steps and criteria were used in the identification of putative 
novel antimicrobilas in this study. These steps are discussed in the ‘materials and 
methods’ sections of Chapters three, four and five below. For ease of comprehension, 
Figure 2.2 below is a schematic flow chart highlighting the filtering steps followed in 
the study. 
 
Figure 2.2 A schematic flow chat of filtering steps followed in the identification and 





Discovery of novel antimicrobials from the rumen microbiome  
3.1 Introduction and aim of chapter 
The rumen is one of the most diverse ecosystems in nature, harboring a complex 
microbial community, composed of an immense diversity of bacteria, protozoa, fungi, 
and viruses (Church 1993, Sirohi et al. 2012). The diverse microbial community adapts 
to a wide array of dietary feedstuffs and management strategies, thus enzymes isolated 
from this ecosystem have the potential to possess very unique biochemical properties. 
Therefore the variation of microorganism communities in the rumen of cattle (Bos 
taurus) is of great interest because of possible links to economically or environmentally 
important traits (Ross et al. 2012). 
Use of culture dependent methods to evaluate bacterial populations in the rumen 
substantially underestimates the diversity of microorganisms within the rumen as only 
around 10-20% of the species present are culturable at present (Edwards et al. 2004, 
Fernando et al. 2010, Sirohi et al. 2012). Direct sequencing of DNA, RNA and proteins 
extracted from an environmental sample through metagenomics and metaproteomics 
can provide snapshots of the complete microbiome and subsequently insights into 
changes of metabolic processes. Ever advancing nucleic acid-based technology and 
high-throughput methods have redefined our understanding and ability to describe 
various microbiomes, including the rumen microbiome. This has created new 
opportunities to investigate the complex relationships and niches within the microbial 
communities (McCann et al. 2014). It is important to improve our understanding of the 
functional capacity of the rumen microbiota, particularly of as yet unculturable bacteria, 
to fully understand the rumen microbiome. Consequently, genome sequencing of 
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microbes in the rumen is currently being undertaken by Hungate 1000 
(www.hungate1000.org.nz/) and FibRumBa database (www.jcvi.org/rumenomics/) 
(Creevey et al. 2014). Increased sequencing efforts supported by continued platform 
development with longer reads at lower costs allow more widespread use of next 
generation sequencing technologies with corresponding proliferation of rates of data 
generation. Consequently, there has been a high demand and subsequent increase in the 
development of additional bioinformatics tools to process data and obtain meaningful 
functional results (McCann et al. 2014). 
As with other ecosystems, several rumen metagenomic datasets have been generated in 
the last few years (Table 3.1). These metagenomic studies focus on nutrition, 
metabolism and the metabolic capabilities within the rumen microbiome due to the fact 
that this is pivotal to improving animal production efficiency and industrial 
fermentation. Unlike the soil and marine ecosystems metagenomes, which are heavily 
prospected for novel antimicrobial compounds (Gillespie et al. 2002, Barone et al. 2014, 
Ling et al. 2015), there are currently no rumen metagenomic studies investigating 
rumen antimicrobial genes and their potential as alternative treatments for multidrug 
resistant bacteria in humans and/or livestock.  
Whole ecosystem metagenomics (marine and terrestrial alike) has shown great promise 
in the discovery of novel and biotechnologically important compounds including 
antimicrobial compounds. The rumen microbiome has also been cited as a resource of 
novel enzymes for cellulosic biofuel production (Rubin 2008, Hess et al. 2011, Del 
Pozo et al. 2012). However, rumen microbial diversity studies using 16S rRNA have 
mainly been focused on targeting genes responsible for biomass degradation, methane 
production and ruminant function. 
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Although antimicrobial activity (bacteriocins) have been identified among rumen 
bacteria (Iverson and Millis 1976, Odenyo et al. 1994, Kalmokoff et al. 1996, 
Kalmokoff et al. 1997, Wells et al. 1997, Kalmokoff et al. 1999, Whitford et al. 2001, 
Mantovani et al. 2002, Russell and Mantovani 2002, Rychlik and Russell 2002, 
Joachimsthal et al. 2010) using traditional methods, again the focus of these studies 
were mainly on the role of these bacteriocin production in fibre degradation, their effect 
on other ruminal bacteria and ammonia production, with only little research on their 
activity against human and livestock pathogens (Wang et al. 2011, Prudêncio et al. 
2015). Exploration of these antimicrobial genes for their potential use in the treatment 
of human and livestock infections is therefore necessary. Given the advancement in 
genomic and sequencing technologies, and the increase in data generation, it is now 
possible to identify and investigate the antimicrobial properties of potentially novel 
antimicrobial compounds from the rumen and their applicability in the treatment of 
resistant bacterial infections.  
The aim of this Chapter was to identify potential antimicrobial genes from the 8,448 
clone fosmid based metagenomic clone library generated from cow rumen solid 
attached bacteria (SAB) at IBERS Aberystwyth University (Privé 2012, Prive et al. 
2015) by a combination of agar-based functional screen, and sequence analysis. The 
chapter will also discuss bioinformatic mining and prediction of antimicrobial 
genes/proteins and antimicrobial peptides (AMPs) using various online databases and 
prediction tools first, in this fosmid library and secondly in the publicly available cow 
rumen metagenomic dataset from (Hess et al. 2011). 
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Table 3.1 Summary of recent bovine rumen metagenomic studies Adapted and modified from McCann et al. (2014) 
 
Title Year Sequencing 
platform 
Major finding Reference 
Gene-centric metagenomics of the fiber-adherent bovine rumen 
microbiome reveals forage specific glycoside hydrolases 
2009 454 GS20 Significant differences exist in rumen metabolic potential 
between animals on the same diet. 
Many unique glycoside hydrolases are present in the 
rumen microbiome. 
(Brulc et al. 
2009) 
Rumen bacterial diversity associated with changing from 
bermudagrass hay to grazed winter wheat diets 
2010 454 GS FLX Switching from hay to wheat diet affects bacterial 
composition and diversity structure in the rumen 
microbiome. 
(Pitta et al. 
2010) 
Rumen microbial population dynamics during adaptation to a 
high-grain diet 
2010 ABI 3700 M. elsdenii, S. bovis, S. ruminantium, and P. bryantii 




Evaluation of bacterial diversity in the rumen and feces of 
cattle fed different levels of dried distillers grains plus solubles 
using bacterial tag-encoded FLX amplicon pyrosequencing 
2010 454 GS FLX Abundance of the phylum Bacteroidetes increased with 
addition of distillers grains to growing diet. 
(Callaway et 
al. 2010) 
Microbiome analysis of dairy cows fed pasture or total mixed 
ration diets 
2011 454 GS FLX Pasture diet increased Prevotella abundance regardless of 
fraction. 
Protozoal community was unaffected by diet or rumen 
fraction. 
(de Menezes 
et al. 2011) 
Metagenomic discovery of biomass-degrading genes and 
genomes from cow rumen 
2011 Illumina Hiseq 
2000 
88% of carbohydrate-active candidate genes were greater 
than 25% dissimilar to deposited genes. 
(Hess et al. 
2011) 
Characterization of the rumen microbiota of pre-ruminant 
calves using metagenomic tools 
2012 454 GS FLX Significant changes in phylogenetic composition of the 
rumen microbiome occurred during development, but the 
metabolic potential remained stable. 
(Li et al. 2012) 
Nitrogen metabolism and rumen microbial enumeration in 
lactating cows with divergent residual feed intake fed high-
digestibility pasture 
2012 454 GS FLX Archaea, bacteria, protozoa, and fungal communities 
were largely similar between inefficient and efficient 
cows. 
Differences were observed for 3 bacterial families and 
two protozoa species. 
(Rius et al. 
2012) 
High throughput whole rumen metagenome profiling using 
untargeted massively parallel sequencing 
2012 Illumina 
GAIIx 
There is greater variation in the rumen metagenome 
between animals than replicates from the same rumen. 
(Ross et al. 
2012) 
Composition and similarity of bovine rumen microbiota across 
individual animals 
2012 454 GS FLX Although significant heterogeneity exists between the 
rumen microbiome of animals on a similar diet, 
phylogenetic comparisons indicate more similarities. 
(Jami and 
Mizrahi 2012) 
Next generation sequencing to define prokaryotic and fungal 2012 454 GS FLX Compared with the bacterial community, archeal and (Fouts et al. 
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diversity in the bovine rumen fungal communities were more consistent in the liquid 
and solid fractions. 
2012) 
Comparative survey of rumen microbial communities and 
metabolites across one caprine and three bovine groups using 
barcoded pyrosequencing and 1H-NMR spectroscopy 
2012 454 GS FLX Microbiome composition is affected by diet, host animal 
breed, and may be associated with rumen metabolites. 
(Lee et al. 
2012) 
Perturbation dynamics of the rumen microbiota in response to 
exogenous butyrate 
2012 454 GS FLX Exogenous butyrate infusion increased Ruminobacter and 
Treponema populations within the rumen microbiome. 
(Berg Miller et 
al. 2012, Li et 
al. 2012) 
Phage-bacteria relationships and CRISPR elements revealed by 
a metagenomic survey of the rumen microbiome 
2012 454 GS FLX, 
Illumina 
GAIIx 
Rumen bacteriophages are diverse, unique to the rumen, 
and likely influence the microbial community. 
(Berg Miller et 
al. 2012) 
The bacterial community composition of the bovine rumen 
detected using pyrosequencing of 16S rRNA genes 
2012 454 GS FLX The core rumen microbiome is affected by rumen 
development and diet. 
(Wu S et al. 
2012) 
The effect of brown midrib corn silage and dried distillers’ 
grains with solubles on milk production, nitrogen utilization 
and microbial community structure in dairy cows 
2012 454 GS FLX Inclusion of dried distillers grains increased 
Bacteroidetes:Firmicutes ratio and nitrogen and neutral 
detergent fiber digestion. 
(Ramirez HR 
et al. 2012) 
Evaluation of the ruminal bacterial diversity of cattle fed diets 
containing citrus pulp pellets 
2012 454 GS FLX Greater inclusion of citrus pulp pellets impacted the 
rumen microbiome and increased bacilli bacteria. 
(Broadway 
P.R et al. 
2012) 
Simultaneous amplicon sequencing to explore co-occurrence 
patterns of bacterial, archaeal and eukaryotic microorganisms 
in rumen microbial communities 
2013 454 GS FLX - Simultaneous pyrosequencing of bacterial, archaeal, and 
eukaryotic DNA can efficiently describe the entire rumen 




Changes in the rumen epimural bacterial diversity of beef 
cattle as affected by diet and induced ruminal acidosis 
2013 454 GS FLX Minor bacteria in the epimural community were most 
affected by acidosis challenge and may indicate acidosis 
susceptibility. 
(Petri et al. 
2013) 
Investigating the effect of two methane-mitigating diets on the 
rumen microbiome using massively parallel sequencing 
2013 Illumina Hiseq 
2000 
Identified contigs associated with lower methane 
production were observed in rumen fluid and feces. 
(Ross et al. 
2013) 
Effect of post-extraction algal residue supplementation on the 
rumen microbiome of steers consuming low-quality forage 
2013 454 GS FLX Dietary inclusion of post-extraction algal residue 
increased proportion of Firmicutes families 
Ruminococcaceae, Lachnospiraceae, and Clostridiaceae. 
(McCann 
2013) 
Comparative analysis of microbial profiles in cow rumen fed 
with different dietary fiber by tagged 16S rRNA gene 
pyrosequencing 
2013 454 GS FLX Fibrobacteraceae and Ruminococcaceae decreased in 
relative abundance with increasing concentrate in a 
forage-based diet. 
(Thoetkiattikul 
et al. 2013) 
Effect of dietary forage sources on rumen microbiota, rumen 
fermentation and biogenic amines in dairy cows 
2013 454 GS FLX Forage source within TMR affected abundance of 
Prevotella, Rikenellaceae, Selenomonas, and 
Ruminococcaceae. 
(Zhang et al. 
2014) 
Impact of subacute ruminal acidosis (SARA) adaptation of 2013 454 GS FLX Induction of SARA decreased Prevotella, Treponema, (Mao et al. 
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rumen microbiota in dairy cattle using pyrosequencing and alpha diversity and may be linked to increased 
ruminal lipopolysaccharides. 
2013) 
Characterizing the microbiota across the gastrointestinal tract 
of a Brazilian Nelore steer 
2013 454 GS FLX Distinct microbiomes exist in segments of the 
gastrointestinal tract and likely correspond to the 
physiological function of each segment. 
(de Oliveira et 
al. 2013) 
The effects of a probiotic yeast on the bacterial diversity and 
population structure in the rumen of cattle 
2013 454 GS FLX High yeast treatment decreased Prevotella abundance and 




Microbial ecology of the rumen evaluated by 454 GS FLX 
pyrosequencing is affected by starch and oil supplementation 
of diets 
2013 454 GS FLX High starch and oil treatment significantly altered the 
microbiome by increasing Prevotellaceae and decreasing 
Ruminococcaceae. 
(Zened et al. 
2013) 
Relationship between the rumen microbiome and residual feed 
intake-efficiency of Brahman bulls stocked on bermudagrass 
pastures 
2014 454 GS FLX Inefficient bulls had greater Prevotella, and lower 
stocking intensity increased microbiome diversity and 
richness. 
(McCann et al. 
2014) 
Microbial biodiversity of the liquid fraction of rumen content 
from lactating cows 
2014 454 GS FLX Supplementation of lyophilized and dried yeast increased 
Bacillus abundance but did not impact fermentation. 
(Sandri et al. 
2014) 
Establishment of ruminal bacterial community in dairy calves 
from birth to weaning is sequential 
2014 454 GS FLX The rumen microbiome is established prior to 
consumption of solid food, but solid food intake 
determines microbiome composition. 
(Rey et al. 
2013) 
Potential role of the bovine rumen microbiome in modulating 
milk composition and feed efficiency 
2014 454 GS FLX Firmicutes:Bacteroidetes was positively associated with 
milk fat content while many taxa were related to residual 
feed intake phenotype. 
(Jami et al. 
2014) 
Effect of feeding dried distillers grains with solubles on 
ruminal biohydrogenation, intestinal fatty acid profile, and gut 
microbial diversity evaluated through DNA pyro-sequencing 
2014 454 GS FLX Greater inclusion of DDG with solubles corresponded to 
higher biohydrogenation of dietary unsaturated fatty 
acids and a decrease in phylum Fibrobacteres. 
Diet did not affect abundance of biohydrogenating 
species. 
(Castillo-
Lopez et al. 
2014) 
Taxonomic identification of commensal bacteria associated 
with the mucosa and digesta throughout the gastrointestinal 
tracts of preweaned calves 
2014 454 GS FLX Three-week-old calves had greater Prevotella in the 
ruminal epithelium-attached community compared to 
digesta, and had region-specific microbiomes in the 
gastrointestinal tract. 
(Malmuthuge 
et al. 2014) 
Metagenomic analysis of buffalo rumen microbiome: Effect of 
roughage diet on Dormancy and Sporulation genes 
2014 Ion Torrent Abundance of bacteria at the domain level and presence 
of Dormancy and Sporulation genes predominantly 
associated with the Clostridia and Bacilli taxa belonging 
to the phyla Firmicutes 




3.2 Materials and methods  
3.2.1 Isolation of antimicrobial genes in IBERS fosmid metagenomic library 
3.2.1.1 Agar based functional screen 
Metagenomic clones (2 µl) were pressed gently using sterile pin replicators (Molecular 
Devices Ltd, Berkshire UK) onto Luria-Bertani agar plates which had 500 µl of 
pathogens S. aureus, E. coli K12, Sal. Typhimurium, Ent. faecalis and List. 
momocytogenes (OD600nm =1) spread evenly over the agar and left to dry just prior. 
Plates were incubated at appropriate temperatures for 24 hours and zones of clearing 
around the clones were noted as being indicative of clones which have gene inserts 
encoding antimicrobials. 
3.2.1.2 Sequence-based screening of putative antimicrobial positive fosmid clones  
Sequencing runs were carried out using the high throughput pyrosequencing Genome 
Sequencer FLX (454 Life Sciences) in Aberystwyth University. In preparation for 
sequencing, the selected putative antimicrobial-positive fosmids genomic DNA were 
extracted as described in Section 2.6.2 and fragmented to 600-900 bp fragments by 
nebulisation. The sheared fosmids were ligated to molecular barcodes (Multiplex 
Identifiers, MID, Roche Life Sciences) containing short oligonucleotide adaptors “A” 
and “B”. This was in order to specifically tag each sample in the sequencing run. The 
MID adaptors included an 11-nucleotide sequence tag on adaptor “A” after the 
sequencing key (see Excel file ‘summary of sequencing results’ in attached Compact 
Disc (CD). It can also be accessed on Figshare; link to Figshare and login details are 
outlined in the list of ‘CD/Figshare content’ section). The MID-adaptor ligated DNA 
libraries were mixed in an equimolar amount. The fosmid MID tagged DNA were then 
clonally amplified by emulsion PCR (emPCR) by using 13.6 x 10
6
 Sepharose beads per 
emulsion reaction. Emulsions were then broken with isopropanol and emPCR beads 
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were enriched for template-positive beads, bead-attached DNAs were denatured with 
NaOH and sequencing primers were annealed. About 790,000 beads with clonally 
amplified DNA were then deposited on two of four 70 x 75 mm regions of the 
PicoTiterPlate. The PicoTiterPlate device was then loaded onto the 454 instrument 
along with the sequencing reagents, and sequences were obtained according to the 
manufacturer’s protocol. An SFF (Standard Flowgram Format) file was obtained for 
each sample, and nucleotide sequence data and phred-like quality scores were extracted. 
The reads from each of the pooled libraries were identified by their MID tags by the 
data analysis software gsAssembler v.2.5.3 (Roche Life Sciences) after the sequencing 
run.  
3.2.1.3 Sequence analysis of positive clones 
Following sequence assembly using the default parameters on the  gsAssembler 
software v.2.5.3 (Roche Life Sciences), BLASTN (v2.2.28) on NCBI and BioEdit 
(version 7.1.11) (Hall 1999) were used to edit and trim the vector sequence from the 
contigs. VecScreen on NCBI was also used to search the sequences for vector 
contamination. The open reading frames (ORFs) were determined using the ORF finder 
programme at (http://www.ncbi.nlm.nih.gov/gorf/orfig.cgi July 2013), which also does 
a BLASTP (v2.2.28) (searches the non-redundant protein sequences database using a 
protein query) search. All ORFs were retained irrespective of peptide length and those 
with any homology to antimicrobial genes and/or peptides were further investigated. 
ORFs encoding peptides ≤ 50 amino acids and/or without significant hits on NCBI 
BLAST were explored as potentially antimicrobial gene and/or peptides (see section 
3.2.1.4). 
These annotations were confirmed with an analysis of the contigs on the RAST server. 
Multiple alignments of predicted putative antimicrobial genes and their blastp hits were 
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performed with ClustalW implemented at http://www.ebi.ac.uk/Tools/msa/muscle/ after 
retrieval of all protein sequences from ‘Batch Entrez’ on the NCBI website. Alignments 
were then imputed into Jalview (Thompson et al. 2006, Waterhouse et al. 2009), a 
multiple sequence alignment visualization software and SeaView (Gouy et al. 2010) (a 
graphical multiple sequence alignment editor) respectively. Alignments saved in Phylip 
format were used to build phylogenetic trees using the RAxML BlackBox (Stamatakis 
et al. 2008) available at http://embnet.vital-it.ch/raxml-bb/. The generated trees were 
visualized and saved on http://itol.embl.de/ (Letunic and Bork 2011). Where number of 
alignments were too few to build phylogenetic trees on RAxML BlackBox, the blast 
pairwise alignment tool was used. 
Signal sequences for peptide cleavage were analysed using SignalP 4.1 (Petersen et al. 
2011) using the Gram-negative model. Conserved domains in the amino acid sequences 
were analysed with Conserved-Domain search on NCBI (MacNeil et al. 2001, 
Marchler-Bauer et al. 2011, Marchler-Bauer et al. 2015) and the Pfam database (version 
27.0, available at pfam.xfam.org). No minimum e-value cut-off was applied as ORFs 
encoding putative positive antimicrobial genes could be potentially novel. 
3.2.1.4 Bioinformatic mining and prediction of antimicrobial peptides 
Due to the growing interest in AMPs, several algorithms for predicting antimicrobial 
activity have been developed (Lata et al. 2007, Wang et al. 2009, Torrent et al. 2011) 
and used to confirm activity of short AMP sequences (Fjell et al. 2009, Hadley and 
Hancock 2010). In this study, prediction of antimicrobial peptide sequences within open 
reading frames (identified using NCBI ORF Finder) was completed using a combination 
of publicly available databases listed below.  
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3.2.1.4.1 The antimicrobial peptide database APD 
APD is a general multifunctional antimicrobial peptide database dedicated to 
antimicrobial peptides from all biological sources, ranging from bacteria, plants, to 
animals, including humans (Wang and Wang 2004, Wang et al. 2009). The database 
collects only ‘mature and active’ peptides (<100 amino acid residues), rather than a 
mixture of mature and precursor proteins. The peptides in APD are classified based on 
their biological activities such as anticancer, antiviral, antifungal and antibacterial, 
allowing users to readily obtain a list of peptides of special interest to them. APD 
provides interactive interfaces for peptide query, prediction and design. It also provides 
statistical data for a select group of or all the peptides in the database APD is a useful 
tool for studying the structure-function relationship of antimicrobial peptides. APD is 
created, maintained and updated by the NMR Structural Biology Group at Eppley 
Institute, the University of Nebraska Medical Centre and can be accessed via the 
Internet at the http://aps.unmc.edu/AP/main.html. 
3.2.1.4.2 AMPA 
The Antimicrobial Sequence Scanning System, AMPA (Torrent et al. 2009, Torrent et 
al. 2012) is a theoretical approach that predicts antimicrobial proteins from their amino 
acid sequence in addition to determining their antimicrobial regions. A bactericidal 
propensity index has been calculated for each amino acid, using the experimental data 
reported from a high-throughput screening assay as reference. Scanning profiles were 
performed for protein sequences and potentially active stretches were identified by the 
best selected threshold parameters. The method was corroborated against positive and 
negative datasets and active antimicrobial sequences could be spotted from 
experimental data. AMPA can correctly identify antimicrobial proteins with an accuracy 
of 85% and a sensitivity of 90%. The method can also predict their key active regions, 
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making this a tool for the design of new antimicrobial drugs. It is available at 
http://tcoffee.crg.cat/apps/ampa/do. 
3.2.1.4.3. BACTIBASE  
BACTIBASE (Hammami et al. 2007, Hammami et al. 2010) contains calculated or 
predicted physicochemical properties of 177 manually curated annotation of 
bacteriocins and their sequences produced by both Gram-positive and Gram-negative 
bacteria. It includes data collected from published literature as well as high-throughput 
datasets. BACTIBASE allows rapid prediction of relationships structure/function and 
target organisms of these peptides and therefore better exploitation of their biological 
activity and could have implications for the development of new drugs for medical use 
in both the medical and food sectors. The database incorporates various tools for 
bacteriocin analysis, such as homology search, multiple sequence alignments, Hidden 
Markov Models, molecular modelling and retrieval. It can be accessed online at 
http://bactibase.pfba-lab-tun.org/antiinfective.php. 
3.2.1.4.4 CAMP 
CAMP (Collection of Anti-Microbial Peptides) (Thomas et al. 2010, Waghu et al. 2014) 
is a manually curated database and currently holds over 6000 sequences and 682 3D 
structures of AMPs. It was developed for advancement of the present understanding on 
antimicrobial peptides. The prediction tools for AMPs are based on machine learning 
algorithms like Random Forests (RF), Support Vector Machines (SVM) and 
Discriminant Analysis (DA) (Norušis 1988, Vapnik 1995, Breiman 2001, Muller et al. 
2001). The prediction models on CAMP gave accuracies of 93.2% (RF), 91.5% (SVM) 
and 87.5% (DA) on the test datasets. CAMP is a useful database for study of sequence-





AntiBP (Antibacterial peptides) (Lata et al. 2007, Lata et al. 2010) uses a robust method 
for predicting antibacterial peptides from amino acid sequence of a given peptide. It 
assesses whether or not they have antibacterial properties based on the observation that 
certain residues are preferred over others in antibacterial peptides, particularly at the N 
and C terminus. The database further classifies antibacterial peptides according to their 
sources with an overall accuracy of 98.95% as well as in their respective families with 
satisfactory results. The database may be helpful in discovering efficacious antibacterial 
peptide, which we may help against antibiotics resistant bacteria. It can be assessed 
online at http://www.imtech.res.in/raghava/antibp2/index.html.  
3.2.1.5 Selection of AMPs for further characterisation 
Briefly, all predicted ORFs were uploaded into different databases discussed previously. 
Only those ORFs which were predicted to be antimicrobial peptides in at least two 
databases were explored further. Because the AMPA server could predict key active 
regions/stretches within ORFs already predicted as AMPs, it was used as a definitive 
tool in the final selection of AMPs. This was also experimentally confirmed; One ORF 
(MRCEIPHRCVRRKYRIRRHSPFSCATVGKGDRCGPLRYYASWRKGDVLQGD  
with 51 amino acid (AA) residues) predicted to be an AMP and the active stretch within 
it (PHRCVRRKYRIRRHSP) highlighted above with 16AAs- designated SHALININ 
and SHALININ 1 respectively) were chosen at random and chemically synthesized at 
>80% purity by GL Biochem Shanghai Ltd. The antimicrobial activities of these 
peptides were then investigated as described in section 2.5.1. This was to determine 
whether the full gene (predicted ORF) was required for antimicrobial activity or 
whether the short predicted active region/stretch within the ORF alone was sufficient 
for antimicrobial activity. If the former were the case, then traditional cloning and 
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expression of the genes would be more logical and economical due to the length of the 
proteins especially when ORFs are longer than 25 AAs. If the latter was to be true, on 
the other hand, it would be logical to chemically synthesize the active stretches alone 
for the same reason, and subsequently investigate their antimicrobial activities. In other 
words, all predicted AMPs were classified as either short (≤25 AAs) or long (>25) 
proteins/peptides. Results from this preliminary analysis revealed that the predicted 
active region within the ORF was more active against tested bacteria strains than the 
full length ORF itself (see Figure 3.10 in CD/Figshare for this data). Therefore, for ease 
of chemical synthesis, only the active regions in ORFs predicted to be AMPs (especially 
those which were ≤ 22 AAs), were included in the peptide library generated for further 
antimicrobial screening. All AMPs >22 AAs were expressed in E. coli. 
3.2.2 Identification of AMPs from cow rumen metagenome dataset 
3.2.2.1 Rationale for choosing the rumen metagenomic dataset used in this study 
As can be seen from Table 3.1, most research publications on bovine rumen 
metagenomic datasets began in 2010. It should also be noted that many of the sequence 
data were not publicly available at the time of publication but one or two years later. At 
the time of investigation (July, 2013), the publicly available cow rumen metagenomic 
datasets were (Brulc et al. 2009, Hess et al. 2011) and other genomic datasets. To date, 
the (Hess et al. 2011) is by far the largest available rumen metagenomic dataset 
containing more than 268 gigabases or 1.5 billion read pairs of metagenomic DNA from 
microbes adherent to plant fiber incubated in cow rumen. De novo assembly of these 
reads resulted in more than 2.5 million predicted open reading frames at an average of 
542 bp and 55% predicted full-length genes, with 27,755 putative carbohydrate-active 
genes and expressed 90 candidate proteins, of which 57% were enzymatically active 
against cellulosic substrates. In addition, 15 uncultured microbial genomes, which were 
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validated by complementary methods including single-cell genome sequencing, were 
assembled. The data set provides a substantially expanded catalog of genes and 
genomes participating in the deconstruction of cellulosic biomass. This is more than 
five times greater than the number of candidate carbohydrate genes from any previous 
study highlighting the benefits of deep sequencing of the rumen metagenome in the 
definition and discovery of metabolic potential. Consequently, this dataset was chosen 
and mined for genes with potentially novel antimicrobial activity purely by use of a 
combination of bioinformatic prediction software/tools. Moreover, it was useful to 
compare the abundance, if any, of antimicrobial genes within another cow rumen 
metagenomic dataset and the dataset available from the fosmid based rumen dataset at 
IBERS. 
3.2.2.2 Method for mining rumen metagenomic dataset  
All datasets (libraries) used for similarity analysis and antimicrobial peptide prediction 
and their respective sources are as follows: The Library "Cow" dataset contained 
predicted protein sequences 'metagenemark_predictions.faa.gz' (2,547,270 sequences) 
available at (http://portal.nersc.gov/project/jgimg/CowRumenRawData/submission/) 
(Hess et al. 2011). The Library "AMP1", containing a list of known antimicrobial 
peptides (AMPs) downloaded from APD2: Antimicrobial Peptide Search database 
containing 2308 peptides (downloaded on November 10, 2013) (Wang et al. 2009) 
available at http://aps.unmc.edu/AP/main.php and the Library "AMP2", containing a list 
of 48 synthetic AMPS found by Kai Hilpert (Ramon-Garcia et al. 2013). The MATLAB 
toolbox Gait-CAD (Mikut et al. 2008) including the Peptides Extension Package (Mikut 
2010) were used for most of the computational analysis. Gait-CAD is free software and 
can be downloaded from http://sourceforge.net/projects/gait-cad/ but requires the 
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commercial MATLAB software to work. MATLAB analysis was done in collaboration 
with Prof Ralf Mikut at Karlsruhe Institute for Technology (KIT), Germany. 
The “Cow” dataset was imported using "fastread" function of MATLAB Bioinformatics 
toolbox. Imported data was split into 26 parts with 100,000 sequences each to make 
computation easier. Only protein sequences with a maximum length of 200 amino acids 
(AA) and not more than 5% unknown AAs (marked by X, *) were selected from the 
“Cow” predicted protein sequences from metagenemark_predictions.faa.gz. The APD2 
recommends that small antimicrobial proteins should have a length <200 AAs and most 
AMPs (>90%) have a length of <60 AAs (Wang et al. 2009). Libraries "AMP1" and 
"AMP2" were fused to produce Library "AMP" with 2356 peptides. AA distribution 
and AA dimer (pair) distribution were then computed, resulting in proportion for 20 
AAs (and 20x20 = 400 AA dimers) for Libraries "Cow" and "AMP" Libraries. For each 
candidate of "Cow", distances ("Distance (20)" and "Distance (420)") to each peptide in 
"AMP" were computed. AA acid distributions with minimal value of 0 for identical and 
maximal value of 2 for only completely different AAs, were termed "Distance (20)". 
AA acid and AA acid pair distributions with minimal value of 0 for identical and 
maximal value of 4 for only completely different AAs and AA pairs, respectively 
(distance for 400 + 20 features), termed "Distance (420)". For each sequence in "Cow", 
minimal distance values from previous computational step and number of most similar 
peptide from "AMP" were saved as separate features. Again, all sequences from "Cow" 
with small AA distances (Distance (20) <0.2 or a small AA and AA pair distances 
(Distance (420) <1.45 were saved. All sequences that fulfill the conditions in the 
previous step were collected and written into Excel (see Table 3.9 "Rumen candidates" 
in CD/Figshare). Some interesting hits were then used to check similarity in APD2 
database (criteria: small distance of AA pairs, different neighbors to explore the variety 
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of found candidates). Finally, descriptors (Figures 3.7 to 3.9) were computed following 
procedures described by (Mikut and Hilpert 2009, Mikut 2010). 
3.3 Results 
3.3.1 Isolation of antimicrobial genes in IBERS fosmid metagenomic library 
3.3.1.1 Agar-based functional screen 
After incubation at appropriate temperatures for 24 hours, zones of clearing around 
clones, indicative of gene inserts encoding antimicrobials was observed in 255 out of 
8448 clones screened. Figure 3.1 shows an example of a plate with clones showing 
zones of clearing around them. Table 3.2 below shows a list of all 255 positive clones.  
 
 
Figure 3.1 Example plate from agar-based screen. Area on plate showing clones with 
zones of clearing around them is in dashed box and arrows point to some clones with a 
clearing around them. Screen was done on LB plate. Red colour from a food dye was 
added to aid visibility. 
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Table 3.2 Results from agar based screening of rumen metagenomic clone library - showing only clones with growth and activity in ≥3 
out of 6 screens. Column 1 is plate ID of the SAB library, columns 2-6, describe the well location on the individual plates, i.e. the specific 




3.3.1.2 Sequence analysis of positive clones 
A total of 24 positive clones selected at random for further analysis were sequenced as 
described in section 3.2.1.2. The selected clones are listed in Table 3.3 below. Table 3.4 
is a snapshot on the assembly metrics after shotgun sequencing and assembly on the GS 
FLX system. It shows the total number of reads, base pairs, GC content, contigs and 
open reading frames (ORFs) in each clone. 
Table 3.3 Positive clones selected for sequencing. Column 1 is plate ID of the SAB 
library, columns 2-6 describe the well location on the individual plates, i.e. the specific 
clone with activity against the different pathogens 
Fosmid/Plate ID 




Typhimurium S. aureus  Ent. faecalis 
List. 
monocytogenes TOTAL 
SAB PL 1 
          
0 
SAB PL 2 
          
0 
SAB PL 3 
          
0 
SAB PL 4 N2 
         
1 
SAB PL 5 C17 




SAB PL 6 
          
0 
SAB PL 7 
          
0 
SAB PL 8 




SAB PL 9 
      
A12 
 
B3 F16 3 
SAB PL 10 
          
0 
SAB PL 11 
          
0 
SAB PL 12 (1/2) C3 
 
H18 
   
D18 
   
3 
SAB PL12 (2/2) A3 
 
G13 




SAB PL 14 
          
0 
SAB PL 15 
          
0 
SAB PL 16 
          
0 
SAB PL 17 
          
0 
SAB PL 18 
          
0 
SAB PL 19 
    
A3 
     
1 
SAB PL 27 G18 L13 L10 L17 G15 H14 
    
6 
SAB PL 28 
          
0 





    
3 






Table 3.4 Snapshot on the assembly metrics after shotgun sequencing and assembly 
on the GS FLX system.  




























SAB PL4 N2 26413 17318197 1102 2102927 25841 56.2 132 
SAB PL5 A1 47599 30986482 691 4325733 67719 52.7 328 
SAB PL5 A2 22427 14871695 1218 2450352 38145 51.5 194 
SAB PL5 C17 5733 3699135 76 131887 12070 52.1 53 
SAB PL12(1) H18 10168 6616004 203 263016 401 43.8 6 
SAB PL8 L14 42326 26689339 1258 3662870 8036 47.9 45 
SAB PL9 A12 4707 3113068 85 90709 2240 53.6 11 
SAB PL9 B3 15899 10345946 387 572057 31665 48.2 160 
SAB PL9 F16 10035 6672761 302 448066 13987 51.9 84 
SAB PL12(1) C3 6626 4307213 82 121460 27728 52.6 149 
SAB PL12(1) D18 10742 6936903 284 392503 8036 47.92 44 
SAB PL12(2) A3 32909 21294400 1261 3447744 27125 47.7 168 
SAB PL12(2) G13 17172 10597944 885 1449480 16816 51.1 34 
SAB PL12(2) J19 26621 16046320 1290 2782997 31708 49.4 39 
SAB PL19 A3 18860 11251168 645 992753 5795 53.4 33 
SAB PL27 G15 22181 13408286 890 1518463 29772 45.5 61 
SAB PL27 G18 14752 9075890 552 817667 24482 39.5 99 
SAB PL27 H14 20027 12073019 950 1581893 12018 50.2 68 
SAB PL27 L10 14117 8650852 349 514455 36694 51 193 
SAB PL27 L13 14336 8770311 353 544607 35970 52.6 182 
SAB PL27 L17 17428 10680537 751 1223750 25007 47.5 124 
SAB PL29 H11 16143 10004756 648 988569 33998 49.3 176 
SAB PL29 I11 21218 12829662 1101 1996994 23851 43.6 118 
SAB PL29 M21 13816 8488354 581 842746 1609 56.6 7 
 
After shotgun sequencing on the GS FLX system and sequence assembly, only contigs 
of clones from which the vector had been trimmed (i.e. contigs carrying the 
CopyControlTM pCC1FOSTM vector and gene insert- was the largest contig in most cases) 
were used for further analysis. The largest contig with a ruminal homolog was used in 
cases where the vector sequence could not be located. Table 3.5.1 to 3.5.24 in 
CD/Figshare indicates blastn results (showing first 20 hits) on chosen putatively 
positive fosmid clones. Only the most similar homologs from blastn hits on all clones 
are outlined in Table 3.6 below. 
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When homology searches were done on the open reading frames predicted in the 
selected clones, very low similarity to already known antimicrobial genes and/or gene 
classes was observed. All predicted ORFs (putative protein-coding genes) in the chosen 
contig of all 24 clones can be found in ‘all open reading frames’ folder in CD/Figshare. 
The blastp results of all ORFs can be accessed on the NCBI, although homologs may 
differ depending on access date. The blastp results used in this study were saved in 
order to avoid discrepancies due to website updates (see folder ‘blastp results for all 
ORFs’ in the attached CD. Only ORFs of interests, i.e. ORFs with some homology to 
antimicrobial biosynthetic genes are listed in the Table 3.7 and 3.8 below. Table 3.9 is a 
list of conserved domains in predicted antimicrobial coding genes/proteins. The 
phylogenetic trees of predicted antimicrobial coding genes/proteins and their protein 
homologs can be found as pdf files in Figures 3.2 to 3.6 in CD/Figshare. 
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Table 3.6 BLASTN hits showing the most similar homologs for all selected clones contigs 
 
Plate/clone ID Description Max score Total score Query cover E-value Identity Accession 
SAB PL4 N2 Prevotella ruminicola 23, complete genome 2542 7478 31% 0 92% CP002006.1 
SAB PL5 A1 Uncultured bacterium Contig939 genomic 
sequence 6739 6739 5% 0 100% KC246977.1 
SAB PL5 A2 Prevotella ruminicola 23, complete genome 1581 9168 32% 0 82% CP002006.1 
SAB PL5 C17 Acinetobacter baumannii AB0057, complete 
genome 
1819 1819 7% 0 99% 
CP001182.1 
SAB PL12(1) H18 Prevotella ruminicola 23, complete genome 160 160 35% 2.00E-35 86% CP002006.1 
SAB PL8 L14 Acinetobacter baumannii AB0057, complete 
genome 1833 1833 11% 0 99% CP001182.1 
SAB PL9 A2 Morganella morganii subsp. morganii KT, 
complete genome 
3538 23606 100% 0 94% 
CP004345.1 
SAB PL9 B3 Prevotella ruminicola 23, complete genome 1127 1791 6% 0 81% CP002006.1 
SAB PL9 F16 Prevotella ruminicola 23, complete genome 469 670 9% 4.00E-127 77% CP002006.1 
SAB PL12(1) C3 Uncultured organism XynA gene, complete cds 544 544 3% 2.00E-149 76% JX154664.2 
SAB PL12(1) D18 
Acinetobacter baumannii AB0057, complete 
genome 1833 1833 11% 0 99% CP001182.1 
SAB PL12(2) A3 
Uncultured bacterium Contigcl_1559 genomic 
sequence 14515 14588 24% 0 99% KC246861.1 
SAB PL12(2) G13 
Uncultured bacterium Contigcl_138 genomic 
sequence 21309 21309 66% 0 99% KC246851.1 
SAB PL12(2) J19 
Uncultured bacterium Contigcl_138 genomic 
sequence 24211 24286 39% 0 99% KC246851.1 
SAB PL19 A3 Prevotella ruminicola 23, complete genome 2250 2250 33% 0 87% CP002006.1 
SAB PL27 G15 Prevotella ruminicola 23, complete genome 6334 20112 74% 0 87% CP002006.1 
SAB PL27 G18 Edwardsiella ictaluri 93-146, complete genome 137 137 0% 1.00E-26 81% CP001600.2 
SAB PL27 H14 
Uncultured bacterium Contig1335 genomic 
sequence 9642 9642 41% 0 99% KC247026.1 
SAB PL27 L10 Prevotella ruminicola 23, complete genome 2532 6713 21% 0 80% CP002006.1 
SAB PL27 L13 Prevotella ruminicola 23, complete genome 6753 28065 82% 0 82% CP002006.1 
SAB PL27 L17 Prevotella ruminicola 23, complete genome 5614 10809 45% 0 81% CP002006.1 
SAB PL29 H11 Prevotella ruminicola 23, complete genome 1377 4261 12% 0 89% CP002006.1 
SAB PL29 I11 Coprococcus sp. ART55/1 draft genome 548 737 5% 1.00E-150 75% FP929039.1 
SAB PL29 M21 Prevotella ruminicola 23, complete genome 931 931 99% 0 77% CP002006.1 
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Table 3.7 Predicted antimicrobial (biosynthetic) protein coding genes in fosmids. 



























synthesis of unusual 
molecules including 
polyketides, atypical 





























DHQS represents a 
potential target for the 
development of novel 
and selective 
antimicrobial agents 










































e value 8.4 22/63(35%) 
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Table 3.8 Nucleotide and protein sequences for predicted antimicrobial genes. 
Gene 
name Nucleotide sequence 
size 






































































Table 3.9 Conserved domains in predicted antimicrobial coding genes and proteins 
 
3.3.1.3 Bioinformatic mining and prediction of antimicrobial peptides 
As previously stated, all ORFs were uploaded into different AMP predicting databases. 




























ACPS pfam01648 4'-phosphopantetheinyl 
transferase superfamily 
99-162 1.02E-09 
pantethn_trn TIGR00556 phosphopantetheine--protein 
transferase domain 
96-157 2.37E-03 
AcpS COG0736 Phosphopantetheinyl transferase 
(holo-ACP synthase) [Lipid 
metabolism] 
100-157 2.92E-03 
Sfp COG2091 Phosphopantetheinyl transferase 
[Coenzyme metabolism] 
21-156 1.08E-22 


















(DHQS) catalyzes the 
conversion of DAHP to DHQ in 





aroB TIGR01357 3-dehydroquinate synthase 24-344 4.88E-101 
aroB PRK00002 3-dehydroquinate synthase 6-344 1.18E-99 
DHQ_synthase pfam01761 3-dehydroquinate synthase 55-312 6.08E-98 
AroB COG0337 3-dehydroquinate synthetase 
[Amino acid transport and 
metabolism] 
13-344 2.07E-96 
PLN02834 PLN02834 3-dehydroquinate synthase 26-346 3.98E-52 
PRK13951 PRK13951 bifunctional shikimate kinase/3-
dehydroquinate synthase 
65-328 9.99E-47 
Gene 17B No conserved domain found 
palG1 No conserved domain found 
palG2 No conserved domain found 
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included in the peptide library generated for further antimicrobial screening. A total of 
181 short AMPs (predicted active regions in ORFs) were identified (see file ‘all AMPs’ 
in CD/Figshare). However, based on length and for ease of synthesis, only 135 of these 
AMPs (≤22 AAs) were included in the peptide library created. Peptide library synthesis 
was carried out as described in section 2.7. The comprehensive list of all 135 peptides 
included in peptide library can be found in the file ‘peptide library’ on CD/Figshare. 
3.3.2 Identification of AMPs from the rumen metagenomic dataset 
3.3.2.1 Antimicrobial genes predicted from the rumen metagenomic dataset using 
computational analysis 
A summary of results from each computational step is summarized in Table 3.10 below. 
There were 917,636 sequences remaining after the first selection criteria (i.e., only 
protein sequences with a maximum length of 200 amino acids (AAs) and not more than 
5% unknown AAs (marked by X, *) were selected from the “Cow” predicted protein 
sequences). Out of these 917, 636 sequences, only a few sequences (829 sequences in 
total) fulfilled the criteria of AA distances (Distance (20) <0.2 or a small AA and AA 
pair distances (Distance (420) <1.45 (see Table 3.11.1 "Rumen candidates" in 
CD/Figshare). For example, only 65 sequences met these criteria in the first 68,724 
















number Number of sequences 
Number of sequences 




0a 1 100000 35027 32 
0b 100001 100000 33247 33 
1a 200001 100000 32561 27 
1b 300001 100000 37820 37 
2a 400001 100000 39000 32 
2b 500001 100000 38806 42 
3a 600001 100000 32499 35 
3b 700001 100000 28537 19 
4a 800001 100000 28701 29 
4b 900001 100000 33811 11 
5a 1000001 100000 34135 35 
5b 1100001 100000 38599 42 
6a 1200001 100000 31472 29 
6b 1300001 100000 35397 21 
7a 1400001 100000 38893 26 
7b 1500001 100000 40084 30 
8a 1600001 100000 40459 40 
8b 1700001 100000 40718 41 
9a 1800001 100000 40593 22 
9b 1900001 100000 40600 23 
10a 2000001 100000 40460 36 
10b 2100001 100000 40688 46 
11a 2200001 100000 34674 41 
11b 2300001 100000 31152 31 
12a 2400001 100000 33339 36 
12b 2500001 47270 16364 33 






























`Figure 3.7 Visualization of distances for AA acids Distance (20) and AA pairs 
(Distance 420) for the first 68,724 sequences from library "Cow". Candidates with 
Distance (20)<0.2 or Distance (420)<1.45 are selected as candidates (here: 65). 
 
Although, it was difficult to rate the probability that these sequences are antimicrobial, 
six most promising sequences (termed Hess-AMP gene 1-6 (H-G1- H-G6)) were 
identified out of the 829 sequences, (marked yellow in Table 3.11.1 in CD/Figshare). 
They are also summarized in Table 3.11 below. Different APD2 hits were also 
identified for these 6 AMP sequences, also shown in Table 3.11 below. Table 3.12 
provides the corresponding nucleotide sequence and other information on the identified 
genes. These can be accessed from the file 
''cow_rumen_initial_velvet_assembly_scaffolds.fas.gz" found at the following 
URL http://portal.nersc.gov/project/jgimg/CowRumenRawData/submission/). 
Fusion project 0a: the first 1-100000 protein sequences 
Fusion project 0b: the first 100001-200000 protein sequences 
The first 68,724 protein sequences in library ‘Cow’ meeting the first 
selection criteria from:  
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Table 3.11 Six of the most promising antimicrobial peptide sequences (H-G1-H-G6) identified in cow rumen metagenome dataset 
Assigned 
name Sequence  
Amino acid (AA) 
(length) Location on cow dataset 
Most similar homolog on APD2 
(stop codon ‘*’ removed) 
APD ID Similarity % 
H-G1 
VKKAPAKKAAPKAAAKENVKAA
AAPATKSTKKPKKV*                                                                                                                                                           37
NODE_3603970_length_237431_cov_15.909123_
orf_36410 39090..39200                                                                                  AP00537 45%
H-G2 MKKLLLILFCLALALAGCKKAP                                                                                                                                                                                   22
NODE_664976_length_19740_cov_2.033485_orf_




L*                                                                                                                           53
NODE_4144838_length_4700_cov_0.195319_orf_
38300 3..161                                                                                                                            AP01999 30.76%
H-G4 VLGLALIVGGALLIKKKQAKS*                                                                                                                                                                                   22
NODE_3958153_length_85376_cov_8.525382_orf
_203250 82784..82849                         AP01737 48%
H-G5 
LFGGGGGTGGFGLGGPGGNGPGG
GGGPGGNVPGS*                                                                                                                                                                      35
NODE_793869_length_3085_cov_43.351379_orf_




L*                                                                                                                                                          47 
NODE_2576652_length_4557_cov_3.402019_orf_





Table 3.12 Scaffold nucleotide sequences from which putative antimicrobials H-G1- H-G6 were identified 
Gene ID 
Nucleotide sequence on scaffold from which genes have been 
identified 
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L* full gene 
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Descriptor computations yielded both positively and negatively charged 
hydrophobicity-loading plots which show that “Cow” sequences (metagenmarks0 to 12) 
are represented in  only a small portion of all AMP regions (blue opaque squares- amp 
and Hilpert library) (see Figures 3.8 and 3.9).  
 
 
Figure 3.8 Standard hydrophobicity - loading (positively charged), blue dots are 
known AMPs (library "AMP"), all other colored signs are hits from library "Cow" as described 




Figure 3.9 Standard Hydrophobicity - loading (negatively charged) plot, blue dots 
are known AMPs (library "AMP"), all other colored signs are hits from library "Cow" as 
described in Table 3.10. 
 
3.4 Discussion 
Functional genomics is a widely used tool for the discovery of novel bioactive 
compounds including antibiotics (Wang et al. 2000, MacNeil et al. 2001, Brady et al. 
2002, Handelsman 2004). Antimicrobial compounds have been identified in many 
functional genomics studies using CopyControl (pCC1FOS™ Vector) E. coli based 
fosmid clone libraries (Brady et al. 2002, Burke et al. 2007, Penesyan et al. 2013) 
similar to the IBERS fosmid based metagenomic library used in this project. Clones are 
usually screened in an overlay using various microorganisms as target strains. 
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In this study, it was observed that a number of clones had activity against several target 
bacteria strains tested including E. coli K12 strain, the parent strain from which the 
recombinant TransforMax™ EPI300™-T1
R
 E. coli strain used in fosmid library 
creation was derived. This raises the question of how activity against E. coli K12 could 
be observed in a recombinant E. coli background without toxicity to the host itself. This 
may be possible as the fosmid clones were not induced to a high copy number during 
screens and encoded genes may have been expressed in levels not toxic to the 
heterelogous host. Unless induced to a high copy number (10 to 50 per cell) through the 
addition of expression inducers (i.e., arabinose or IPTG [isopropyl-β-D-
thiogalactopyranoside]) to the growth medium (Penesyan et al. 2013), CopyControl 
fosmid clones grow at single copy to ensure insert stability and successful cloning of 
encoded and expressed toxic proteins and unstable DNA (Park et al. 2008). 
Additionally, in some cases, a zone of clearing could be observed around spots where 
the clones have been stabbed, even when the clone appeared not to have grown (results 
not shown). In these cases therefore, it is possible that the encoded genes had killing 
activity against both the host E. coli strain and the target E. coli strain tested. This 
toxicity to host is a common problem in the heterologous expression of antibiotic genes 
(Uchiyama and Miyazaki 2009, Kimelman et al. 2012) and partly accounts for low 
discovery rate typically observed in metagenomic screens as is the case in this study. 
This may also explain the difficulty encountered during expression of proteins discussed 
in Chapter Four.  
Furthermore, many clones in the agar based screen still had a zone of clearing, even in 
the absence of expression inducers. This may indicate that more antimicrobial gene hits 
could have been found, if screens were carried out in the presence of an inducer. 
However, this could also mean that the target E. coli strain, and not the genes from the 
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fosmid inserts were responsible for the antibacterial activity observed (Yung et al. 
2011). Nonetheless, the genes identified in this study were verified by blast and PCR to 
be of ruminal DNA origin (see Figure 3.11 in CD/Figshare). 
In terms of the results from the IBERS based metagenomic library, the hits of about 
50% of the nucleotide sequences in clones indicative of encoding antimicrobial gene 
inserts were related to Prev. ruminocla 23, 29% were related to various uncultured 
rumen bacteria and the other clones were related to various rumen bacteria, including A. 
baumannii, Morganella morganii, Edwardsiella ictaluri and Coprococcus sp. Recent 
publications of Prev. ruminocla 23 genome (Purushe et al. 2010) may account for why 
most of the fosmid sequences were similar to this entry. Moreover, Prevotella has been 
shown to be one of the more dominant genera in the rumen (Stevenson and Weimer 
2007, Bekele et al. 2010, Kong et al. 2010). The high similarity to uncultured rumen 
bacteria confirms the evidence that many rumen bacteria are yet to be cultured and need 
to be further explored (Creevey et al. 2014). 
When homology searches were done on the ORFs predicted in the selected clones, very 
low similarity to already known antimicrobial genes and/or gene classes was observed. 
This could be because antimicrobial activities observed in the agar-based assay are 
encoded by putatively novel genes not previously annotated to having antimicrobial 
function. In total, five putative genes (Genes 6, 17A, 17B, palG1 and palG2) showing 
similarity to known antimicrobial genes were retrieved in addition to predicted 
antimicrobial peptides (AMPs). The overall number of genes may however, be 
underestimated in this study since 454 sequencing results did not allow for the closure 
of all fosmids and further sequencing could not be repeated due to time constraints. A 
total of 181 antimicrobial peptides, again with low similarity (<50%) to known AMPs 
were predicted in all open reading frames using different AMP databases.   
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Predicted genes included a 4’- phosphopantetheinyl transferase family protein which is 
involved in the synthesis of unusual molecules including polyketides, atypical fatty 
acids, and antibiotics, one 3 dehydroquinate synthase, a potential target for the 
development of novel and selective antimicrobial agents, one colicin V (bacteriocin) 
production protein, and two penicillin amidase/acyclase genes which catalyse the 
hydrolysis of benzylpenicillin to phenylacetic acid and 6-aminopenicillanic acid (6-
APA) a key intermediate in the synthesis of penicillins. Genes 6 and 17A have 
conserved domains matching the putative functions of their most similar homologs. 
Genes 17B, palG1 and palG2 did not have any conserved domains. None of the five 
proteins had a predicted signal sequence and/or cleavage position. Phylogenetic analysis 
of the five proteins and their protein homologs again revealed a distant relationship 
between the sequences. It was impossible to build a phylogenetic tree to include all five 
protein coding genes as they were quite dissimilar in size and sequence.  
On the other hand, very few antimicrobial genes (6) were predicted in the cow 
metagenomic dataset, probably due to the stringent parameters used for prediction. Also 
only AMPs from two datasets were used for homology searching and prediction, as it 
was challenging to pull out antimicrobial genes from the NCBI and other protein 
databases, as one would need to search for each antimicrobial gene individually to 
obtain its sequence before a homology search is performed. Furthermore, a search for 
antimicrobial genes very readily provides antimicrobial resistance genes instead. It is 
likely that more antimicrobial genes hits would be identified if more databases were 
included in the analysis. This highlights the need to create a single and more 
comprehensive repository/database where all antimicrobial genes are stored especially 
for ease of prediction and drug design purposes, instead of several currently available 
databases with limited coverage.  
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In summary, all predicted AMPs were classified as either short (≤25 AAs) or long (>25 
AAs) proteins/peptides. Five longer antimicrobial genes or miniproteins >25 AAs in 
length (Gene 6, 17A, 17B palG1 and palG2) including 181 short antimicrobial peptides 
≤25 AAs were identified from the in-house metagenome library. Six genes H-G1 to 6 
were also identified from the rumen metagenomic sequence dataset. The low similarity 
of these interesting antimicrobial genes hits to documented sequences in public 
databases may indicate their novelty. Experimental evaluation to determine the 
antimicrobial properties of these putative antimicrobial proteins and peptides (AMPPs) 
is necessary to ascertain their applicability in the treatment of bacterial infections. To 
investigate the antimicrobial properties of these genes, DNA amplification, expression 
and purification (or chemical synthesis of shorter AMPs ≤22 AAs) and characterization 














Expression purification and characterisation of recombinant 
antimicrobial proteins 
4.1 Introduction and aim of chapter 
Novel antimicrobial compounds, especially antimicrobial peptides (AMPs) have been 
regarded as a potential solution to the worldwide emergence and rapid horizontal spread 
of antibiotic-resistant traits in bacteria of (human and veterinary) clinical significance 
(Ingham and Moore 2007). They have also been considered as one of the most 
promising alternative antibiotics because of their strong antimicrobial activity and 
microorganism eradication with less likelihood of resistance developing (Shin et al. 
2013). Therefore, Herculean efforts to develop this new class of antibiotics with novel 
targets and modes of action have attracted a large amount of attention (Makovitzki et al. 
2006). However, in comparison to most antimicrobials, the high manufacturing cost of 
synthesizing AMPs has hindered their therapeutic application. This has led to the 
isolation, purification and characterisation of a large number of antimicrobial peptides 
during recent years using recombinant production of AMPs (Guerreiro et al. 2008, 
Zorko et al. 2009, Bommarius et al. 2010, Pei et al. 2014). 
Gene cloning and expression (recombinant DNA technology), is a process by which 
genes can exert their function (.i.e. convert the information stored in a gene to a 
functional product) and is the only way of isolating long genes or those that have never 
been studied before (Brown 2006). E. coli is one of the organisms of choice for the 
production of recombinant proteins and its use as a cell factory is well-established 
(Samuelson 2011). It has become the most popular expression platform with many 
molecular tools and protocols at hand for high-level production of heterologous proteins 
due to its rapid growth, a variety of portable vectors, relatively simple genetics, and the 
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potential for high-density cultivation (Samuelson 2011, Rosano and Ceccarelli 2014). 
However, difficulties have been encountered in the expression of antimicrobial 
proteins/peptides in bacterial and other hosts due to their toxicity to host cells, 
susceptibility to proteolysis and low expression levels (Doherty et al. 1993, Dong et al. 
1995, Jin et al. 2006, Chen et al. 2008). As a result, various expression systems with 
AMPs fused to a partner protein have become popular as the most effective method of 
recombinant AMP production because they have reduced toxicity, enhanced product 
stability and recovery (Wei et al. 2005, Moon et al. 2006, Xu et al. 2006, Chen et al. 
2009). However, although these fusion technologies overcome some of the 
disadvantages of traditional recombinant methods mentioned above, some of these 
methods are still being studied and many of them are still commercially unavailable. 
In Chapter three, 5 putative antimicrobial peptide genes (Gene 6, 17A, 17B, palG1 and 
palG2) were discovered through functional and sequence based screening of the fosmid 
metagenome library. In addition, six genes (H-G1 to H-G6) were identified in an 
already existing cow rumen metagenomic dataset (Hess et al. 2011). This chapter 
therefore, describes the amplification, expression and purification of these never before 
studied potential antimicrobial genes (predicted AMPs > 22 AAs) using a conventional 
and E. coli expression system in the first instance, in order to enable further 
characterisation of the antimicrobial potential of the genes identified. AMPs ≤22 AAs in 
length were chemically synthesised (section 2.7) before characterisation of their 
activity. 
4.2 Materials and methods 
4.2.1 Amplification of antimicrobial genes 
Fosmid DNA to be used as templates for PCR amplification were extracted as described 
in section 2.6.2. For the amplification of H-G 1 to 6, DNA was extracted from milled 
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rumen samples from our laboratory, and not from the original rumen sample from 
which the data was generated (see section 2.6.2.1). Primers used for the amplification of 
the antimicrobial genes were designed using the online tool available at 
http://tmcalculator.neb.com/#!/. As none of the genes were predicted to have a signal 
peptide (using the SignalP 4.1 server), the primers were designed to start and stop at the 
first predicted methionine and at the last stop codon respectively in order to conserve 





C. All designed primers were synthesised by Sigma Aldrich, Dorset, UK. It was 
not necessary to add restriction enzymes or a Histidine tag (His-Tag) sequence to the 
primer sequences of genes to be expressed using the pTrcHis TOPO® TA Expression 
kit as the pTrcHis-TOPO® cloning vector carries a His-Tag and allows for the ligation 
reaction between the amplified gene insert and the vector without requiring an enzyme 
restriction step. The primers used are presented in Table 4.1 below. 
Table 4.1 Primers for amplification of antimicrobial genes in putative positive 
fosmid clones using the pTrcHis TOPO® TA Expression System (F, forward primer 















SABPL5 C17/11   
Gene 6 
F ATGATTACTCTGGTGCGTGAGG  
555 R CTATTCACATATGGTGTAAATATACCGC
TGTCG 








SAB PL12(1) C3/50  
Gene 17B 
F ATGGGCTGTTCTATCGAGTGG  
243 R CTACGACGAGATGCTTGCACGATTG 
SAB PL27 L10/66   
palG1 
F ATGAGGCTGTCACACGTTTG  
216 R TCACCAATCTGTATGGCACCG 
SAB PL27 L10/73  
palG2 
F ATGAGCGCCATGAGGCAC  
207 R TCAGACAAGGCATATTTCAAGGATGCC 
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Table 4.2 Primers for amplification of antimicrobial genes from metagenomics 























F CACCATGGACCATCCCTGC 1971 
R AGATAAAATCAACCCCACCATCG 
H-G5 
F CACCATGAGTGATGTAATTGACGATAA 788 
R ATGATATCGTTAAATATCTTTACGCTTCTT 
H-G6 
F CACCATGCTATCATTCCTATTCATGC 138 
R AAGAAACTTCCTCTTCAGGAATCTCTT 
 
All primers were diluted to a concentration of 100 µM and a total volume of 50 µl PCR 
reaction was set up as follows: 2 µl DNA template, 1 µl each of forward and reverse 
primers, 39.5 µl molecular grade water and 1 µl Titanium
®
 Taq DNA Polymerase 
(Clonetech- Takara Bio Europe/SAS, France). Taq was initially activated for 1 minute at 
95
o
C, followed by 30 cycles of 95
o
C for 30 seconds, 68
o
C for 1.5 minutes, followed by 
a final extension step at 68
o
C for 1.5 minutes. PCR products were verified by 
electrophoresis on a 1.5% agarose gel using a 1kb ladder. Gel image was taken after 




 system (BIO-RAD Hertfordshire, UK). 
Subsequently, the band of interest was excised with a clean sterile scalpel under a Dark 
Reader blue transilluminator (Clare Chemical Research Inc. USA) and DNA was 
purified and eluted as described in section 2.6.5. 
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4.2.2 In vivo cloning of antimicrobial genes 
4.2.2.1 Cloning using the pTrcHis TOPO® TA Expression System  
The cloning of antimicrobial genes was initially carried out using the pTrcHis TOPO® 
TA Expression kit. Briefly, the cloning reaction was set up by mixing 4 µl of purified 
PCR amplified gene (section 4.2.1) with 1 µl of pTrcHis TOPO® cloning vector. The 
reaction was gently mixed and incubated for 5 minutes at room temperature. Thereafter, 
2 µl of the cloning reaction was added to a vial of OneShot® E. coli TOP10 cells and 
left to incubate on ice for 30 minutes, after which, the cells were heat shocked for 1 
minute at 42
o
C and then immediately placed on ice. Subsequently, the cells were added 
to 250 µl room temperature SOC medium (Super Optimal broth (SOB) with catabolite 
repression i.e., with 20 mM glucose) and incubated with horizontal shaking at 37
o
C for 
60 minutes. Volumes of 30 µl and 70 µl were then plated onto pre-warmed LB plates 




4.2.2.2 Confirmation of cloning reaction 
Sequencing and tip-dip PCR were used to analyze positive transformants. Five colonies 
from each transformation were analyzed for correct size sequence and orientation. The 
selected colonies were cultured overnight in LB medium containing 100 µg/ml 
ampicillin and 0.5% glucose. Their plasmid DNA was then isolated as described in 
section 2.6.2. The Xpress™ Forward sequencing primer for pTrcHis-TOPO® (5´-
TATGGCTAGCATGACTGGT-3´) was then used to sequence the insert by Sanger 
sequencing (reaction was made up of at least 250 ng and 1.6 ρM of plasmid DNA and 
primer respectively). Sequence alignments confirming that transformants had the correct 
sequence can be found in the file ‘cloning transformants alignment’ in CD/Figshare.  
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For analysis of positive transformants by tip-dip PCR, 1 ml aliquots of the same 
selected five colonies were cultured overnight and lysed by heating for 10 minutes at 
95
o
C in sterile 1.5 ml microcentrifuge tubes. The cell debris was then pelleted by 
centrifugation at 13,000 x g for 2 minutes. The supernatant was used as the template for 
PCR. The PCR reaction was set up in a total volume of 50 µl as follows: 2 µl of 
template DNA, 1 µl each of gene specific forward primer (Table 4.1) and vector 
specific reverse primer (5´-GATTTAATCTGTATCAGG-3´), 21 µl molecular grade 
water and 25 µl MyTaq™ Red Mix (Bioline, UK Ltd, London UK). Initial Taq 
activation was performed at 95
o
C for 1 minute, followed by 35 cycles of 95
o
C for 15 
seconds, at insert specific annealing temperature for 15 seconds and an extension step at 
72
o
C for 10 seconds, then a final extension step at 72
o
C for 7 minutes and holding at 
4
o
C. Again, PCR products were verified by electrophoresis on a 1.5% agarose gel using 
a 1kb ladder. A positive PCR control was also prepared using the control PCR template 
(expected size of 750bp) and primers provided with the pTrcHis-TOPO® Expression 
kit. 
After analysis and confirmation, single colonies of positive transformants with correct 
inserts were grown at 37
o
C with shaking in LB broth containing 100 µg/ml ampicillin 
and 0.5% glucose until culture reached mid-log (OD600nm of ~ 0.5-0.7). Aliquots (2 ml) 
were then stored in 30% (v/v) sterile glycerol in cryovials at -80
o
C. 
4.2.3 Expression of His-tagged antimicrobial proteins 
Firstly, a pilot expression was carried out to determine the best conditions for maximum 
expression of each protein. A single recombinant E. coli colony of the clones chosen for 
each protein was inoculated into 2 ml of LB broth containing 100 µg/ml ampicillin and 
grown overnight at 37°C with shaking (225-250 rpm). The following day, 10 ml of LB 
containing 100 µg/ml ampicillin was inoculated with 0.2 ml of the overnight culture and 
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incubated at 37°C with vigorous shaking to an OD600nm = 0.6 (mid-log phase), after 
which 1 ml aliquot of cells was removed, centrifuged at maximum speed (15,000 x g) in 
a microcentrifuge for 30 seconds, and the cell pellet was frozen at -20°C after aspirating 
the supernatant. This was taken as the zero time point. IPTG was then added to a final 
concentration of 1 mM (9 µl of a 1 M IPTG stock to 9 ml) and grown at 37°C with 
shaking. Every hour for five hours, 1 ml samples were removed and treated in the same 
way as above after normalising cell densities. Pellets from all time points were 
subsequently analyzed by sodium dodecyl sulphate polyacrylamide gel ((SDS-PAGE)-
Section 4.2.4) to determine the optimal time point for maximum expression. TOP10 
cells containing pTrcHis-TOPO®/lacZ and TOP10 cells that did not contain any vector 
were used as positive and negative expression controls respectively. Expression of 
proteins was then scaled up to 1 litre volumes. Cells were harvested by centrifugation 
(3,000 x g for 10 minutes at 4
o
C) at the pre-determined optimal time point. Pellets were 
then stored at -80
o
C for subsequent protein purification (section 4.2.5) 
4.2.4 Polyacrylamide gel electrophoresis  
Proteins were analysed using SDS-PAGE on a 20% resolving gel (1.5 M Tris-HCl (pH 
8.8), 0.4 % SDS, 20% (w/v) acrylamide) and a 5 % stacking gel (0.5 M Tris-HCl (pH 
6.8), 0.4 % SDS, 5% (w/v) acrylamide), cross linked by addition of 40 % N, N‟-bis 
acrylamide solution (BIO-RAD Hertfordshire, UK)) (Laemmli, 1970). Polymerisation 
of both the resolving and stacking gels was initiated by addition of 0.5% freshly made 
10% (w/v) ammonium persulphate (APS) and 0.4 and 0.1% (w/v) N,N,N‟,N‟-
Tetramethylenediamine (TEMED) respectively. The running gel solution was poured 
between the glass plates with a pipette, with about 1/4 of space free for the stacking gel. 
It was then carefully covered with ultra pure water. The resolving gel was then left to 
polymerize for ~30 minutes (a clear line appears between the gel surface and the water 
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on top when polymerization is complete). The water is then discarded and the stacking 
gel solution (prepared as described above) is carefully poured into the glass plates with 
a pipette to avoid formation of bubbles. This was followed by the insertion of 
appropriate sized combs, after which the stacking gel was allowed to polymerize for at 
least 60 minutes. Then, the combs were carefully removed and the gels were transferred 
into an electrophoresis tank with bottom and top reservoirs, filled with fresh 1X Tris-
glycine-SDS Buffer. Protein samples and protein molecular weight markers (precision 
plus (BIO-RAD Hertfordshire, UK) or NEB #P7703 (New England Biolabs Hitchin, 
UK)) were then loaded onto the gels. Vertical electrophoresis was run at 25 mA (for two 
minigels 100 x 80 x 1mm) until the dye front (bromophenol blue line) reached the base 
of the gel. 
Preparation of protein samples was as follows: when the cell pellets from the different 
expression time points were collected and prepared as described in Section 4.2.3, they 
were each resuspended in 100 µl of 1X SDS-PAGE sample buffer (17.5% double 
distilled water, 0.5 M Tris pH 6.8, 5 ml 25% Glycerol, 10% SDS, 2.5% 2-β-
mercaptoethanol and 0.1% bromophenol blue). They were then heated at 95
o
C for 5 
minutes and centrifuged briefly, after which 5 µl of each sample was analysed on an 
SDS-PAGE gel. 
Upon completion of electrophoresis, protein bands were detected by first fixing the gels 
with a solution of 40% (v/v) methanol and 10% (v/v) glacial acetic acid for at least 40 
minutes, before staining the gel with Coomassie stain (0.25% Coomassie Brilliant Blue 
R-250 (Sigma Aldrich, UK), 50% (v/v) methanol and 10% (v/v) glacial acetic acid for 
up to 2 hours. Background stain was then removed by a destaining solution (40% (v/v) 
methanol and 10% (v/v) glacial acetic acid). Gel images were taken using the GS-800
TM
 
calibrated densitometer (BIO-RAD Hertfordshire, UK). The recombinant proteins were 
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identified by a band of increasing intensity in the expected size range with the His-tag 
contributing ~ 3 to 4 kDa to expressed protein. The negative control (E. coli TOP10 
only cells) were used to distinguish recombinant proteins from background proteins 
while the positive control (pTrcHis-TOPO®/lacZ which should yield a 40 kDa protein 
between 3- 4 hours) was used to confirm that growth and induction was done 
successfully. 
4.2.5 Purification of His-tagged proteins 
Purification of the proteins was carried out under native conditions using the Amicon® 
Pro Purification System (Merck Millipore Ltd Carrigtwohill, Ireland).  
4.2.5.1 Preparation of E. coli lysate for purification under native conditions 
Briefly, the cell pellets from a scaled up expression (1000 ml culture) of recombinant 
antimicrobial proteins prepared as described in section 4.2.3 were resuspended in 40 ml 
native binding (lysis) buffer (15 mM imidazole, 500 mM sodium chloride (NaCl), 20 
mM Tris-hydrochloride pH 7.9). Lysozyme from chicken egg white (Sigma-Aldrich, 
UK) to a final concentration of 1 mg/ml and four tablets of protease inhibitor cocktail 
(one tablet per 10 ml) (Roche, Burgess Hill, UK) were then added, mixed and incubated 
at room temperature for 30 minutes. The solution was then sonicated using a Vibracell 
VCX130 (Sonics and Materials, USA) on ice (twelve 10-second bursts at 50% 
amplitude with a 30-second cooling period between each burst). Afterwards, the lysate 
was centrifuged at 7,000 x g for 15 minutes to pellet the cell debris and the supernatant 
(lysate) was transferred to a fresh tube and chilled at -20
o
C until purification. 
4.2.5.2 Resin preparation in the Amicon® Pro purification system 
Up to 1000 µl of previously vortexed packed Nickel-nitrilotriacetic acid (Ni-NTA) 
Agarose slurry (0.5 ml bed volume) (Qiagen, Crawley, UK) was pipetted into the 
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Amicon® Pro exchange device and centrifuged in a swinging-bucket rotor at 1,000 x g 
for 1 minute to remove the storage buffer from the resin. The binding buffer (5 ml) was 
then added to the resin and centrifuged at 1,000 x g for 1 minute. 
4.2.5.3 Protein binding and wash in the Amicon® Pro purification system 
Approximately 9 ml of lysate (from 4.2.5.1) was added to the equilibrated resin matrix 
and incubated at room temperature for 60 minutes with gentle agitation (shaking 200 
rpm) on a rotary shaker. The device was thereafter centrifuged at 2,000 x g for 4 
minutes and sample flow-through was recovered. Three wash steps were performed by 
adding 9 ml wash buffer (35 mM imidazole, 1 mM NaCl, 20 mM Tris-HCl pH 7.9) and 
centrifuging at 2,000 x g for 4 minutes. Wash fractions were recovered following each 
wash step. 
4.2.5.4 Sample elution, buffer exchange and concentration in the Amicon® Pro 
purification system 
For simultaneous elution and concentration of purified proteins, the Amicon® Ultra-0.5 
(molecular weight cut-off 3 kDa) was inserted into the exchange device and placed back 
into the device holder. The resin was then gently resuspended in up to 1.5 ml of elution 
buffer (400 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl pH 7.9) and centrifuged at 
4,000 x g for 60 minutes. A total volume of 1.5 ml of the desired exchange buffer (100 
mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer (pH 7.5)) was 
then added to the exchange device/Amicon® Ultra-0.5 assembly and centrifuged at 
4,000 x g for a further 60 minutes. The purified protein samples were subsequently 
collected from the Amicon® Ultra-0.5 device by reverse spin. A 2 ml collection tube 
was placed over the top of the Amicon® Ultra-0.5 device held in an upright position. 
The assembly was then inverted and centrifuged in a microcentrifuge with fixed-angle 
rotor at 15,000 x g for 60 minutes. Sample protein concentration was determined at an 
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absorbance of 280 nm using the BioTek’s Epoch™ Multi-Volume Spectrophotometer 
(BioTek Instruments, Inc. Vermont, USA). The concentration of the protein was 
calculated as the ratio of A280nm to the extinction coefficient absorbance (Abs 0.1% 
(=1 g/l) obtained inputing protein sequence into the ExPASy ProtParam tool available at 
http://web.expasy.org/cgi-bin/protparam/protparam) (Gasteiger et al. 2005). 
4.2.6 In vitro expression of antimicrobial genes 
In vitro expression of antimicrobial genes was performed for those genes which were 
difficult to express in vivo in E. coli cells. This was completed using the PURExpress
®
 
In Vitro Protein Synthesis kit (New England BioLabs Inc, Hitchin, UK). Primers for in 
vitro expression were designed as described in the manufacture’s manual. Adaptor 
sequences (homologous to part of the regulatory region DNA) were added to the 5´ and 




Figure 4.1 Suggested primer design for PCR for generation of template DNA for 
use with PURExpress (A), suggested primer design sequence for PCR. (B), Illustration 
of 3´ UTR Stem Loop of PCR Templates for PURExpress. 
 
The primers used for amplification and preparation of template DNA of antimicrobial 
genes for use with PURExpress in vitro expression are given in Table 4.3 below. The 
expression reaction was assembled on ice in microcentrifuge tubes in a total volume of 
25 µl as follows: 10 µl Solution A, 7.5 µl Solution B, 1 µl (20 units) of Murine RNAse 
inhibitor (NEB #M0314, Herts, UK), at least 500 ng DNA template (amplified as 




Table 4.3 Primers for amplification of antimicrobial genes for use with PURExpress (F, 
forward primer and R, reverse primer). 
Gene name Primer sequence (5'-3') 
Gene 6 -F GCGAATTAATACGACTCACTATAGGGCTTAAGTATAAGGAGGAAAAAATA
TGATTACTCTGGTGCGTGAGGATATTTGG 
Gene 6-R AAACCCCTCCGTTTAGAGAGGGGTTATGCTAGTTA 
CTATTCACATATGGTGTAAATATACC 
Gene 17A - F GCGAATTAATACGACTCACTATAGGGCTTAAGTATAAGGAGGAAAAAATA
TGGATAAACAGAAGGTTATCATATCGCTCCAG 
Gene 17A -R AAACCCCTCCGTTTAGAGAGGGGTTATGCTAGTTATTAGTTCCCCTCGCGA
TAAAAGTC 
Gene 17B -F GCGAATTAATACGACTCACTATAGGGCTTAAGTATAAGGAGGAAAAAATA
TGGGCTGTTCTATCGAGTGGATGTTG 











The reaction was then incubated at 37
o
C for 4 hours. Dihydrofolate reductase (DHFR) 
positive control template was used to determine a successful expression reaction. Upon 
completion of in vitro expression, 2.5 µl of expression product was added to 10 µl of  
4X SDS loading buffer, heated at 100
o
C for 5 minutes and analysed by SDS-PAGE as 
described in section 4.2.4.  
Purification of synthesized proteins was carried out using reverse His-tag purification as 
described in the user manual. Briefly, 10 mM magnesium acetate was added to the 
reaction to a final volume of 125 µl in order to increase the volume and make handling 
of the sample easier. The diluted reaction mixture was then applied to an Amicon 
Ultracel 0.5 ml-100K spin concentrator (0.5 ml maximum load volume) (Merck 
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Millipore Ltd Carrigtwohill, Ireland) and centrifuged for 30–60 minutes at 15,000 x g at 
4°C. The permeate/flow-through was thereafter transferred to a new 2 ml round-bottom 
microcentrifuge tube with a leak-proof cap. This was followed by the addition of 0.25 
volumes Ni-NTA Agarose and mixed thoroughly at 4°C for 60 minutes to allow His-
tagged components to bind to the resin. The reaction mixture slurry was subsequently 
transferred to an empty Bio-Rad micro-spin column and centrifuged for 60 minutes at 
15,000 x g at 4°C. The eluate containing purified protein was collected and analysed by 
SDS-PAGE for presence of purified protein. 
4.3 Results 
4.3.1 Cloning expression and purification in in vivo expression systems 
PCR amplification of antimicrobial genes was successful for all the genes as illustrated 
on Figure 4.2 and 4.3. Bands of the correct size were excised from the gel before 
proceeding to cloning to ensure subsequent clones were carrying the correct PCR 
product as some had more than one amplicon present. Five colonies per transformation 
for each gene cloned into the pTrcHis-TOPO® vector were analysed for size and 
orientation of the insert. The electrophoresis results for tip-dip PCR presented in Figure 
4.4 show that chosen clones were confirmed as carrying the genes of the correct size. 
Figure 4.4 also shows the clones that were stored as glycerol stocks and chosen for 
protein expression. The antimicrobial proteins were expressed with an N-terminus six-
histidine tag in E. coli in order to enable purification and investigation of their 
biochemical properties. The pilot protein expression assay showed that protein 
expression was optimal 4 hours after induction of the clone cultures with 1 mM IPTG, 
as illustrated by SDS-PAGE results in Figure 4.5. This Figure also shows the 
appearance of target protein bands visualised on Coomassie-stained gels compared to 
the positive and negative expression controls at different expression time points after 
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induction with IPTG. Based on the level of expression of the proteins in the pTrcHis-
TOPO® TA expression system (Figure 4.5), only proteins palG1 was chosen for 
purification, as there was no visible increase in band intensity over time during 
expression of the other proteins (Gene 6, 17A, 17B and palG2). This may be because 
the proteins were insoluble as they could not be detected on SDS-PAGE (Figure 4.5 A, 
B, C, E) or because high expression levels of the proteins induced by IPTG was toxic to 
the host E. coli cells. Cultures of palG1 transformants were scaled up appropriately for 
harvesting cell pellets for protein purification. The recombinant proteins were purified 
in native conditions in order to preserve their activity as described in Section 4.2.5. 
Figure 4.6 shows the SDS-PAGE analysis of the purification fractions from palG1. The 






Figure 4.2 PCR amplification product analysis on 1.5% agarose gel of 
antimicrobial genes- using primers in Table 4.1. Neg, negative control. Expected size is 555, 






Figure 4.3 PCR amplification product analysis on 1.5% agarose gel of antimicrobial genes from Hess etal. (2011) dataset- using 
primers in Table 4.2. Each gene was amplified using 6 rumen samples, Neg, negative control. Expected size is 213, 444, 156, 1971, 788 and 1386bp for 
H-G1 to H-G6 respetively. 
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The antimicrobial genes from the IBERS fosmid library were successfully amplified by 
PCR using fosmid DNA from the clones from which they were identified (Figure 4.2 
above). Only H-G2 and H-G6 had specific PCR amplified product band for at least one 
rumen sample used. H-G1 and H-G4 had unspecific DNA products while H-G3 and H-
G5 were not amplified at all.  
Also, as can be seen in Figure 4.4 below, Tip-dip PCR analysis confirmed that cloned 






Figure 4.4 Tip-dip PCR amplification product analysis on 1.5% agarose gel of transformants (colonies) of antimicrobial genes using 
gene specific forward primers and pTrcHis-TOPO® reverse primers. Neg, negative control, Cc, clones with correct insert size (one of which was 





Figure 4.5 SDS-PAGE analysis of expression of the His-tagged antimicrobial proteins in E. coli TOP10 cells - from 0 to 5 hours after 
induction with 1 mM IPTG. Pellets from 1 ml samples taken before induction (T0) and hourly after induction (T1, T2, T3, T4 and T5). M is the Protein Ladder. The 
red dot indicates the expected size of protein of interest. Expected sample size for proteins Gene 6, Gene 17A, Gene 17B, palG1, palG2, and pTrcHis-TOPO/LacZ are 
21.4, 38.71, 9.98, 8.35, 7.32 and 40 kDa (±3-4 kDa from His-tag) respectively. 
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Only palG1 was successfully expressed over time after induction with IPTG. Negative 
and positive control proteins were as expected. 
 
Figure 4.6 SDS-PAGE analysis of purification steps of palG1 protein expressed in 
E. coli TOP10 cells on a 20% denaturing polyacrylamide gel (5 hours after induction with 1 
mM IPTG). The red arrow indicates band of purified protein of interest. Expected size is 8.35 
(±3-4 kDa from His-tag). 
 




4.3.1 Cloning expression and purification in in vitro expression systems 
Genes 6, 17A, and 17B were successfully expressed in vitro using PURExpress (E. coli 
lysate with a T7 promoter) as shown in Figure 4.7 below. However, several attempts to 




Figure 4.7 SDS-PAGE analysis of PURExpress reaction for antimicrobial proteins 
after 4 hours incubation. The red dots indicate the protein band of interest. M, Protein Ladder. 
DHFR, control DNA template. Expected sample size is 23, 21.4, 38.71, 9.98 kDa for DHFR, Gene 6, 
Gene 17A, Gene 17B respectively. 
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4.4  Discussion 
Although, PCR amplification was successful for all antimicrobial genes identified from 
the in house rumen metagenomic library, in vivo expression of selected putative 
antimicrobial genes (cloned into pTrcHis TOPO vector and transformed into chemically 
competent E. coli TOP10 cells) was only successful for palG1 (Figures 4.5 and 4.6). No 
visible expression profile was observed over time for all other proteins even when 
expression conditions were changed. Positive control showed an increasing expression 
over time and as expected, negative control had no expression profile. 
DNA amplification of Hess et al, (2011) genes (H-G1 to H-G6) was problematic. H-G2 
and H-G6 were the only AMPs in this group successfully amplified without unspecific 
DNA amplicons in at least one rumen DNA template/sample used. An attempt to 
recover these DNA amplicons through gel purification yielded DNA products very low 
in concentration and sequencing showed that the gene was only partially amplified 
(results not shown). This could be due to the fact that many of the genes were partial 
genes and some had unknown bases and/or no start codons. Another reason could be 
that the genes were being amplified from different rumen samples and not the original 
sample used to generate the data. Due to time constraint, attempt to express the H-G1 to 
H-G6 genes was aborted. It will be necessary to redesign primers and attempt to amplify 
these genes again in the future and attempt to successfully express them. In the 
meantime, H-G2 and H-G4, which were both 22 AAs long were chemically synthesized 
to determine their antimicrobial activity (discussed in Chapter Five). 
All in-house proteins were successfully expressed in an in vitro expression system. 
However, several attempts to purify these genes were unsuccessful. This may be due 
either to low expression levels or the reverse purification efficiency. Proteins of interest 
may have expressed well but not in high yield, and even with high protein yield, it may 
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still be difficult to go through the purification if the protein was insoluble. Expression of 
palG2 was still unsuccessful even in the in vitro system (results not shown). 
The preparation of the cell pellet for purification is a critical step for protein yields, as 
the lysis should be as efficient as possible. A yield of around 0.2 to 0.5 mg/ml of 
purified palG1 protein was routinely achieved from 1 litre cultures. This yield is not as 
efficient as those reported in previous studies where purified antimicrobial proteins 
ranging in concentrations of 0.5 mg/ml (Guerreiro et al. 2008) to 2.5 mg/ml (Pei et al. 
2014), 0.8 mg/ml (Zorko et al. 2009), 10 mg/ml and up 100 mg/ml (Lee et al. 2008) 
were retrieved respectively from 1 litre culture using Ni-NTA columns. It should be 
noted that different prokaryotic expression systems as well as use of fusion proteins 
were used in these studies mentioned. Moreover, antimicrobials expressed in a simple 
E. coli host will probably have low yields as E. coli growth may be inhibited by the 
expressed proteins (Doherty et al. 1993, Chen et al. 2008). The purification process was 
nevertheless efficient for isolating the desired protein, as SDS-PAGE analysis showed 
that there was a single band corresponding to the expected size of 8.35 ± 3 kDa (Figure 
4.6) indicating that the protein had been purified successfully in an active form. 
The polyhistidine-tag used during expression is one of the most popular affinity tags 
used as an efficient tool for purifying proteins (Hochuli et al. 1987, Hochuli 1988, 
Lichty et al. 2005). It allows efficient purification of tagged proteins in high yields 
without any prior knowledge of their biochemistry, and has a minimal effect on the 
tertiary structure and biological activity of the protein (Arnau et al. 2006). It can be 
subsequently eluted from the resin by competition with free imidazole. The removal of 
the affinity tag is controversial and principally depends on the downstream use of the 
purified proteins. More than 60% of proteins produced for structural studies include a 
polyhistidine tag (Derewenda 2004). Affinity tags could either improve target protein 
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properties or lower yields and enzyme activity (Cadel et al. 2004, Arnau et al. 2006, 
Kou et al. 2007). It was chosen not to remove the affinity tag after purification of palG1 
due to economical and practical reasons, for example the total yields and time saving 
resulting from the low numbers of chromatographic steps. To assess whether the protein 
functions are affected by the His-tag, activity of recombinant palG1 protein could be 
compared to untagged proteins and the positive control protein included in the 
expression kit to see if the activity levels are different. Structural models could also be 
used to ascertain whether the tag affects the protein structure or not. This method relies 
on comparative methods using existing models of previously crystallized proteins as 
templates and the low similarity of the protein sequences identified here could 
potentially cause a problem. 
In conclusion, out of 11 genes identified in the two cow rumen metagenomic libraries, 
only one gene, palG1 could be successfully expressed and purified in sufficient yields 
for downstream applications. It may be necessary to attempt expression of the other 
identified AMPs in other E. coli expression systems (pET-22b(+) or using fusion 
technology described above. However, fusion technology methods require that the AMP 
be separated from its fusion partner, and recombinant fusion proteins, including 
multimeric ones, are usually cleaved with enzymes such as furin or chemicals such as 
cyanogen bromide (CNBr) (Lee et al. 2002, Kim et al. 2008), which results in 
inefficient cleavage and thus poor recovery of AMPs from fusion partners, as well as 
unwanted amino acid residue(s), which can decrease antimicrobial activity and cause 
problematic side effects (Li et al. 2005). Irrespective, it is still possible to express novel 
AMPs from natural environments using the ptrchisTOPO in E. coli TOP10 cells as 





Antimicrobial activity and mode of action studies of novel 
antimicrobial genes identified from the rumen  
5.1 Introduction and aim of chapter 
In Chapters three anf four, a number of novel antimicrobial genes were identified from 
the IBERS fosmid based cow rumen metagenome library (Prive 2011) and from an 
already existing cow rumen metagenome (Hess et al. 2011) using both functional and 
sequence based metagenomic techniques, as well as, other bioinformatic and 
computational platforms. Five long (>22 AAs) antimicrobial genes (Gene 6, 17A, 17B 
palG1 and palG2) were identified from the in-house metagenome library, including 181 
short antimicrobial peptides. Six genes H-G1, H-G2, H-G3, H-G4, H-G5, and H-G6 
were identified from the (Hess et al. 2011) dataset. Of these, only palG1 was 
successfully amplified and expressed in a suitable E. coli host. Also, a peptide library of 
the short AMPs containing 135 peptides (≤22 AAs) was chemically synthesized. H-G2 
and H-G4 (22 AAs) were also chemically synthesized.  
This chapter describes the antimicrobial susceptibility and activity screens of the 
antimicrobial proteins identified above in this study, as well as various mode of action 
studies to understand the killing mechanisms of the AMPs against pathogenic bacteria. 
5.2 Materials and methods 
5.2.1 Antimicrobial screen and analysis of peptide library from fosmid-
based cow rumen metagenomic library 
The activity of the 135 peptides in the peptide library (section 3.3.1.3) was screened by 
a high throughput method using both luminescent and non-luminescent bacterial strains 
described in section 5.2.1.1 and 5.2.1.2 below 
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5.2.1.1 Antimicrobial activity screen of peptide library against luminescent P. 
aeruginosa strain H1001  
The antimicrobial activity of peptides in the synthesized library against a luminescent P. 
aeruginosa strain H1001 (Lewenza et al. 2005) was performed as described by (Hilpert 
and Hancock 2007). A single colony of P. aeruginosa strain H1001 from a freshly made 
Mueller Hinton (MH) agar plate was inoculated into a sterile tube containing 3 ml MH 
followed by overnight incubation at 37
o
C in a shaker at 225 rpm. Fifty microlitres of the 
overnight culture (1:100 dilution) was added to 4,950 µl MH broth in a tube, and 
incubated in a shaker at 37
o
C at 225 rpm until the OD600nm reached 0.35 
(approximately 2 hours). Thereafter, 1,920 µl of the microbial culture was added to 
48,000 µl solution A (100 mM Tris–HCl buffer, pH 7.3, 20 mM glucose) to make 
solution B. This amount of solution B is sufficient for ten complete 96-well plates. 
Solution B was then vortexed gently for 2 minutes and the assay was set up in a clear, 
sterile, U shaped polypropylene 96-well plate (Greiner Bio One Ltd, Stonehouse, UK) 
(Figure 5.1) as follows. Solution B (110 µl) was transferred into each of the 12 wells of 
row A. The luminescence signal of the bacteria in these wells was tested using a Tecan 
infinite F200 pro Quad4 Monochromator micro-plate reader (Tecan Group AG, 
Switzerland) at excitation/emission spectra of 470/695 nm to avoid wasting peptides in 
case the bacteria do not display any luminescence. If a luminescence signal was 
detected (at least more than 900 light units), 70 µl of solution B was added into each of 
the 12 wells of rows B-F, rows G2-6 and rows H1-6, while 110 µl was added wells G1. 
Wells G7-12 and H7-12 were empty. Thirty microlitres of the prepared peptide solution 
(from punched cellulose membrane from spot synthesis) were then transferred into the 
corresponding 12 wells of row A of the 96-well plate and well G1 (140 ml in total in 
these wells). In other words, peptides 1–12 were added to the corresponding wells in 
row A, positive control peptide is added to well G1. The control peptide 
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(KRRWRIWLV) used was a peptide synthesised in the same run as the other peptides 
being tested. Its MIC was predetermined, as it had been previously synthesized on resin 
No peptide is added to the wells in row H. This serves as the growth/negative control to 
obtain 100% luminescence value for the untreated microbes. The contents of row A was 
thoroughly mixed using a 12-channel multipipette and 70 µl was transferred into each 
corresponding well of row B. This stepwise dilution series was continued until row F. A 
serial dilution of the positive control peptide was also carried out. After mixing the 
solution in the last wells of the dilution series, 70 µl was discarded so that the total 
volume in all wells was 70 µl. The luminescence of the plate is again measured and then 
incubated at 37
o
C for 4 hours, after which a final luminescence reading is taken. Results 
obtained were thereafter analysed using the MATLAB extension Gait-CAD (section 
5.2.1.3). 
In addition, 70 µl MH medium was added into each well and plates were sealed and 
incubated at 37
o
C for 16–20 h or when satisfactory growth is obtained (wells show 
visible turbidity). Wells in which no microbial growth has occurred are determined 
visually. Alternatively, OD600nm of the entire plate can be taken. By comparing the 
luminescence data with these growth data, it is possible to identify those peptides whose 
activity is strongly influenced by cation concentration (e.g. magnesium) as well as those 
peptides with killing abilities over a longer period of time. It should be noted that there 
was no change observed in activity for any of the peptides whether after 4 hours or after 





Figure 5.1 Arrangement of 96 well plate in peptide library screens. 
5.2.1.2 Antimicrobial activity screen of peptide library against non-luminescent 
bacterial strains 
The peptide library was also screened for activity against non-luminescent bacteria 
strains including EMRSA-15, Sal. typhimurium and E. coli K12. Overnight cultures 
were prepared and diluted to yield a bacterial concentration of 5 x 10
5
 CFU/ml 
(Friedrich et al. 2000). Into a black, opaque, polypropylene 96 well plate (Greiner Bio 
One Ltd, Stonehouse, UK) 110 µl of culture was added in all wells of the first row A 
and the first well of row G. Into the last 5 wells of row G, 70 µl of sterile MH was 
added to act as a negative control. Into all other empty wells (except wells G7-12 and H7-
12, which were empty), 70 µl of bacteria culture in MH broth (5 x 10
5
 CFU/ml) was 
added. Into wells 1-12 of row A and well G1, 30 µl of peptides in solution (from spot 
synthesised peptides) was added. A two-fold serial dilution was then carried out as 
described in section 5.2.2.1 above. The control peptide used was the same as in the 
section 5.2.2.1 and has a previously determined MIC against MRSA of 16 µg/ml. The 
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first 6 wells of row H contained bacteria but no drug, this served as a measure of 
maximum growth. 
The plates were then covered and incubated for 4 hours at 37°C, after which 14 µl of 
500 µM resazurin in sterile, demineralised H2O was added to each well (100 µm final 
concentration). The plates were then returned to the incubator for an additional hour, 
after which fluorescence readings of each well was measured using a Tecan infinite 
F200 pro Quad4 Monochromator micro-plate reader (Tecan Group AG, Switzerland) at 
excitation/emission spectra of 560/590 nm. The results were then analysed using the 
MATLAB extension Gait-CAD (section 5.2.2.3). 
5.2.1.3 Activity analysis of luminescence and fluorescence dilution series for 
peptides in antimicrobial peptide library against pathogenic bacteria 
MATLAB analysis was carried out in collaboration with Prof Ralf Mikut at Karlsruhe 
Institute for Technology (KIT), Germany. Data obtained from dilution series for activity 
of 135 peptides (including positive and negative controls) against P. aeruginosa, 
EMRSA-15, E. coli K12 and Sal. typhimurium were imported into Gait-CAD (Mikut et 
al. 2008) separately for each Excel table. Concentration values with a 75% reduction of 
luminescence or fluorescence (IC75) in relation to the control were computed to identify 
artifacts of positive and negative controls (Mikut 2010). Fuzzy features were also 
computed according to Mikut and Hilpert (2009). Then all the projects (activity of 135 
peptides against all four pathogens) were fused to get the overview for all peptides. The 
analysis was then based on IC75 values instead of relative values to positive control 
(RelIC75) as pre-analysis showed some problems with positive controls (positive 
control peptide showed the same killing activity on all plates for the same organism but 
not across organisms) (Hilpert and Hancock 2007, Mikut 2010). The minimum, mean 
and median values of IC75 against all four microorganisms were computed. This was 
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followed by the computation of three activity classes: active (IC75≤0.25), semi-active 
(0.25<IC75≤0.50) and inactive (IC75>0.5) for the minimum, mean and median values 
against all microorganisms. IC75, RelIC75 and derived values were saved into an Excel 
table (see Table 5.1 in CD/Figshare), and finally, amino acid distribution and 
hydrophobicity vs. charge were visualized (Mikut and Hilpert 2009) (see Figure 5.3 in 
section 5.3). 
5.2.2 Determination of minimum inhibitory concentration (MIC) of selected 
antimicrobial proteins 
Minimal inhibitory concentrations (MICs) were determined using two-fold serial 
dilutions of antimicrobial agents in MH broth as described by the National Committee 
of Clinical Laboratory Standards (NCCLS) (NCCLS, 1997). The MICs for 
antimicrobial peptides and comparator antimicrobials were measured using a modified 
broth microdilution method in MH broth. Briefly, the peptides were dissolved and 
stored in sterile polypropylene tubes. The assay was performed in sterile U bottom 96 
well polypropylene microplates with lids (Greiner Bio One Ltd, Stonehouse, UK). 
Serial dilutions of antimicrobials were performed in sterile distilled water at 10-fold the 
desired final concentrations. Ten microlitres of this 10 fold dilutions were added to each 
well of a 96 well polypropylene microplates containing 90 µl of MH broth per well. 
Bacteria from overnight culture (adjusted to 1 × 10
8
 CFU/ml) were added to the wells of 
the plate (final inoculum concentration of 5 × 10
5
 CFU/ml) (Cherkasov et al. 2008, 
Wiegand et al. 2008). The MIC was defined as the lowest concentration of drug that 




5.2.3 Erythrocyte leakage assay  
Erythrocyte leakage assay using defribinated sheep blood (Oxoid Ltd Hampshire, UK), 
was used to determine whether antimicrobial peptides would cause erythrocyte lysis, 
and therefore possible cytotoxicity. Briefly, six sterile microcentrifuge tubes were each 
filled with 1 ml fresh defibrinated sheep red blood cells (RBC) and centrifuged for 5 
minutes at 1,000 x g in a sci spin mini centrifuge in a microbiology safety cabinet. The 
supernatant was discarded and the pellet washed 3 times with phosphate buffered saline 
(35 mM PBS) (pH 7.3). Centrifugation at 1,000 x g was carried out between each wash. 
The red blood cells were then diluted in PBS to 4% v/v in one vial (8.6 ml total volume 
was used per 12 peptides to be tested/per 96 well plate). Thereafter, 90 µl of the 4% 
solution was added to all wells in the plate. Ten micro litres of peptides (at 10X desired 
final concentration) were added to RBC solution in all wells of columns 1-9 of all rows 
on plate, mixed through pipetting and serially diluted down the rows. Wells in column 
10 contained RBC with triton X-100 (Sigma-Aldrich UK) at different concentrations (1, 
0.8, 0.6, 0.4, 0.2, 0.1, 0.05% and 0.025%), while wells in column 11 contained RBC 
with 0.1% triton-X which served as a positive control (0.1% causes 100% cell lysis). 
The serial dilution of the triton-X in column 10 provided an added control to identify 
any differences between plates. Column 12 contained RBC with no peptide as this was 
the negative control. Plates were then covered and left for 1 hour in a 37°C incubator, 
after which they were centrifuged for 5 minutes at 1,000 x g in a refrigerated centrifuge. 
After centrifugation, 70 µl of supernatant from each well of the plate was then 
transferred to a transparent, flat bottom 96 well plate and the absorbance (OD450nm) of 
the supernatant was measured using the Hidex Sense Plate Reader Software 0.5 pre-
release (LabLogic, Sheffield UK) or the Synergy™ H4 Hybrid Multi-Mode reader 
(BioTek Swindon UK) to detect any haemoglobin that had leaked from the erythrocyte 
cytoplasm. The results obtained were used to determine the percentage haemolysis 
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given that the 0.1% triton-X represented 100% lysis, the negative control was taken as 
background. Experiments were performed in quadruplicates at sub-MIC (0.5 X MIC), 
MIC and supra-MIC (2 X MIC and 4 X MIC) concentrations. 
5.2.4 Time kill assays 
5.2.4.1 Time kill assay for synthesized antimicrobial peptides 
The growth kinetics or rate of kill of pathogens by peptides assay was adapted from 
(Oliva et al. 2003). Again, the assay was performed in 96 well plates. In summary, 
overnight cultures were prepared as stated previously and an optical density 
measurement (OD600nm) taken to provide an estimate of cell numbers in the culture. To 
ensure the bacteria were in logarithmic growth phase a 1:25 dilution was carried out on 
the culture using MH broth and the culture was then left for 2 hours shaking at 37⁰C. A 
second optical density measurement was taken and compared to a previously 
determined standard for the organism that related optical density to colony forming 
units (CFU) per ml. This provided a rough quantification of the cells in culture and the 
amount of MH broth required to dilute the culture to 1 x 10
6
 CFU/ml was added. 
The bacterial suspension (1 x 10
6
) (180 µl) was added to all wells of the first row A of 
the 96 well plate. The antimicrobial compounds to be tested were then added to columns 
1-11 of the same row at a final concentration of 3 times the MICs. No drug was added 
to column 12, which served as negative control and depicted a “healthy” bacterial 
growth curve. The plate was then placed in a 37⁰C shaking incubator. The culture used 
for the assay was also serially diluted (1:10) in 100mM Tris buffer pH 7.5 and each 
dilution plated onto MH agar plates. At time points:  10, 20, 30, 40, 50, 60, 90, 120, 
150, 180, 210, 240, 300, 360 and 1440 minutes, 5 µl of culture containing the 
antimicrobial (in 96 well plate) was removed from each well, serially diluted (1:10) in 
100mM Tris buffer pH 7.5, and each dilution was plated onto MH agar. The agar plates 
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were then incubated for 15 hours at 37⁰C before CFU/ml was calculated. Experiments 
were performed in quadruplicates. 
5.2.4.2 Time kill assay for palG1 
Due to low expression and yield of palG1 in vivo (highest concentration being 400 
µg/ml), it was impossible to measure the rate of kill against the susceptible pathogen 
(Ent. faecalis), at 3 X MIC concentration as described for synthetic AMPs above. The 
time course of cell killing by palG1 was therefore calculated by optical density 
measurements. An increase both in cell mass and cell number can readily be estimated 
by measuring the turbidity of a cell suspension using a spectrophometer, thereby 
offering a rapid and sensitive alternative to cell counting (Hobson et al. 1996, Dalgaard 
and Koutsoumanis 2001, Prescott et al. 2004, Madrid and Felice 2005). This method has 
been shown to produce comparable results to plate counting, flow cytometric and green 
fluorescence viability analysis methods (Lehtinen et al. 2006). In a 96 well plate, palG1 
at MIC concentration (200 µg/ml) was added to cells in mid-logarithmic phase (1 x 10
6 
OD600nm of ≤0.2) in LB broth and serially diluted as previously described. Plates were 
incubated at 37⁰C in a microplate incubator shaker. Cells with no drug were taken as 
growth controls. The rate of kill was calculated as a percentage (OD600nm) of surviving 
cells (percentage of viable cells was equal to 100% for the control (cells without 
antibiotics)) over a 24 hour period (Lehtinen et al. 2006, Hazan et al. 2012). 
5.2.5 Inner membrane depolarisation assay (diSC3(5) 
To measure the ability of peptides to disrupt the electrochemical potential across the 
bacterial cytoplasmic membrane, the release of the membrane-associated probe, 3,3′-
dipropylthiadicarbocyanine iodide [diSC3(5)], from E. coli K12 and EMRSA-15 cells  
was monitored by fluorescence spectroscopy as described previously (Wu et al. 1999, 
Lee et al. 2004). The dye quenches its own fluorescence once inside the cytoplasmic 
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membrane. Upon addition of a peptide, dye is released into the aqueous medium (if the 
membrane is depolarized i.e. inside becomes less negative), resulting in increased 
fluorescence (Sims et al. 1974). 
The assay was carried out in 96 well plates. Briefly, mid-logarithmic phase bacteria 
cells (OD600nm of 0.2) were washed with 5 mM HEPES, pH 7.2, 5 mM glucose buffer, 
and resuspended to an OD600nm of 0.05 in the same buffer. The cell suspension was 
incubated with 100 mM Potassium chloride (KCl) and 0.4 mM 3,3′-
dipropylthiadicarbocyanine iodide [diSC3(5)] until a stable reduction of fluorescence 
was achieved (approximately 1 hour). The KCl was added to equilibrate the cytoplasmic 
and external K
+
. After 1 hour, 90 µl of appropriate bacterial cell suspension was added 
to all wells in columns 1-12. Peptides (10 µl) prepared at 10X the desired final 
concentration ((3 X MIC) except for palG1 (MIC)) were then added to corresponding 
wells in columns 1-10 and mixed thoroughly. Wells in column 11 contained Triton X-
100 (to give 0.1% final concentration) as positive control, while wells in column 12 
were untreated. The plate was incubated at 37°C with shaking and the fluorescence was 
continuously monitored (excitation λ 622 nm, emission λ 670 nm) upon addition of 
peptide at 2 to 5 minute intervals for 20 to 30 minutes.  
5.2.6 Transmission electron microscopy 
Overnight cells were cultured in Mueller-Hinton (MH) broth to mid-log phase and 
harvested by centrifugation at 1,000 x g for 10 minutes. Cell pellets were washed twice 
with 10 mM PBS and resuspended to an OD600nm of 0.2. The cell suspension (1 ml) 
was incubated at 37°C for 60 minutes with different peptides at a concentration of 3 X 
MIC in microcentrifuge tubes. After incubation, the cells were centrifuged and washed 
3 times at 5,000 x g for 5 minutes with PBS. These were then sent in sealed 
microcentrifuge tubes to the Advanced Microscopy and Bio-Imaging Laboratory at 
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IBERS. Embedding and examination of treated bacterial samples by transmission 
electron microscopy were carried out with the assistance of Mr Alan Cookson and Dr 
Susan Girdwood. The protocol used is described below. 
All timed steps involving fixatives, washes, ethanol mixtures and resin infiltration were 
conducted on a suitable rotator at room temperature in a fume hood unless otherwise 
stated. Centrifugation was always for 5 minutes at 10,000 rpm. The entire contents of 
the microcentrifuge tubes were mixed with 1 ml of a primary fixative (2.5% 
glutaraldehyde in 0.1 M sodium cacodylate at pH 7.2 both from Agar Scientific Ltd). In 
the meantime, a 2% ultra-low gelling temperature agarose solution (Sigma Aldrich 
Dorset, UK Cat. No. A-5030) was made up in ultra-pure H2O. This was dissolved at 
50⁰C, cooled and filtered with a 0.22 µm syringe filter (Whatman) and kept at 25⁰C 
until use. After 30 minutes fixation, the samples were centrifuged and the supernatant 
discarded. The pellets were re-suspended in another 1 ml of fresh fixative as above for a 
further 30 minutes, followed by centrifugation. Thereafter, the pellets were re-
suspended in 1 ml 0.1 M sodium cacodylate wash buffer pH at 7.2. The samples were 
centrifuged and the supernatant discarded. They were re-suspended in 1 ml of a 
secondary fixative (1% osmium tetroxide (Agar Scientific Ltd. Essex, UK) made up in 
0.1 M sodium cacodylate buffer pH at 7.2). After 30 minutes fixation, the samples were 
centrifuged and the supernatant was carefully discarded and replaced with a rinse in 1 
ml of wash buffer as above for 5 minutes and were again centrifuged and supernatant 
discarded. This step was repeated twice. Following the wash steps, the sample pellets 
were re-suspended in 100 µl agarose solution at 25⁰C and placed in a refrigerator to gel 
at 4⁰C. 
After gelling overnight, the agarose containing the treated bacteria samples was cut 
from the microcentrifuge tubes and transferred into 1 ml wash buffer in 5 ml glass vials 
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with push-on lids at 4⁰C. After 30 minutes, the gelled agarose pellets were placed in 
fresh wash buffer. The samples were then progressed through an alcohol series of 30%, 
50%, 70%, 95% and three changes of 100% for at least an hour. Afterwards, they were 
transferred to a 1:2 mixture of ethanol to LR White-hard grade resin (London Resin 
Company Ltd. London, UK), then a 2:1 mixture of ethanol to resin and finally 100% 
resin overnight at 4⁰C. The next morning, the resin was removed and replaced with 
fresh resin and later that day, the samples were placed in size 4 gelatine moulds (Agar 
Scientific Ltd. Essex, UK), filled up with fresh resin and polymerised overnight in an 
oven at 60ºC. 
Thick sections (2 µm), which contained the bacteria were cut and dried down on drops 
of 10% ethanol on glass microscope slides. They were stained with Ammonium 
molybdate (AMB) stain and photographed using a Leica DM6000B microscope. 
Ultrathin sections (60–80 nm) were then cut on a Reichert-Jung Ultracut E 
Ultramicrotome with a Diatome Ultra 45 diamond knife and collected on Gilder 
GS2X0.5 3.05 mm diameter nickel slot grids (Gilder Grids, Grantham, UK), float-
coated with Butvar B98 polymer (Agar Scientific Ltd. Essex, UK) films. All sections 
were double-stained with uranyl acetate (Agar Scientific Ltd. Essex, UK) and Reynold's 
lead citrate (TAAB Laboratories Equipment Ltd, Aldermaston, UK) and observed using 
a JEOL JEM1010 transmission electron microscope (JEOL Ltd, Tokyo, Japan) at 80 
kV. The resulting images were photographed using Kodak 4489 electron microscope 
film (Kodak Ltd, Hemel Hempstead, UK), developed in Kodak D-19 developer for 4 
minutes at 20°C, fixed, washed and dried according to the manufacturer's instructions. 
The resulting negatives were scanned with an Epson Perfection V800 film scanner and 
converted to positive images. 
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5.2.7 Molecular modelling of peptide 3D structures 
Molecular modeling was done with the help of Dr Narcis Fernandez-Fuentes, IBERS 
Aberystwyth University.  
The modeling of the 3D conformation of peptides was carried out using algorithms from 
the PEP-FOLD program (web server http://bioserv.rpbs.univ-paris-diderot.fr/PEP-
FOLD/ (Maupetit et al. 2009, Maupetit et al. 2010), a de novo approach aimed at 
predicting peptide structures from amino acid sequences. PEP-FOLD is based on Monte 
Carlo simulation that explores the assembly of fragments derived for each peptide. 
Firstly, a limited number (200) of local conformations at each position of the structure is 
predicted using a Hidden Markov Model-derived structural alphabet (HMM-SA) 
(Camproux et al. 2004). Subsequently, the assembly is performed using a greedy 
procedure (Tuffery and Derreumaux 2005, Tuffery et al. 2005), driven by a coarse-
grained energy score using the Optimal Potential for Efficient Peptide-Structure 
Prediction (OPEP) force-field (Maupetit et al. 2007). The best 3D models for each 
peptide were selected according to PEP-FOLD score, considering the lowest energy 
model (sOPEP, score Optimized Potential for Efficient structure Prediction). The three 
top scoring models were selected for each sequence. Given the intrinsic nature of 
peptides that are highly heterologous in conformation, it is better to consider an 
ensemble rather than the lowest energy conformation (Saladin et al. 2014). However, 
the structural modeling of palG1, a longer polypeptide (71 AAs), i.e. a mini protein, 
was done using the PHYRE2 web portal http://www.sbg.bio.ic.ac.uk/phyre2 (Kelley 
and Sternberg 2009, Kelley et al. 2015). The method and approaches used above are 
briefly described below. Results from all modeling were visualized using PyMOL 
v1.7.6 program (Schrödinger 2010). 
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5.2.8.1 PEP-FOLD: a de novo peptide structure prediction tool 
PEP-FOLD (Maupetit et al. 2009, Maupetit et al. 2010, Thevenet et al. 2012) is a de 
novo structural modelling of peptides between 9 and 25 residues in free form. By using 
a HMM-SA library of 27 structural 4-mers, PEP-FOLD assigns the more likely 
structural fragment for a given amino acid sequence (Camproux et al. 2004). 
Subsequently, the fragments are assembled into peptides using a greedy procedure 
driven by a modified version of the OPEP coarse-grained force field (Tuffery and 
Derreumaux 2005, Tuffery et al. 2005, Maupetit et al. 2007). Given an amino-acid 
sequence, PEP-FOLD performs series of 50 simulations and returns the most 
representative conformations identified in terms of energy and population. Under 
benchmark conditions, PEP-FOLD was able to predict successfully the conformation of 
52 peptides between 9–23 residues long with a root-mean-square deviation (RMSD) 
between 2.8 and 2.3 Å (considering Cα only), outperforming previous approaches. In 
the case of 13 miniproteins, i.e. between 27–49 residues long, PEP-FOLD reached an 
accuracy of 3.6 and 4.6 Å Cα RMSD considering the lowest-energy conformations. 
PEP-FOLD simulations are fast (a few minutes only) opening therefore, the door to in 
silico large-scale rational design of new bioactive peptides and miniproteins. PEP-
FOLD has also been used in other research projects to predict biologically relevant 
peptide structures (Duvignaud et al. 2010, Kawaguchi et al. 2010, Steckbeck et al. 
2011). 
5.2.8.2 The Hidden Markov model derived structural alphabet (HMM SA) for 
proteins 
An important aspect of PEP-FOLD is the use of a fragment library composed of 
structural fragments. The fragments derive from a structural alphabet: HMM-SA 
composed of 27 structural prototypes 4-mers called structural letters, allowing the 
simplification of the 3D protein structures into 1D sequences of structural letters 
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(Camproux et al. 2004, Regad et al. 2011). The method for predicting SA letters using 
HMM is described in Maupetit et al. (2010). It has been shown that HMM-SA is an 
effective and relevant tool for the study of protein structures, to study protein contacts, 
or protein deformations, to search for 3D similarity across proteins, to predict the 
conformation of peptides in aqueous solutions, and to extract structural motifs from 
protein loops (Guyon et al. 2004, Regad et al. 2006, Martin et al. 2008, Martin et al. 
2008, Regad et al. 2008, Maupetit et al. 2009, Maupetit et al. 2010, Regad et al. 2010, 
Baussand and Camproux 2011). 
5.2.8.3 The Optimal potential for efficient peptide-structure prediction (OPEP) 
force field 
The search and scoring of peptide conformation is done against a force-field. PEP-
FOLD utilizes the OPEP force-field (Maupetit et al. 2007), which is a coarse-grained 
protein model based on a six-bead model per residue (hydrogens not considered). OPEP 
uses a detailed representation of all backbone atoms (N, H, Cα, C and O) and reduces 
each side-chain to one single bead with appropriate geometrical parameters and van der 
Waals radius. The implicit solvent OPEP energy function is expressed as a sum of local 
potentials (taking into account the changes in bond lengths, bond angles, improper 
torsions of the side-chains and backbone torsions), non-bonded potentials (taking into 
account the hydrophobic and hydrophilic properties of each amino acid) and hydrogen-
bonding potentials (taking into account two- and four- body interactions) (Nasica-
Labouze et al. 2011). The potential function was parameterized to differentiate native 
and non-native (or decoys) structures and in relation to the lowest free energy (Kar et al. 
2013). The OPEP force field has been used in several protein studies (Chebaro and 
Derreumaux 2009, Chebaro et al. 2012) and extensively tested on peptides using 
multiple approaches such as the activation-relaxation technique, Monte Carlo, 
Molecular Dynamics (MD) and Replica Exchange Molecular Dynamics (REMD) 
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simulations as well as greedy-based algorithms (Maupetit et al. 2009, Maupetit et al. 
2010). 
5.2.8 Analysis of variance (ANOVA) and post-hoc tests 
Two-way Analysis of variance (ANOVA) with factors ‘antimicrobial treatments’ and 
‘time’ using Microsoft Excel was performed in order to determine whether there were 
significant changes in cell viability and membrane depolarisation in relation to time, 
before and after peptide treatments (Harmon 2011). Results obtained from the ANOVA 
were then verified by post-hoc multiple comparisons using Tukey’s HSD (Honestly 
Significant Difference) Studentized test. The Tukey’s post-hoc test is useful for 
calculating simultaneous confidence intervals for all pairwise differences between 
means in a balanced design, especially with large group sizes (≥4 groups); accurately 
maintaining alpha (α) levels at their intended values (Jaccard et al. 1984, Tukey et al. 
1985, Wright 1992, Bender and Lange 2001, Feise 2002) Alpha (α) levels were set at P 
< 0.05. This method is fully described by Harmon (2011). 
5.3 Results 
5.3.1 Analysis of antimicrobial activity screen of peptide library 
Activity analysis of highthroughput screen of the 135 peptides in the peptide library 
against luminescent and non-luminescent bacteria pathogens (see Figure 5.2 for 
examples of 96 well plates from this screen) using the MATLAB GAIT_CAD software 
revealed that some peptides had some activity against all microorganisms with the best 
activity against E. coli K12. Table 5.2 is a summary of the number of peptides per 




Figure 5.2 96 well plate showing antimicrobial activity screen. i. luminescent, ii. non-luminescent pathogens 
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Table 5.2 Summary of activity class of peptides against pathogens 
 
In total, 25 peptides had activity against at least one pathogen tested as shown on Table 
5.3 (see Table 5.1 in CD/Figshare for complete activity analysis data of all 135 
peptides).  
Mean and median values of 2 peptides indicate a good average activity against all 
pathogens, the best ones being LPRRNRWSKIWKKVVTVFS and 
HLRRINKLLTRIGLYRHAFG (peptides 2 and 3). 
Some peptides had selective activities, e.g. SIKILKIYFIQGKRHWSF (peptide 12) 
against P. aeruginosa H1001. Amino acids like W, R, F, T tended to improve activity 
while amino acid C tended to decrease activity (see Figure 5.3). As in previous studies 
(Mikut and Hilpert 2009, Ramon-Garcia et al. 2013), a similar pattern of hydrophobicity 
vs. positive charge balance, i.e., a "yin-yang balance" was observed. A low proportion 













Pseudomonas aeruginosa H1001 3 11 121 
EMRSA-15 0 6 129 
E. coli K12 11 6 118 
Salmonella typhimurium 2 6 127 
MEAN 2 5 128 
MEDIAN 2 5 128 
MINIMUM 12 13 110 
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1 69 THRLRRWCRARGLAR        0.05 1.03 1.04 0.71 0.71 0.87 0.05 
2 124 LPRRNRWSKIWKKVVTVFS    0.06 0.38 0.24 0.14 0.21 0.19 0.06 
3 58 HLRRINKLLTRIGLYRHAFG   0.09 0.29 0.09 0.14 0.15 0.11 0.09 
4 110 VLHTGYRKFLHRSKRFFHLR   0.09 0.32 0.27 0.43 0.28 0.30 0.09 
5 100 TMSLRFWRWKVR           0.11 0.55 0.44 0.62 0.43 0.49 0.11 
6 111 LTKKTKKQKRNLVGTT       0.12 1.15 0.36 0.39 0.50 0.37 0.12 
7 91 NRFTARFRRTPWRLCLQFRQ   0.16 0.65 0.41 0.54 0.44 0.47 0.16 
8 108 AWRWKAFRNCWRVRSSSL     0.17 0.78 3.81 0.40 1.29 0.59 0.17 
9 86 LIRCSRTCLQYKTSRFMRW    0.19 1.15 0.79 0.58 0.68 0.68 0.19 
10 48 RSITRPVLVRRRWRVRPVF    0.20 0.68 0.48 0.61 0.49 0.55 0.20 
11 128 RICRTRLTRRAGNSL        0.22 0.93 0.63 1.69 0.86 0.78 0.22 
12 135 SIKILKIYFIQGKRHWSF     303.61 11.53 17.09 0.25 83.12 14.31 0.25 
13 22 QVRWWGRYWRRKWATCR      0.31 0.33 0.46 0.31 0.35 0.32 0.31 
14 80 MRILSIIRWTRMKKSSA      0.62 0.44 0.82 0.31 0.55 0.53 0.31 
15 15 GTAWRWHYRARS           0.34 0.89 0.67 0.78 0.67 0.72 0.34 
16 72 VGVKRRLKCLLSLRS        0.34 7.65 1.02 0.45 2.37 0.73 0.34 
17 47 RRLRTTTKLPPV           0.35 1.99 0.73 1.24 1.08 0.98 0.35 
18 87 TTAPCKCWIGLRRCFK       0.36 3.77 1.99 1.55 1.92 1.77 0.36 
19 70 RLLLVMIGLRSKIKWHSGI    0.72 0.96 10000000000 0.39 2500000000 0.84 0.39 
20 133 THILLLRLRKKVMS         0.63 0.40 0.70 0.67 0.60 0.65 0.40 
21 109 SRATWARVRRLGLYG        0.41 0.84 0.69 0.85 0.70 0.76 0.41 
22 96 KFVRLKIYCRDKNKGRGISF   0.64 5.34 7.79 0.43 3.55 2.99 0.43 
23 68 AVWMTRSCVIWKR          0.69 2.48 6.98 0.47 2.66 1.59 0.47 
24 105 
LLMRKLIKGYGYLFGKGKRK
KR 0.62 0.71 1.30 0.47 0.78 0.67 0.47 





Figure 5.3 Visualization of amino acid (AA) distributions for activity classes (based 
on minimum IC75 for all microorganisms), color-coded bars for AA distributions.  
 
Figure 5.4 Hydrophicity (measured by TERM1 SEQ Hoop-Woods) vs. Positive 
Charge (measured by TERM3 SEQ Isoelectric point) for activity classes (Mikut 2010), red 
points mean high activity against at least one microorganism (IC75≤0.25), blue means 
inactivity against all microorganisms (IC75>0.5), green points represent semi-active 
peptides (0.25<IC75≤0.5). 
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Based on this analysis, 15 peptides, peptides 1-10, 12, 13, 19, 20 and 22 (Table 5.3) 
were selected for further analysis as they had higher activity ranking, broad-spectrum 
and or specific activity against pathogens. They were reassigned numbers - peptides 1-
15. These 15 peptides were then synthesized by (GenScript USA Inc. New Jersey, 
USA) at >95% purity on resin using solid phase Fmoc chemistry as described in 
sections 2.7.2 and 2.7.4. All peptides were linear and C-terminal amidated (see 
‘Genscript 1’ in CD/Figshare for Mass Spectometry and HPLC information for all resin 
synthesized peptides).  
5.3.2 Minimum inhibitory concentration (MIC) of all identified 
antimicrobial peptides 
The MIC was defined as the lowest concentration of drug that inhibited visible cell 
growth of the organism after an 18-24 hour incubation at appropriate temperatures. Cell 
growth was defined as a visible clot in an individual well, regardless of its size (Kim et 
al. 2015). Therefore, the MICs determined using this method would be more stringent 
(accounting for at least a 2-fold increase in MIC) than those determined using the 
Sensititre™ system (Saini et al. 2011) which defines growth as the generation of a clot 
following antibiotic treatment that is similar in size to the clot generated in the absence 
of antibiotic. The determined MICs values outlined in Table 5.4 below were 
reproducible in duplicates within three different experiments. 
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Table 5.4 Minimum inhibitory concentration values of identified antimicrobial peptides (n = 6) nt (not tested), > (precedes the highest 
concentration tested). 
Peptide ID Peptide Sequence 
Minimum inhibitory Concentrations MICs ( µg/ml) 
P. aeruginosa 
Sal. 
typhimurium E. coli EMRA-15 S. aureus Ent. faecalis 
List. 
monocytogenes 
1 THRLRRWCRARGLAR-NH2        250 250 125 250 250 250 31.25 
2 LPRRNRWSKIWKKVVTVFS-NH2    31.25 31.25 31.25 31.25 31.25 31.25 31.25 
3 HLRRINKLLTRIGLYRHAFG-NH2   125 31.25 62.5 31.25 31.25 31.25 31.25 
4 VLHTGYRKFLHRSKRFFHLR-NH2   500 31.25 62.5 62.5 125 62.6 62.5 
5 TMSLRFWRWKVR-NH2           62.5 62.5 62.5 31.25 62.5 62.5 62.5 
6 LTKKTKKQKRNLVGTT-NH2       >1000 >1000 >1000 >1000 >1000 >1000 >1000 
7 NRFTARFRRTPWRLCLQFRQ-NH2   31.25 62.5 62.5 31.25 31.25 62.5 31.25 
8 AWRWKAFRNCWRVRSSSL-NH2     31.25 31.25 62.5 31.25 62.5 62.5 62.5 
9 LIRCSRTCLQYKTSRFMRW-NH2    500 62.5 250 125 250 500 125 
10 RSITRPVLVRRRWRVRPVF-NH2    500 62.5 250 31.25 250 500 500 
11 SIKILKIYFIQGKRHWSF-NH2     500 500 250 125 250 250 250 
12 QVRWWGRYWRRKWATCR-NH2      500 250 250 250 250 250 125 
13 RLLLVMIGLRSKIKWHSGI-NH2    500 250 250 250 250 250 250 
14 THILLLRLRKKVMS-NH2         500 500 250 500 500 500 500 
15 KFVRLKIYCRDKNKGRGISF-NH2   125 125 62.5 62.5 125 125 125 
Control peptide KRRWRIWLV-NH2 15.6 7.81 7.81 15.6 7.81 15.6 15.6 
Hess Gene 2 (H-G2) MKKLLLILFCLALALAGCKKAP-NH2 >1024 >1024 >1024 >1024 >1024 >1024 >1024 
Hess Gene 4 (H-G4) VLGLALIVGGALLIKKKQAKS-NH2 ≥1000 512 512 32 128 128 512 
Bactenecin 2A (Bac2A) RLARIVVIRVAR-NH2 256 128 128 64 64 64 64 
Polymyxin B sulphate 
 
1.95 1.95 1.95 250 250 31.25 62.5 
Ciprofloxacin 
 
0.49 0.12 0.06 >250 >250 62.5 62.5 
Vancomycin hydrochloride 
 
62.5 250 125 0.98 0.98 62.5 62.5 
palG1 
 
nt >200 >200 nt >200 200 nt 
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MICs of some peptides (2, 3, 4, 5, 7, 8, 9, 10 and 15) showed similar activity spectra 
and confirmed broad spectrum activity observed in the peptide library screen with MIC 
range of 32 to 64 µg/ml across all pathogens. Other peptides (1, 6, 11, 12, 13, and 14) 
had higher MICs (>64 µg/ml). AMPs also showed antimicrobial activity against Ent. 
faecalis and List. monocytogenes, which were not included in the initial screen. Peptide 
H-G2 and H-G4 were predicted to be AMPs using computational methods and had not 
been previously tested for activity against pathogens. H-G2 seemed not to have any 
activity against all pathogens tested. This may be because H-G2 was synthesized as a 
linear peptide instead of a cyclic peptide as it has equal number of cysteine residues and 
may form disulphide bonds. H-G4 on the other hand, showed some activity against 
Gram positive but not Gram negative organisms, and seems to have specific activity 
against EMRSA-15 (MIC 32 µg/ml). palG1 was only active against Ent. faecalis with 
an MIC of 200 µg/ml. It also showed minimal inhibition of E. coli growth (observed in 
growth curves) with no detectable MIC at the highest concentration tested. This may 
account for the low level of expression of palG1. The highest concentration of palG1 
tested was 200 µg/ml due to low levels of protein expression and/or yield of purified 
protein. 
Based on MIC results, eight peptides (2, 3, 4, 5, 7, 8, 10, and 15) with broad spectrum 
activity were chosen for further activity and mode of action studies. E. coli K12 and 
EMRSA-15 were chosen as representative organisms for Gram negative and Gram 
positive organisms respectively. 
5.3.3 Erythrocyte leakage assay 
The haemolytic activity of antimicrobial peptides against erythrocytes is often used as a 
measure of their cytotoxicity to eukaryotic cells and to estimate their therapeutic index. 
The haemolysis or erythrocyte leakage induced by antimicrobial peptides was calculated 
171 
 
as a percentage using the formula: haemolysis (%) = [(A450 in treated supernatant−A450 in 
PBS)/(A450 in 0.1 % Triton X-100−A450 in PBS)]×100. All experiments were performed 
in quadruplicates and the results represent means ± standard deviations of four 
independent experiments. Figure 5.5 is a chart showing % erythrocyte leaked of all 
peptides at varying concentrations. 
 
Figure 5.5 Haemolytic activities of peptides at sub-MIC, MIC and supra-MIC 
concentrations (values from four independent replicates; error bars represent one 
standard deviation). 
All peptides had little haemolytic effect on sheep blood, with only around 10% 
haemolysis even at 4 X MIC concentrations (2 X MIC for palG1). 
5.3.3 Time kill assay 
5.3.3.1 Time kill assay for synthesized antimicrobial peptides 
Time kill assays were performed to determine the rate of antimicrobial peptides induced 
cell death against EMRSA-15 and E. coli K12 (see Figures 5.6 and 5.7). The killing 
activities of the selected peptides (2, 3, 4, 5, 7, 8, 10, and 15) with broad spectrum 
activity were measured in MH broth. Colonies on MH agar plates were counted and 
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viability was calculated as the number of colony forming units per millilitre of culture. 
Results are from four independent replicates and error bars represent standard 
deviations from the mean. 
 
 
Figure 5.6 Time dependent kill of EMRSA-15 by peptides (values from four 





Figure 5.7 Time dependent kill of E. coli K12 by peptides (values from four 
independent replicates; error bars represent one standard deviation). 
 
There was a significant difference between peptide treated and untreated E. coli K12 
cells (P < 0.001). All peptides triggered a rapid decline in E. coli K12 viability with 
complete cell death within 10 minutes (for peptides 2, 3, 7, 8) and 1 hour for peptides 5 
and 15. Interestingly, although peptide 4 caused > 5 log reduction in viability in the first 
30 minutes, cells seemed to recover after 4 hours of incubation. Polymyxin B and 
ciprofloxacin showed expected killing activities against E. coli K12. In contrast, 
although there was a significant difference between peptide treated and untreated 
EMRSA-15 cells (P < 0.05), the peptides generally showed lower activity against 
EMRSA-15. No bactericidal activity was observed in EMRSA-15 cells treated with 
peptides 4, 5, 8, 10, 15 and H-G4 (≤ 2 log reduction in viability). Peptide 2, and 7 had 
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the most activity against EMRSA-15 causing rapid kill and complete cell death within 1 
and 3 hours respectively. Peptide 3 had comparable killing activity to Vancomycin with 
≥ 4 log decrease in cell viability. Ciprofloxacin had no activity against EMRSA-15 as 
expected. Tukey’s post-hoc tests also show that loss of viability was significantly higher 
in peptides 2 and 7, Vancomycin and peptides 3 in that order (q = 63.477, 48.452, 
29.173 and 31.207). Table 5.5 below provides a summary of q and qcritical values 
obtained from post-hoc tests. The folder ‘statistical analysis’ in CD/Figshare contains 
all ANOVA and Tukey’s post-hoc tests for all multiple comparisons (combinations of 
pairs). 
5.3.3.1 Time kill assay for palG1 
Figure 5.8 shows the killing activity of palG1 against Ent. faecalis, calculated as a 
percentage (OD600nm) of surviving cells. 
 
Figure 5.8 Time dependent kill of Ent. faecalis by palG1 (values from four 
independent replicates; error bars represent one standard deviation). 
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As can be seen from Figure 5.8 above, palG1 had a steady kill with only ≤30% of 
surviving cells after 24 hours. Tukey’s post-hoc test showed that the treated 
(vancomycin and palG1 treated) cells had significantly higher loss of viability than the 
untreated Ent. faecalis cells (Table 5.5). 
5.3.4 Inner membrane depolarisation 
AMP induced membrane depolarisation in E. coli K12 and EMRSA-15 is shown in 
Figure 5.9 and 5.10 respectively. palG1 induced membrane depolarisation in Ent. 
faecalis is shown in Figure 5.11. Error bars represent the standard deviations from the 
mean from three different experiments. 
 
Figure 5.9 AMP induced membrane depolarisation in E. coli K12 (values from three 





Figure 5.10 AMP induced membrane depolarisation in EMRSA-15 (values from 
three independent replicates; error bars represent one standard deviation). 
 
 
Figure 5.11 palG1 induced membrane depolarisation in Ent. faecalis (values from 




Generally all peptides had some membrane depolarisation effect against both organisms 
tested with around 10-30% depolarisation (Figures 5.9 and 5.10). Tukey’s post-hoc test 
revealed that peptide treatments induced significantly higher membrane depolarisation 
of E. coli K12 (Table 5.5 - all q values < q Critical). Peptide 8 had the most membrane 
depolarisation effect (>50% depolarisation) against E. coli K12 (Figure 5.9). Tukey’s 
post-hoc test also showed that peptides had no significant depolarisation effect on 
EMRSA-15 membrane (all q values < q Critical - Table 5.5). Although there were 
significant differences between treatments (palG1, triton, and untreated cell), palG1 did 





Table 5.5 Summary of Tukey's HSD Post-hoc test and pair wise multiple comparisons: α = 0.05, Asterisks (*) indicate significantly different groups. 
There is a significant difference between group means if q > q Critical, (TRUE) at α level of 0.05 and vice versa (FALSE). 
Level 
comparisons 
Full description of 
comparisons Mean of pairs compared MSwithin n 
Absolute 
difference in 
means of pair q q Critical Significance 
Time Kill assays 
EMRSA-15 (ANOVA, P = 2.3486E-272)  
1,2 untreated vs pep2* 8.880 1.891 0.776 64.000 6.989 63.477 4.635 TRUE 
1,3 untreated vs pep3* 8.880 5.668 0.776 64.000 3.212 29.173 4.635 TRUE 
1,4 untreated vs pep4* 8.880 8.236 0.776 64.000 0.644 5.851 4.635 TRUE 
1,5 untreated vs pep5* 8.880 7.912 0.776 64.000 0.968 8.793 4.635 TRUE 
1,6 untreated vs pep7* 8.880 3.545 0.776 64.000 5.335 48.452 4.635 TRUE 
1,7 untreated vs pep8* 8.880 8.229 0.776 64.000 0.651 5.909 4.635 TRUE 
1,8 untreated vs pep10 8.880 8.440 0.776 64.000 0.439 3.992 4.635 FALSE 
1,9 untreated vs pep15 8.880 8.482 0.776 64.000 0.398 3.612 4.635 FALSE 
1,10 untreated vs H-G4 8.880 8.497 0.776 64.000 0.383 3.481 4.635 FALSE 
1,11 untreated vs Ciprofloxacin 8.880 8.667 0.776 64.000 0.213 1.936 4.635 FALSE 
1,12 untreated vs Vancomycin* 8.880 5.444 0.776 64.000 3.436 31.207 4.635 TRUE 
3,12 pep3 vs  Vancomycin 5.668 5.444 0.776 64.000 0.224 2.034 4.635 FALSE 
E. coli (ANOVA, P = 0, i.e. P < 0.001)  
1,2 untreated vs pep2* 9.965 0.744 0.419 64.000 9.221 113.918 4.496 TRUE 
1,3 untreated vs pep3* 9.965 0.744 0.419 64.000 9.221 113.918 4.496 TRUE 
1,4 untreated vs pep4* 9.965 4.733 0.419 64.000 5.232 64.635 4.496 TRUE 
1,5 untreated vs pep5* 9.965 0.988 0.419 64.000 8.977 110.902 4.496 TRUE 
1,6 untreated vs pep7* 9.965 0.744 0.419 64.000 9.221 113.918 4.496 TRUE 
1,7 untreated vs pep8* 9.965 0.744 0.419 64.000 9.221 113.918 4.496 TRUE 
1,8 untreated vs pep15* 9.965 1.699 0.419 64.000 8.266 102.123 4.496 TRUE 
1,9 untreated vs Ciprofloxacin* 9.965 4.302 0.419 64.000 5.663 69.965 4.496 TRUE 
1,10 untreated vs Polymyxin B* 9.965 0.744 0.419 64.000 9.221 113.918 4.496 TRUE 
Ent. faecalis (ANOVA, P =3.5495E-279)  
1,2 untreated vs palG1* 100.000 31.666 80.418 222.000 68.334 113.538 3.314 TRUE 
1,3 untreated vs Vancomycin* 98.676 11.234 80.418 222.000 87.441 145.284 3.314 TRUE 
2,3 palG1 vs Vancomycin* 31.666 11.234 80.418 222.000 20.431 33.947 3.314 TRUE 
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Inner membrane depolarisation (diSC3(5)) assays 
EMRSA-15 (ANOVA, P = 7.57519E-29)  
1,2 untreated vs pep2 0.167 0.334 0.086 36.000 0.168 3.436 4.552 FALSE 
1,3 untreated vs pep3 0.167 0.304 0.086 36.000 0.137 2.807 4.552 FALSE 
1,4 untreated vs pep4 0.167 0.352 0.086 36.000 0.185 3.801 4.552 FALSE 
1,5 untreated vs pep5 0.167 0.275 0.086 36.000 0.108 2.215 4.552 FALSE 
1,6 untreated vs pep7 0.167 0.266 0.086 36.000 0.099 2.030 4.552 FALSE 
1,7 untreated vs pep8 0.167 0.309 0.086 36.000 0.142 2.914 4.552 FALSE 
1,8 untreated vs pep10 0.167 0.307 0.086 36.000 0.140 2.876 4.552 FALSE 
1,9 untreated vs pep15 0.167 0.275 0.086 36.000 0.108 2.213 4.552 FALSE 
1,10 untreated vs H-G4 0.167 0.188 0.086 36.000 0.022 0.447 4.552 FALSE 
1,11 untreated vs Triton* 0.167 1.000 0.086 36.000 0.833 17.081 4.552 TRUE 
E. coli (ANOVA, P = 7.67871E-81)  
1,2 untreated vs pep2* 0.250 17.021 54.212 24.000 16.771 11.159 4.427 TRUE 
1,3 untreated vs pep3* 0.250 17.815 54.212 24.000 17.565 11.687 4.427 TRUE 
1,4 untreated vs pep4* 0.250 9.306 54.212 24.000 9.056 6.026 4.427 TRUE 
1,5 untreated vs pep5* 0.250 13.927 54.212 24.000 13.677 9.100 4.427 TRUE 
1,6 untreated vs pep7 0.250 -0.788 54.212 24.000 1.038 0.691 4.427 FALSE 
1,7 untreated vs pep8* 0.250 44.024 54.212 24.000 43.774 29.125 4.427 TRUE 
1,8 untreated vs pep15* 0.250 22.465 54.212 24.000 22.215 14.781 4.427 TRUE 
1,9 untreated vs Triton* 0.250 75.250 54.212 24.000 75.000 49.902 4.427 TRUE 
Ent. faecalis (ANOVA, P =1.38502E-78)  
1,2 untreated vs palG1* 0.167 -4.092 16.885 72.000 4.258 8.793 3.377 TRUE 
1,3 untreated vs Triton* 0.167 83.500 16.885 72.000 83.333 172.083 3.377 TRUE 
2,3 palG1 vs Triton* -4.092 83.500 16.885 72.000 87.592 180.876 3.377 TRUE 
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5.3.5 Transmission electron microscopy 
TEM was carried out to determine whether the loss of viability in EMRSA-15, E. coli 
K12 and Ent. faecalis following exposure to peptides was a result of, or accompanied 
by cell morphological and cell wall ultrastructure changes. Figures 5.12, 5.13 (i and ii) 
and 5.14 show TEM images obtained for the different peptide treatments. Magnification 
scale of each micrograph is indicated below each image. 
 
Figure 5.12 TEM images of EMRSA-15 - following 60 minutes (A) Untreated (B) 
exposure to peptide 2 (C), exposure to peptide 3 and (D) exposure to peptide 7 at 3 X MIC 
concentrations. PL = Peptidoglycan layer, CM = cytoplasmic membrane, M = Mesosomes. 










TEM images show that compared to untreated EMRSA-15 cells, which had intact cell 
morphology (Figure 5.12 A), peptide treated cells induced notable mesosome-like 
structures and defects in the cell wall (Figures 5.12 b, C D). Outer cell detachment and 
spilling off of the cytoplasmic content can be seen in cells treated with peptide 3 (Figure 
5.12 C - red arrow). The cell wall also appears to be severely damaged and shows 
undulations. Cell shrinkage and numerous protrusions (a ‘hairy’ appearance) were 




Figure 5.13 (i) TEM images of E. coli K12- following 60 minutes (A) Untreated (B) 
exposure to peptide 2 (C), exposure to peptide 3 (D) exposure to peptide 4, at 3X MIC 
concentrations. OM = Outer membrane, CM = cytoplasmic membrane Scale bars are 





Transmission electron micrographs of E. coli K12 cells revealed that all peptides had 
varied effects and induced major damage to E. coli K12 cell membrane (Figure 5.13). 
Compared to the untreated cells (5.13 (i) A - black arrow) with intact membrane and 
intracellular content, large vacuoles (holes) could be observed in cells treated with 
peptides 5, 7, 8, and 15 (Figure 5.13 (i) - green arrows). Peptides 2, 3 and 4 caused 
rupturing, and almost a total disintegration of the cell membrane and spilling of 
intracellular content (Figures 5.13 (i) B, C and D - red arrows). 
(ii)  
 
Figure 5.13 (ii) TEM images of E. coli K12- following 60 minutes of (E) exposure to 
peptide 5, (F) peptide 7, (G) exposure to peptide 8 and (H) exposure to peptide 15 at 3 X 
MIC concentrations. Scale bars are 200nm. Magnification is 30,000X (E and F), 25,000X 
(G) and 20,000X (H). 
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Once again, numerous hair-like protrusions and cell shrinkage were observed in cells 
treated with peptide 7 (Figure 5.13 (ii) F). Blebs on cell membrane surface, vacuoles, as 
well as a lysed cytoplasm are visible in cells treated with peptides 5, 8 and 15 (Figure 
5.13 (ii) E, G and F - red arrows),  
 
 
Figure 5.14 TEM images of Ent. faecalis - following 60 minutes (A) Untreated (B) 
exposure to palG1, and after 24 hours (C), untreated (D) exposure to palG1 at MIC 
concentration (200 µg/ml). PL = Peptidoglycan layer, CM = cytoplasmic membrane. Scale 
bars are 200nm. Magnification is 20,000X (A), 30,000X (B and D) and 25,000X (C).    
TEM images of untreated and palG1 treated Ent. faecalis cells were taken after 1 hour 
and 24 hours incubation. Untreated cells showed intact oval-spheres (Figure 5.14 A and 
C - green arrows). However, changes in cell morphology were observed in images of 




5.14 B - purple arrow), as well as outer membrane detachment (Figure 5.14 B and D - 
red arrows) in Ent. faecalis cells were observed after 1 hour, and more so, after 24 hours 
of exposure to  palG1. 
5.3.6 Molecular modelling of peptide 3D structures 
The structures of peptides 2, 3, 4, 5, 7, 8, 10 and 15 were predicted using PEP-FOLD, 
while that of palG1 was done using Phyre2 server. The three-dimensional structures of 
the peptides were visualized in PyMOL (Schrödinger 2010). The lowest energy 
conformation predicted for peptide 2, 3, 4, 5, 7, 8 and palG1 were α-helical structures. 
A β-sheet structure was predicted for peptide 15, Images are shown in Figures 5.15 to 
5.22 (a, and b). Table 5.6 below also summarizes some biophysical parameters of the 
peptides. A periodic chart of amino acids (Figure 5.23) is included in CD/Figshare. 
Table 5.6 Biophysical parameters of peptides 











2 LPRRNRWSKIWKKVVTVFS    α- helix 19 6 42 30 
3 HLRRINKLLTRIGLYRHAFG   α- helix 20 5 40 25 
4 VLHTGYRKFLHRSKRFFHLR   α- helix 20 6 35 30 
5 TMSLRFWRWKVR           α- helix 12 4 33 50 
7 NRFTARFRRTPWRLCLQFRQ   α- helix 20 6 40 30 
8 AWRWKAFRNCWRVRSSSL     α- helix 18 5 50 27 














Figure 5.15 Predicted structure of peptide 2 (LPRRNRWSKIWKKVVTVFS). Main-
chain and side chains depicted in ribbon and stick representation respectively. Atoms colored 
according to type: Red: Oxygen; Grey: Carbon; Blue: Nitrogen. Figures were rendered using 
PyMol. 
  
The hydrophobic residues of the peptide are situated on one side of putative helices, 
whereas the charged residues are situated on the other, an arrangement typical of many 






Figure 5.16 Predicted structure of peptide 3 (HLRRINKLLTRIGLYRHAFG). Main-
chain and side chains depicted in ribbon and stick representation respectively. Atoms colored 
according to type: Red: Oxygen; Grey: Carbon; Blue: Nitrogen. Figures were rendered using 
PyMol. 
 
Peptide 3 has a typical α-helix, again with an amphipathic structure (i.e. hydrophobic 





Figure 5.17 Predicted structure of peptide 4 (VLHTGYRKFLHRSKRFFHLR). Main-
chain and side chains depicted in ribbon and stick representation respectively. Atoms colored 
according to type: Red: Oxygen; Grey: Carbon; Blue: Nitrogen. Figures were rendered using 
PyMol. 
Peptide 4 also has a typical α-helical structure, with hydrophobic and charged residues 
on either side of the helix (hydrophobic residues facing inwards and charged residues 





Figure 5.18 Predicted structure of peptide 5 (TMSLRFWRWKVR). Main-chain and 
side chains depicted in ribbon and stick representation respectively. Atoms colored according to 
type: Red: Oxygen; Grey: Carbon; Blue: Nitrogen. Figures were rendered using PyMol. 
Peptide 5 is a three dent helix, again with hydrophobic residues (e.g. phenylalanine, 
(position 6) and tryptophan (position 8 and 9)) on one side of the helix, and charged 
residues (e.g. the C-terminal Arginine (position 12) and lysine (position 10)) on the 






Figure 5.19 Predicted structure of peptide 7 (NRFTARFRRTPWRLCLQFRQ). Main-
chain and side chains depicted in ribbon and stick representation respectively. Atoms colored 
according to type: Red: Oxygen; Grey: Carbon; Blue: Nitrogen. Figures were rendered using 
PyMol. 
Peptide 7 is composed of a pair of antiparallel helices joined by a short turn. The two 
helices are closely packed with hydrophobic side chains on each helix intercalating in a 




Figure 5.20 Predicted structure of peptide 8 (AWRWKAFRNCWRVRSSSL). Main-
chain and side chains depicted in ribbon and stick representation respectively. Atoms colored 
according to type: Red: Oxygen; Grey: Carbon; Blue: Nitrogen. Figures were rendered using 
PyMol. 
Like peptide 5, peptide 8 is a three dent helix, again with hydrophobic and charged 




Figure 5.21 Predicted structure of peptide 15 (KFVRLKIYCRDKNKGRGISF). 
Main-chain and side chains depicted in ribbon and stick representation respectively. Atoms 
colored according to type: Red: Oxygen; Grey: Carbon; Blue: Nitrogen. Figures were rendered 
using PyMol.  
Peptide 15 takes a typical antiparallel β-sheet turn. This peptide is the only peptide 
predicted as a β-sheet in this study. Charged residues are again situated on the surface of 
the peptide (arginine (position 4, 10, 16), aspartic acid (position 11), asparagine 
(position 13), and Lysine (position 1, 6, 12 and 14)), while hydrophobic residues (e.g 






Figure 5.22 Predicted structure of the miniprotein palG1 
(MRLSHVCSQSSSKYPAGSCNLMTHDRATSSEHRSASRCDRVIRRFCRSDPASR
YWRYPVRGMRHGRCHTDW). Main-chain and side chains depicted in ribbon and stick 
representation respectively. Atoms colored according to type: Red: Oxygen; Grey: Carbon; 
Blue: Nitrogen. Figures were rendered using PyMol. 
 
The structure of palG1 consists of a pair of helices connected by a long turn. It also 





Many of the synthesized peptides had similar activities against all microorganisms with 
an average MIC of 32 µg/ml. Peptides, 2, 3, 4, 5 7, 8, 10 and 15 had a broader activity 
spectrum than all other peptides tested. Some peptides which had activity in the peptide 
library screen (6, 11, 12, 13, 14) showed no activity when they were synthesized on 
resin. This may be caused by the difference in method of synthesis or folding of the 
peptide. Peptide 12 (QVRWWGRYWRRKWATCR) for instance, has an N-terminal 
Glutamine, which might form glutamic acid and inactivate the peptide. Therefore, the 
peptide was resynthesized with an acetylated N-terminus and retested for activity 
against EMRSA-15 (new MIC 32 µg/ml). palG1 was only active against Ent. faecalis 
with an MIC of 200 µg/ml. It also showed slight inhibition of E. coli K12 growth 
(observed in growth curves) with no detectable MIC at the highest concentration tested. 
Although, palG1 was successfully expressed in E. coli TOP10 cells, this mild inhibition 
observed here, may account for the low level of expression and yield of the protein. 
Time kill studies demonstrated time dependent microbicidal action of peptides 2, 3 and 
7 against EMRSA-15 and peptides 2, 3, 4, 5, 7, 8 and 15 for E. coli K12 in MH broth, a 
rich medium. After exposure to peptides, reductions of >8 log10 CFU/ml (peptides 2, 7 
after 1 and 3 hours respectively) and >3log10 CFU/ml (peptide 3 after 30 minutes) of 
EMRSA-15 cells were demonstrated. Reductions of >8 log10 CFU/ml of E. coli K12 
cells was observed for all peptide treatments. Apart from peptide 4, where E. coli K12 
cells seemed to recover after 4 hours, no increase in cell density or cell numbers was 
observed for all other peptide upon continued incubation (up to 24 hours (results not 
shown) indicating possibly a complete kill. palG1 demonstrated over 70% kill against 
Ent. faecalis cells over a 24 hour period. Also, for all pathogens tested, no antimicrobial 
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activity was observed in peptide free controls, demonstrating that antimicrobial activity 
was directly related to the addition of the peptides to the bacteria cultures. 
There was no obvious correlation between antimicrobial activity and membrane 
depolarisation for many of the short AMPs, a phenomenon that has previously been 
observed in CP29 and Bac2A-NH2 (Wu and Hancock 1999). Individual peptides 
demonstrated varied membrane depolarising ability. Apart from peptide 8, which had 
>50% membrane depolarisation of E. coli K12 cells, other peptides had moderate 
membrane depolarisation effects (10-30% depolarisation) against both E. coli K12 and 
EMRSA-15. This may be because other factors, and not membrane depolarisation alone 
are responsible for killing of cells. No membrane depolarisation was observed in Ent. 
faecalis cells treated with palG1. Irrespective, the greater permeabilization and overall 
faster killing kinetics of E. coli K12 with respect to EMRSA-15, and its susceptibility to 
the various peptides, confirm the conclusion from previous studies that the double 
membrane of the Gram-negative bacterium is a less efficient barrier than the single 
membrane and peptidoglycan layer of the Gram-positive bacterium (Tossi et al. 1997, 
Tiozzo et al. 1998).  
Transmission electron micrographs revealed that compared to untreated cells, which 
retained their morphology, all peptide-treated cells had distorted cell morphology. This 
is evidence that the peptides may interact with the cell division machinery of the cells. 
TEM images of all untreated bacteria cells showed smooth, intact surfaces while peptide 
treated cells showed breakage and roughness of the cell wall in general. Peptide 3 
induced outer cell detachment and spilling off of the cytoplasmic content in EMRSA-
15. Moreover, the cell wall appeared to be severely damaged and showed undulations 
indicating a loss of integrity. EMRSA-15 cells treated with peptides 2 and 7 had 
markedly reduced sizes (cell shrinkage) compared with the untreated cells. This cell 
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shrinkage may be due to loss of turgor (Pathak and Chauhan 2011) or may represent a 
type of stress response to the peptides or that cells are going into dormancy. Mesosome-
like structures were also observed in EMRSA-15 cells treated with peptides 2 and 3. 
These mesosomes are intracytoplasmic membrane inclusions which have been 
confirmed as a definite pattern of membrane organisation in S. aureus cells treated with 
antibiotics, including antimicrobial peptides (Balkwill and Stevens 1980, Friedrich et al. 
2000, Santhana Raj et al. 2007, Rabanal et al. 2015). Their presence indicates 
cytoplasmic membrane alteration/damage and possible uncoupling of the synthesis of 
call wall polymers caused by antimicrobial activity (Friedrich et al. 2000). Compared to 
the untreated E. coli K12 cells which had intact membranes and intracellular content, 
large vacuoles (holes) could be observed in cells treated with peptides 5, 7, 8, and 15. 
Peptides 2, 3 and 4 seemed to cause rupturing and almost a total disintegration of the 
cell membrane and spilling of intracellular content. In addition, a compete loss of 
membrane integrity can be seen in some of the peptide treatments, with some showing 
‘empty nests’ and missing cytoplasm. A type of cell shrinkage is again observed in E. 
coli K12 cells treated with peptide 7. Membrane lysis and leakage of cytoplasmic 
content, as well as, outer membrane detachment were observed in Ent. faecalis cells 
treated with palG1 for 1 hour, and more so, after 24 hours. 
The hairy appearance observed in some of the peptide treated cells under TEM could be 
due to an electrostatic interaction between the peptides and the cell surface. This 
phenomenon has been observed in another study (Rojas-Chapana et al. 2005) and can 
be explained through the interaction between the positively charged surface of the 
peptides and the negatively charged bacterial cells. This observation is also in good 
agreement with the structural models predicted for these peptides. Structural modelling 
of peptides revealed that all peptides had α-helical conformations apart from peptide 15, 
196 
 
which is a β-sheet. The hydrophilic-hydrophobic behaviour of these peptides as evident 
in the predicted peptide structures (hydrophilic/charged residues on one side, and 
hydrophobic residues on the other side), and their interaction with phospholipids, could 
also play a role in the penetration and perforation of the bacterial surface. All peptides 
have a net positive charge ≥4, which attracts them to the anionic microbial membranes 
and an ability to assume amphipathic structures (hydrophobicity ratio of >30%) that 
favour insertion into microbial membranes (Hancock and Lehrer 1998). There is 
evidence in many studies that computer modelling studies correlate with structures 
indicated by circular dichroism (CD) -an excellent method of determining the secondary 
structure of proteins (Greenfield 2006). However, this is not always the case and CD 
studies in different solutions/environments, as well as, X-ray crystallography and 
Nuclear magnetic resonance (NMR) methods, which give the residue-specific 
information (Greenfield 2006) may be required to confirm the accuracy of predicted 
structures upon peptide interaction with membranes. 
As no peptide was haemolytic to sheep erythrocytes up to concentration of 500 µg/ml, 
activity of these peptides may be prokaryotic specific suggesting their use in 
intravenous treatment applications in mammals. It is however, necessary to carry out 
cytotoxicity assays on human and other mammalian cell lines to determine whether the 
peptides can induce necrosis in cells. In addition, although AMPs are known to possess 
remarkable resistance to microorganism adaptation, the mutation frequencies to 
ascertain the likelihood of resistance arising in the use of these peptides were not 
determined in this study. 
In conclusion, in vitro susceptibility data suggests that whereas all synthesized AMPs 
had similar activity against E. coli K12, peptides 2, 3, and 7 have the most activity 
against EMRSA-15. Loss of viability also seemed to have occurred in the first hour and 
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perhaps simultaneously as membrane depolarisation and/or damage. Data presented 
here support the potential use of AMPs (2, 3, 7), AMPs (2, 3, 4, 5, 7, 8, 15) and the 
polypeptide palG1 in the treatment of S. aureus, E. coli and Ent. faecalis infections 
respectively in the future. We are not aware of other reports of isolation of clinically 
relevant antimicrobial peptides from cow rumen using metagenomics methods. These 
AMPs show activity against human pathogens and have potential application in the 
treatment of multidrug resistant pathogens. Furthermore, this novel antimicrobial 


















General discussion, conclusions and future work 
6.1 General discussion 
Bacterial resistance to classical antibiotics poses a growing challenge to medicine and 
public health. Increasing resistance to preferred therapies has limited the options for 
treatment, and as a result, the scientific community is urged to develop new drugs in 
order to efficiently control resistant microorganisms (Lipsitch 2001). These new 
antimicrobial compounds must have potent antimicrobial activity but without 
undesirable side effects and with low risk of microbial resistance arising (Perry and Hall 
2009). Among these new compounds, antimicrobial peptides (AMPs) and derivatives 
have emerged as an important field of research in the fight of microbial resistance 
(Yeaman and Yount 2003, Toke 2005, Guani-Guerra et al. 2010). Antimicrobial 
peptides (AMPs) are a growing class of natural and synthetic peptides with a wide range 
of targets including viruses, bacteria, fungi and parasites (Brown and Hancock 2006). 
Their ability to avoid bacterial resistance mechanisms due to their multiple mechanism 
of action, broad range of activity and low/selective toxicity to hosts (Yeaman and Yount 
2003, Matsuzaki 2009) makes them particularly interesting as potential lead 
compounds. 
Most antibiotics introduced into the clinic were discovered by screening cultivable soil 
microorganisms (Ling et al. 2015). More recently, the marine environment has also 
been recognised as a large potential source of biodiversity and it is being increasingly 
searched for novel chemicals with useful bioactivity (Blunt et al. 2007, Simmons et al. 
2008, Liu et al. 2010, Hu et al. 2011). However, as natural product resources are 
practically inexhaustible, the majority of the world's biodiversity remains to be explored 
(Harvey 2007, Berdy 2012)  as approximately 99% of all species in external 
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environments do not grow under laboratory conditions (Lewis 2013). Several studies 
already suggest that new organisms such as uncultured bacteria are likely to harbour 
new antimicrobials (Degen et al. 2014, Doroghazi et al. 2014, Gavrish et al. 2014, 
Wilson et al. 2014). The metagenomes of complex microbial communities are also rich 
sources of novel biocatalysts (Kang et al. 2015). Therefore, exploiting uncultured 
bacteria in these different natural and complex environments is likely to revive the 
platform of natural product/drug discovery (Lewis 2012). The rumen microbiome, 
which has also been cited as a resource of novel enzymes especially for cellulosic 
biofuel production (Rubin 2008, Hess et al. 2011) is one of the many unexploited 
environments for novel antimicrobial compound discovery. It presents a rich and 
underutilized source of novel enzymes with tremendous potential for industrial 
application. Advent of nucleic acid-based molecular technologies has ushered in a new 
culture-independent perspective of microbial ecology unbiased by the culturing aptitude 
of microbial species (McCann et al. 2014). Among the methods designed to gain access 
to the physiology and genetics of uncultured organisms, metagenomics, the genomic 
analysis of a population of microorganisms, has emerged as a powerful centrepiece 
(Handelsman 2004). The potential for application of metagenomics to biotechnology 
seems endless as functional screens have identified new enzymes, antibiotics and other 
reagents in libraries from diverse environments (Gillespie et al. 2002, Lorenz and 
Schleper 2002, Piel 2002, Voget et al. 2003). 
The aim of this thesis was to characterise antimicrobial proteins and peptides (AMPPs) 
from the rumen microbiome using metagenomic approaches and bioinformatic tools. In 
order to do this, a number of microbiology, molecular and computational/informatics 
methods were used. Firstly, a fosmid-based cow rumen metagenomic clone library 
created from the solid attached bacteria (SAB) of rumen content was functionally 
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screened for antimicrobial activity (Chapter 3). Clones with antimicrobial activity were 
subsequently sequenced after which antimicrobial genes were expressed (genes/proteins 
≥25 AAs in length) or chemically synthesized (<25 AAs in lenghth) (Chapter 4), and 
characterised for antimicrobial activity (Chapter 5). Secondly, sequence data from an 
already existing cow rumen metagenomic dataset was bioinformatically mined for 
antimicrobial proteins and peptide sequences (Chapter 3), which were then 
characterized for antimicrobial activity against bacterial pathogens in the same way as 
the antimicrobial genes identified from the IBERS fosmid metagenomic library 
(Chapter 4 and 5) in order to gain understanding of their applicability in the treatment of 
infections. 
Functional and sequence based metagenomic screening strategies were used 
complementarily as they both present advantages and limitations (Uchiyama and 
Miyazaki 2009). Whereas, sequence homology based analysis allows for identification 
of new enzymes from a range of environments, discovery is limited to the identification 
of members from known gene families. Functional screening of metagenomic libraries 
on the other hand does not depend on previous knowledge and so has the potential to 
discover novel classes of genes coding known or new functions (Ferrer et al. 2009, 
Simon and Daniel 2009). 
In the present study, novel antimicrobial genes were identified from the fosmid based 
cow rumen metagenome library (Prive 2011) and from an already existing cow rumen 
metagenome (Hess et al. 2011). This is no surprise as AMPs are components of the 
innate host immune/defence system found among all classes of life ranging from 
prokaryotes to humans (Boman 1995, Zasloff 2002, Giuliani et al. 2007). Five longer 
antimicrobial genes/proteins (Gene 6, 17A, 17B palG1 and palG2) were identified from 
the in-house metagenome library, including 181 short antimicrobial peptides. Six genes 
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H-G1, H-G2, H-G3, H-G4, H-G5, and H-G6 were identified from the (Hess et al. 2011) 
dataset. Antimicrobial proteins- longer genes were amplified and expressed in a suitable 
E. coli host while shorter genes (≤22 AAs 135 in total) were chemically synthesized in a 
peptide library. 
After initial antimicrobial and haemolytic activity screens, seven (7) of the short 
chemically synthesized AMPs designated peptides 2, 3, 4, 5, 7, 8 and 15, as well as, 
palG1, the only longer protein successfully expressed and purified, were chosen for 
further analysis. These AMPPs displayed antimicrobial activity (around 32 to 64 µg/ml) 
against both Gram positive bacteria strains (including Methicillin sensitive and resistant 
S. aureus strains MSSA RN4220 and EMRSA-15, Ent. faecalis JH2-2 and List. 
monocytogenes NCTC 11994 (serovar 4b)), as well as, Gram negative bacteria strains 
(E. coli K12, Salmonella enterica serovar Typhimurium SL1344 and P. aeruginosa 
(15692) PAO1 strain H103) in MHB. These MIC values fall in the range of data from 
published work for other cationic AMPs (Zasloff 1987). The MIC of palG1 against Ent. 
faecalis was 200 µg/ml. Time kill studies carried out at 3 X MIC demonstrated time-
depended microbicidal action of peptides against EMRSA-15 and E. coli K12 alike. 
Reductions of >8 log10 CFU/ml (peptides 2 and 7 after 1 and 3 hours respectively) and 
>3 log10 CFU/ml (peptide 3 after 30 minutes) of EMRSA-15 cells were demonstrated. 
Reductions of >8 log10 CFU/ml of E. coli K12 cells was observed for all peptide 
treatments. Apart from peptide 4 where E. coli K12 cells seemed to recover after 4 
hours, no increase in cell density or cell numbers was observed for all other peptides 
upon continued incubation (up to 24 hours (results not shown) indicating a possible 
bacterioststic effect. palG1 demonstrated over 70% kill against Ent. faecelis cells over a 
24 hour period. This rapid kill within minutes, observed with the peptides in this study 
is also a common observation with many AMPs (Maloy and Kari 1995, Hancock and 
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Lehrer 1998, Shai 2002). All peptides were non-haemolytic against sheep erythrocytes 
and only around 10% haemolysis was observed even at concentrations up to 500 µg/ml. 
This suggests that the peptides may have selective activity against microbial cells, thus 
making them promising candidates for alternative therapies, not just in topical 
applications but potentially in intravenous use against MDR bacteria. It is however, 
necessary to carry out cytotoxicity assays on human and other mammalian cell lines to 
determine whether the peptides can induce apoptosis and necrosis in cells (Paredes-
Gamero et al. 2012). 
The peptides depolarization capacity was tested by diSC3(5) method for EMRSA-15 
and E. coli K12, a Gram-negative and Gram-positive strain respectively. An increase in 
the fluorescent signal, albeit moderate (between 10-50% membrane depolarisation) 
compared to the Triton-X 100 treatment was observed shortly after the addition of the 
short AMPs, indicating that peptides are active against both organism types. No 
membrane depolarisation was observed in Ent. faecalis cells treated with the longer 
AMP, palG1. This may be because palG1 may require a longer time (>20 minutes) to 
induce membrane depolarisation (as is observed in the time kill assay). Irrespective, the 
depolarization capacity is higher in E. coli K12, the Gram-negative strain tested, 
probably because of the easier access of peptides to the cytoplasmic membrane. This 
confirms the findings from previous studies that the double membrane of Gram-
negative bacterium is a less efficient barrier than the single membrane and 
peptidoglycan layer of the Gram-positive bacterium (Tossi et al. 1997, Tiozzo et al. 
1998). Moreover, as an outer-membrane-barrier defective mutant E. coli strain was not 
used as required for some antimicrobial agents (Wu and Hancock 1999, Zhang et al. 
2000), it can be assumed that peptides by themselves can destabilize E. coli K12 outer 
membrane and have an effect on cytoplasmic membrane, without requiring any 
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additional treatment to remove the outer layer barrier. This could be a result of peptide 
interaction and binding to lipopolysaccharides (LPS) or peptidoglycans (PGNs) for E. 
coli K12 and EMRSA-15 respectively (Torrent et al. 2008) and would need to be 
confirmed using the appropriate assays. PGNs are a major constituent of Gram-positive 
bacteria cell walls, which can induce several inflammatory responses upon bacterial 
infection (Dziarski and Gupta 2005). It is believed that peptide binding to PGNs at the 
bacteria surface can trigger the cell autolysins (Sahl et al. 2005), thus leading to cell 
death. Given the low depolarising activity of the short AMPs in this study, it would 
seem that membrane-destabilizing activity does not solely explain the bactericidal 
capacity of these peptides. 
Furthermore, TEM images of the peptide treated cells also confirmed cell wall and inner 
membrane damage leading to large vacuoles in the cytoplasm, cell rupture, shrinkage 
and disintegration in some cases. This provides additional evidence of a putative 
multimodal action of the peptides as previously described in other AMP studies (Pathak 
and Chauhan 2011, Parween et al. 2013, Rao et al. 2013). In E. coli K12 for instance, 
membrane depolarisation observed in the peptides (especially peptide 8) and the 
concomitant physical destabilization of the outer membrane as observed in the TEM 
images is by itself an antimicrobial mechanism.                                                                                                                                                  
The antimicrobial peptides tested in this study are mostly cationic α-helical peptides 
with the exception of peptide 15 which has a β-sheet structure as predicted by computer 
modeling using peptide sequences. Their structures display a cationic and amphiphilic 
nature which complies with the main “rules” for antimicrobial peptide definition 
(Hancock and Sahl 2006). They have an overall positive charge and contain a good 
proportion of hydrophobic residues. This positive charge should greatly facilitate their 
accumulation at the polyanionic microbial cell surfaces. Many AMPs bind in a 
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membrane parallel orientation, interacting only with one face of the bilayer and this may 
be sufficient for antimicrobial action (Hwang and Vogel 1998), thus perturbing the 
membrane integrity. Some peptides and phospholipids have been shown to translocate 
or form multimeric transmembrane channels promoting the membrane depolarization 
that also seem to contribute to their activity (Shai 1999, Bhattacharjya and 
Ramamoorthy 2009) at higher concentrations. The amphipathic nature of the predicted 
peptide structures in this study as well as the membrane damage observed in the TEM 
images is in good agreement with this type of interaction. TEM images indicate that the 
peptides are membrane destructive and although membrane disruptive peptides have 
been reported to be of the α-helical structural class (as is the case for most of the 
peptides in this study), not all α-helical peptides are membrane disruptive (Park et al. 
1998, Friedrich et al. 2001, Patrzykat et al. 2002). Even peptides with β-sheet structure 
(as in the case of peptide 15 in this study- Figure 5.21) can be membrane disruptive. For 
example, gramicidin, a highly hydrophobic β-sheet peptide with a lethal mechanism of 
action has been shown to be involved in cytoplasmic membrane permeabilization and 
form disruptive transmembrane pores and cation specific channels (Burkhart et al. 1998, 
Panchal et al. 2002). Still it is difficult to say which of the known membrane interaction 
and disruption models (i.e. barrel stave, carpet models, or micellar aggregate model) 
explains the activity of these peptides without further experimental evidence.  
6.2 Conclusions 
Antimicrobial peptides are promising candidates for overcoming the critical and 
accelerating problem of bacterial resistance to currently utilized antibiotics. The high 
cost and low yield of isolation from natural sources, which hindered peptide application 
in medicine in the past have been overcome by new technological advances and 
improvements in traditional recombinant methods (Ling et al. 2015). Using a 
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combination of metagenomic and bioinformatic techniques in this project, the rumen 
has been shown to be a great resource for bio-prospecting of novel antimicrobial 
proteins and peptides. AMPs discovered in this study display low haemolytic activity 
against blood cells and have broad-spectrum activity against both Gram positive and 
Gram negative organisms alike, including epidemic methicillin resistant S. aureus 
EMRSA-15, E. coli K12 and Ent. faecalis. The results presented here indicate events 
that lead to loss of cell viability to be cytoplasmic leakage and some evidence of 
interference with the cell division mechanism as observed in TEM images. The non-
haemolytic property of the peptides suggest that they could be used both as topical 
agents and intravenously in the treatment of MDR bacterial infections. Overall, the data 
support the potential use of AMPs (2, 3, 7), AMPs (2, 3, 4, 5, 7, 8, 15) and the 
polypeptide palG1 in the treatment of S. aureus, E. coli and Ent. faecalis infections 
respectively in the future. To the best of my knowledge, this is the first study to 
prospect the cow rumen metagenome for novel antimicrobials. The antimicrobial 
compounds discovered here are not only novel, but demonstrate potent activity against 
clinically relevant human pathogens, indicating that the rumen is an untapped goldmine 
for the discovery of antimicrobials. These AMPPs could have direct application either 
in the treatment of infections caused by these pathogens or form templates for the 
development of new drug targets in the future. 
6.3 Future work 
Due to time constraints, alternative gene cloning and protein expression methods could 
not be explored especially for those antimicrobial proteins which failed to express in 
vivo in E. coli using the pTrcHis TOPO expression system. It would also be necessary 
to optimize in vitro expression of proteins in order to recover expressed protein in high 
enough yields for downstream applications. 
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Since the viable count and optical density (OD) methods used in this study are not a real 
time measure of viability, the activity of macromolecular biosynthetic pathways 
following exposure to peptides should be considered. Further mechanism of action 
studies using advanced bio-imaging technologies, like confocal microscopy etc with 
radio-labelled peptides as well as ionic leakage assays would also be required to 
completely understand the killing mechanism of these peptides. It is also necessary to 
perform cytotoxicity assays on human and other mammalian cell lines to determine 
whether the peptides can induce necrosis in cells. Circular dichroism studies in different 
solutions/environments as well as X-ray crystallography and Nuclear magnetic 
resonance (NMR) methods, which give the residue-specific information (Greenfield 
2006) may be required to confirm the accuracy of predicted structures upon peptide 
interaction with membranes.  
Furthermore, although AMPs such as the ones identified in this study, are known to 
possess remarkable resistance to microorganism adaptation, the mutation frequencies to 
ascertain the likelihood of resistance arising in the use of these peptides were not 
determined in this study and need to be determined in the future. Moreover, as many 
AMPs are known to prevent biofilm formation or eradicate already established biofilms 
(Batoni et al. 2011, Jorge et al. 2012, Di Luca et al. 2014), it will be useful to 
investigate the effect of the AMPs discovered in this study on biofilm populations. An 
open-access, manually curated database of AMPs specifically assayed against microbial 
biofilms (BaAMPs, accessible at http:// www.baamps.it) has recently been generated 
and will benefit AMP-biofilm research and support the design of novel molecules active 
against biofilms (Di Luca et al. 2015). In the long run, the efficacy of these AMPs in 
animal models would be tested. 
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In addition, the rumen eukaryotic metagenome will be prospected for potentially novel 
antimicrobials, which will then be tested in vitro for activity against bacterial pathogens. 
We currently have available, an eukaryotic metatranscriptome dataset at IBERS, which 
will be a great starting point for this work. A catalogue consisting of a reference set of 
rumen microbial genome sequences from cultivated rumen bacteria, methanogenic 
archaea, anaerobic fungi and ciliate protozoa is currently being developed through the 
Hungate1000 project (http://www.hungate1000.org.nz/). This provides an enormous 
amount of data for bioprospecting the rumen microbiome for novel antimicrobials, and 

















Summary of thesis output 
A variety of outputs have been created from the research carried out in this thesis. 
Thesis outputs have been presented at different international and national conferences in 
form of poster sessions, talks and submitted article manuscripts are outlined below 
beginning from the most recent.  
7.1 Antimicrobial peptide patent application 
We are currently in discussion with the Aberystwyth University Intellectual Property 
Office and will shortly be filling a patent application to the UK intellectual Property 
Office on the antimicrobial peptides identified in this study. 
7.2 Articles 
7.2.1 Oyama et al., (2015) 
Oyama, LB., SE Girdwood, A. Cookson, N. Fernandez-Fuentes, JE Edwards, P 
Golyshin, O Golyshina, F Privé, R Mikut, K Hilpert, C Creevey
 
and SA Huws (2015). 
The rumen: an untapped goldmine for novel antimicrobial discovery. Manuscript 
submitted at Nature Biotechnology. 
Abstract: 
Antimicrobial peptides (AMPs) are considered as future drug alternatives to combat the 
escalating problem of antimicrobial resistance. The community of competitive 
culturable and non-culturable bacteria in the rumen present an untapped goldmine for 
the discovery of antimicrobial compounds. We used metagenomic and bioinformatics 
techniques to prospect two rumen bacterial metagenomes for potentially novel AMPs. A 
total of 192 AMPs were identified. Seven of these (peptides 2, 3, 4, 5, 7, 8, and 15) 
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displayed potent antimicrobial activity (MICs between 32 to 64 µg/ml) against 
Epidemic methicillin resistant Staphylococcus aureus EMRSA-15 and Escherichia coli 
K12 and had no haemolytic activity against red blood cells. They also induced 
cytoplasmic leakage with some evidence of interference with the cell division 
mechanism. Our findings indicate that the rumen may provide viable alternative broad 
spectrum antimicrobial options for the prevention and treatment of multidrug resistant 
bacteria in the future. 
7.2.2 Oyama et al., (2015b) 
Oyama, LB., JA Crochet, SE Girdwood, A. Cookson, N. Fernandez-Fuentes, JE 
Edwards, P Golyshin, O Golyshina, F Privé, R Mikut, K Hilpert, C Creevey and SA 
Huws (2015). palG1: a novel protein from cow metagenome with activity against 
Enterococcus faecalis. Manuscript in preparation. 
7.3 Offered oral presentations 
 7.3.1 Society for General Microbiology (SGM) Annual Conference, Birmingham, 
UK- March 30 to September 2. 2015.  
A 15 minute oral presentation- title and abstract as below. 
Broad spectrum antimicrobial peptides derived from a bovine rumen metagenome 
Oyama. L. B., SE Girdwood, JE Edwards, P Golyshin, O Golyshina, F Privé, R Mikut, 
K Hilpert, C Creevey
 
and SA Huws 
Infections caused by multi drug resistant bacteria are exceptionally difficult to treat and 
overall the choice of currently available treatment options is very restricted. Urgent 
action is needed to increase the number of antimicrobials available for the treatment of 
these infections, a problem further compounded by the evolution of antimicrobial 
resistance. Antimicrobial peptides are a growing class of natural and synthetic peptides 
with a wide spectrum of targets including viruses, bacteria, fungi, and parasites gaining 
popularity as a potentially new option that can offer a solution to the problem. 
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A method of high throughput synthesis and screening was used to measure the 
antimicrobial activity of four novel antimicrobial peptides derived from a cow rumen 
metagenome library. These peptides show broad spectrum activity against and array of 
Gram positive and Gram negative organisms including Pseudomonas aeruginosa, 
EMRSA-15, Enterococcus faecalis and Salmonella typhimurium and were 
simultaneously be non-toxic to the host. Although, work on to investigate the killing 
kinetics and mode of action of these peptides is currently ongoing and still in the early 
stages, current results clearly demonstrate that these cow rumen derived peptides have 
potential for use in the treatment of bacterial infections, and the rumen is a potential a 
source of novel antimicrobial peptides that could provide templates for the design of 
novel therapeutics in the future. 
7.3.2 First annual International Environmental ‘Omics Synthesis conference, 
Cardiff, UK- September 9-11, 2013. 
A 15 minute oral presentation: title and abstract below. 
Use of functional and sequence based metagenomics to prospect the rumen 
metagenome for novel antimicrobials 
The challenge of antimicrobial resistance in bacteria, coupled with the decrease in drug 
discovery rate is now a serious medical challenge. As such, there is a pivotal need for 
accelerated development of new antimicrobials. Metagenomic techniques allow the 
study of the whole microbiome (culturable and as yet unculturable bacteria), and allow 
the discovery of novel compounds. To date, turbomycin is the only antibiotic 
discovered using metagenomics but the potential to discover useful antibiotics from 
microbiomes in which bacteria commonly compete with each other is enormous. As 
such, we prospected a rumen fosmid based metagenome for antimicrobial activity 
against Staphylococcus aureus, Escherichia coli, Listeria monocytogenes, Salmonella 
typhimurium, and Enterococcus faecalis. Metagenomic clones (2µl) were pressed gently 
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using pin replicators onto Luria-Bertani agar plates which had 500µl of a pathogen 
(OD600nm =1) spread evenly over the agar just prior. Plates were incubated overnight 
and the following day zones of clearing around the clones were noted as being 
indicative of clones which have gene inserts encoding antimicrobials. Antimicrobial 
activity was observed in 255 of 8448 clones, which are now undergoing high 
throughput pyrosequencing. Alongside functional metagenomics, we have mined 
existing rumen metagenomic datasets (Hess et al 2011; Brulc et al 2009) and pure 
culture genomic datasets using BLAST and BioEdit software, for homology to known 
antimicrobial gene sequences obtained from  NCBI BLAST. Sequences with homology 
to antimicrobial genes across many antimicrobial classes, especially aminoglycosides, 
penicillins and carbapenems were found. We now aim to fully characterise 




 International Meeting on Antimicrobial peptides (IMAP), Graz Austria- 
September 29-30, 2014. 
palG1: A novel antimicrobial from cow rumen 
The development of antibiotic molecules for use in the treatment of infections and for 
the upstream control of contamination has been declining over recent decades. Urgent 
action is needed to address this problem which is further compounded by the evolution 
of antibiotic resistance. Vancomycin-resistant Enterococci (VRE) have emerged as a 
major cause of nosocomial infections, and within this group Enterococcus 
faecalis causes the majority of human enterococcal infections.  
In this study, a novel antimicrobial peptide palG1 discovered by functional and 
sequence based screening of a fosmid-based cow rumen metagenomic library was 
successfully expressed and tested for activity against Enterococcus faecalis JH2-2. 
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Growth of E. faecalis in Luria Bertani broth in the presence of palG1 was monitored 
over a 24 hour period. Bacterial growth was inhibited by palG1 (100 µg/ml) compared 
to medium with bacteria alone. Although, still in the early stages of characterisation, 
current results clearly demonstrate that palG1 has potential for use in the treatment of 
enterococcal infections, and the rumen is a potential a source of novel antimicrobial 







7.4.2 Rowett-INRA 2014, Gut Microbiology: from sequence to function, Aberdeen, 
UK- June 16-19, 2014. 
From metagenomic sequences to antimicrobial function: mining the rumen microbiome. 
Due to their broad-spectrum activity, antimicrobial peptides (AMPs) are considered as 
future drug alternatives to combat the problem of antimicrobial resistance in medicine. 
The community of competitive culturable and non-culturable bacteria in the rumen 
present a potential source of novel bioactive compounds. In this study, we screened a 
bovine fosmid based metagenomic library for antimicrobial activity against a range of 
pathogens including Staphylococcus aureus, Escherichia coli, Listeria monocytogenes, 
Salmonella typhimurium, and Enterococcus faecalis. Metagenome clones were pressed 
onto a lawn of a pathogen on Luria-Bertani agar plates. After overnight incubation at 
appropriate temperatures, zones of clearing around the clones, indicative of 
antimicrobial gene inserts, were observed in 255 of 8448 clones. Twenty two putatively 
positive clones were sequenced using 454 FLX titanium technology. Sequence analysis 
and antimicrobial peptides/gene prediction were employed using bioinformatics 
techniques and AMP predicting software e.g. NCBI BLAST, ANTIBP2, AMPA, and 
CAMP. Numerous antimicrobial peptides across many antimicrobial peptide classes 
were identified in many of the open reading frames. Research into the antimicrobial 
activities of the predicted antimicrobial peptide sequences is currently ongoing. 
Preliminary antimicrobial activity studies of a few of these peptides show activity 
against human pathogens including Salmonella typhimurium. These novel AMPs will be 










 International Meeting on Antimicrobial peptides (IMAP), London, UK- 
September 23-24, 2013.  
Abundant antimicrobial peptides in cow rumen revealed by metagenomics. 
Antimicrobial resistance is a serious challenge in medicine, which calls for an urgent 
need for the development and/or discovery of new antimicrobials. Antimicrobial 
peptides (AMPs) are currently being considered as future drug alternatives because of 
their broad-spectrum activity. The rumen consists of a huge community of competitive 
culturable and non-culturable organisms and so present a potential source for novel 
compound discovery. Using modern metagenomic and bioinformatics techniques, it is 
possible to mine the entire microbial population in an environment. Many bioactive 
compounds and the antibiotic, turbomycin have been discovered using these methods. 
Here, we screen a fosmid-based rumen metagenome library for antimicrobial genes. 
Sample sequences were obtained by 454 pyrosequencing and sequence analysis is 
currently ongoing. Antimicrobial peptides sequences were predicted using various 
bioinformatics and AMP predicting software including NCBI BLAST, ANTIBP2, 
AMPA, and CAMP. Numerous antimicrobial peptides across many antimicrobial 
peptide classes were identified in many of the sample open reading frames. These 
AMPs will be fully characterized to determine their novelty and potential applicability. 
Preliminary data from this study show that the rumen environment presents a potentially 









7.4.4 First annual International Environmental ‘Omics Synthesis conference, 
Cardiff, UK- September 9-11, 2013.  




7.4.5 Society for General Microbiology (SGM) Autumn Conference, Sussex, UK- 
September 2-4, 2013.  
Metagenomic technology as a tool for the discovery of novel antimicrobials 
The increasing emergence of antimicrobial resistance in bacterial pathogens has 
led to a demand for novel antimicrobial compounds. Metagenomic techniques 
allow the study of the whole microbiome (culturable and as yet unculturable 
bacteria), and as such play a major role in novel compound discovery. Indeed, 
the discovery of turbomycin from soil metagenome suggests that novel 
antimicrobial compounds can be identified using metagenomics. We 
prospected a rumen fosmid based metagenome library for antimicrobial activity 
against Staphylococcus aureus, Escherichia coli, Listeria monocytogenes, 
Salmonella typhimurium, and Enterococcus faecalis. Metagenomic clones (2µl) 
were gently pressed onto a lawn of 500µl of a pathogen (OD600nm =1) on Luria-
Bertani agar plates. Zones of clearing around the clones, indicative of 
antimicrobial gene inserts, were observed in 255 of 8448 clones after overnight 
incubation at appropriate temperatures. These putatively positive inserts are now 
in the process of being pyrosequenced. Rumen metagenomic and pure culture 
genomic datasets have also been mined, using BLAST and BioEdit, for 
homology to known antimicrobial gene sequences obtained from NCBI BLAST. 
Numerous hits were identified across many antimicrobial classes, especially 
aminoglycosides, penicillins and carbapenems. These antimicrobial genes will 
be expressed in a host and fully characterised in order to determine their novelty 
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